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Summary
The focus of the present thesis is the use of different, multiscale molecular dynamics (MD)
approaches to investigate the microscopic mechanisms underlying complex molecular
processes, namely peptide aggregation and protein-ligand association. A first project
deals with the employment and extension of a phenomenological coarse-grained model
developed by Dr. Riccardo Pellarin and Prof. Dr. Amedeo Caflisch in order to assess the
influence of macromolecular crowding on the aggregation kinetics of a model peptide. MD
simulations show that the intrinsic amyloidogenic propensity of the peptide determines
the extent to which the presence of large and inert cosolutes (i.e., crowders) accelerate
the peptide self-assembly. In a second project, in collaboration with the group of Prof. E.
Gazit at the University of Tel Aviv, we performed MD simulations to obtain microscopic
details on the structure of the early aggregates formed by the amino acid phenylalanine.
Our results show that this monopeptide is able to aggregate into ordered assemblies and
confirm the data acquired with electron diffraction experiments. We further studied how
carnosine, a putative small inhibitor of amyloid aggregation, interacts with the amyloid
β monomer (Aβ) and affects its conformational ensemble and aggregation propensity.
In agreement with the various experiments performed at the University of Udine and
University of Catania, our simulations reveal that carnosine establishes transient and
non-specific interactions with the Aβ monomer, without modifying its structural features.
However, a reduced tendency to interpeptide hydrogen bonds was observed for Aβ peptide
segments in presence of carnosine. Finally, full atomistic MD simulations in conjunction
with an explicit representation of the aqueous environment were used to shed light on
I
the intrinsic flexibility of the binding sites of 20 bromodomains, protein modules which
specifically recognize acetylated lysine, and to unveil the mechanism of acetyl-lysine
binding to the bromodomain TAF1(2). We observed a large variability in the orientation
of several conserved residues in the bromodomains binding groove, which complete the
static picture provided by crystallographic experiments. Moreover, our computational
approach proved able to reproduce the acetyl-lysine binding pose observed in the X-ray
structures and unmasked the existence of a new stable binding conformation, in which
the acetyl-lysine side chain is more buried in the binding pocket and displaces some of
the structured water molecules at the bottom of the binding cleft.
II
Zusammenfassung
Der Fokus der vorliegenden Thesis liegt auf dem Einsatz von verschiedenen, multi-
skalen Moleküldynamik- (MD-) Methoden, um die mikroskopischen Mechanismen, welche
molekularen Prozessen zu Grunde liegen, zu untersuchen. Speziell wurden die Peptid-
Aggregation und die Protein-Ligand Bindung betrachtet. Ein erstes Projekt handelt von
der Anwendung und Erweiterung eines phänomenologischen grobkörnigen Modells, das
von Dr. Riccardo Pellarin und Prof. Amedeo Caflisch entwickelt wurde. Mit Hilfe dessen
kann man untersuchen, wie makromolekulare Verdrängung die Aggregationskinetik eines
Modellpeptids beeinflusst. MD-Simulationen zeigen, dass die intrinsische Amyloid-Ten-
denz des Peptids bestimmt, inwiefern die Präsenz grosser und inerter Kosolute (bzw.
Crowders) die Peptid-Aggregation beschleunigt. Für ein erstes Projekt, eine Kollabora-
tion mit der Gruppe von Prof. E. Gazit an der Universität Tel Aviv, haben wir MD-
Simulationen ausgeführt, um mikroskopische Details über die Struktur der Frühaggre-
gate der Aminosäure Phenylalanin zu erhalten. Gemäss unserer Ergebnisse hat dieses
Monopeptid die Fähigkeit, geordnete Aggregate zu bilden. Ausserdem bestätigen unsere
Resultate die Daten, welche mit Elektronen-Diffraktion gefunden wurden. Weiter haben
wir erforscht, wie Carnosin, ein mutmasslicher Hemmstoff der Amyloid-Aggregation, mit
dem Amyloid-β (Aβ) Monomer wechselwirkt und wie es das konformative Ensemble
und die Amyloid-Tendenz von Aβ beinflusst. In Übereinstimmung mit den verschiede-
nen Experimenten, die an der Universität Udine und Universität Catania durchgeführt
wurden, enthüllen unsere Simulationen, dass Carnosin mit dem Aβ Monomer transiente
und unspezifische Wechselwirkungen formt, ohne seine strukturellen Eigenschaften zu
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verändern. Trotzdem wurde für Aβ Peptid-Segmente im Beisein von Carnosin eine re-
duzierte Tendenz zu interpeptidischen Wasserstoffbrücken beobachtet. Zuletzt wurden
vollständig atomistische MD-Simulationen zusammen mit einer expliziten Darstellung
der wässigren Umgebung benutzt, um die intrinsische Flexibilität der Bindungsstelle
von 20 Bromodomänen, Proteinmodule, welche Acetyl-Lysin spezifisch erkennen, ans
Licht zu bringen und den Mechanismus der Acetyl-Lysin Bindung an die Bromodomäne
TAF1(2) aufzudecken. Wir beobachteten, dass verschiedene konservierte Residuen in der
Bindungsstelle von Bromodomänen mehrere verschiedene Orientierungen einnehmen kön-
nen. Das kompletiert das statische Bild, welches kristallographische Versuche schaffen.
Ausserdem wurde gezeigt, dass unsere computergestützte Herangehensweise die Fähigkeit
besitzt, die in Kristall-Strukturen gefundene Bindungspose des Acetyl-Lysins zu repro-
duzieren. Zusätzlich enthüllten die MD-Simulationen eine neue stabile Bindungspose, in
der die Seitenkette des Acetyl-Lysins tiefer in der Bindungsstelle liegt und einige struk-
turierte Wassermoleküle in der Bindungsstelle ersetzt.
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Chapter 1
Introduction
Computer simulations are nowadays an established research tool used in a variety of
scientific fields, from condensed matter physics and astrophysics to meteorology and eco-
nomics. In biology, in silico experiments are routinely performed to complement and
extend in vivo and in vitro investigations which are often limited in time and spatial
resolution. They are particularly useful to study the kinetic properties, as well as the
thermodynamic stability and structure of the different states encountered within a molec-
ular system during a specific process, i.e., protein folding and aggregation, ligand binding
and enzymatic catalysis. The real experiment is modeled and replicated in the computer
and some observables are measured and compared with known data. If an agreement
between the model and the experiment is observed, the simulation can be used to make
predictions to be further tested experimentally. Therefore, computational studies rep-
resent a sort of “middle way” between theoretical models and experiments [1]: on one
hand they allow to test the validity of theoretical predictions on a certain phenomenon,
on the other hand they can shed light on details that would be otherwise unaccessible to
experimental techniques.
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2 1 Introduction
1.1 Molecular dynamics simulations
In 1957 Alder and Wainwright published the first molecular dynamics (MD) study of a
system of hard spheres [2]. This computational method reproduced the evolution in time
of the investigated system by solving the equation of motion for its constituents. Today,
there are essentially two types of MD simulations [3]:
• ab initio simulations, in which the degrees of freedom of electrons and atomic nuclei
are explicitly taken into account and, therefore, the laws of quantum mechanics are
used;
• molecular mechanics simulations, which are based on classical mechanics.
In the latter representation, a molecular system is represented as a collection of
point masses moving in a conservative field, often called force field, which dictates the
structure-energy relationship for the studied system. Several force fields for proteins and
nucleic acids are currently available, such as CHARMM [4, 5], AMBER [6], OPLS [7]
and GROMOS [8]. In general, the force field is given by the following pairwise function:
E(r) = Ecov(r) + Enoncov(r) (1.1)
where Ecov and Enoncov are the covalent and non-covalent energy terms, respectively and
r is the 3N set of atomic coordinates. We will focus hereafter on the CHARMM force
field. The covalent term is given by the sum over the energies of bonds b, angles θ,
dihedral angles φ and improper dihedral angles ω:
Ecov(r) = Eb + Eθ + Eφ + Eω =
=
∑
b
kb(b− b0)2 +
∑
θ
kθ(θ − θ0)2+
∑
φ
kφ[1 + cos(nφ− δ)] +
∑
ω
kω(ω − ω0)2
(1.2)
where kb, kθ, kφ and kω are the force constants, b0, θ0 and ω0 represent the minimum of the
corresponding harmonic potential, and n and δ govern the position and the multiplicity
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of the minimum of the dihedral periodic potential.
The non-covalent term in 1.1 is given by the sum of Lennard-Jones (LJ) and Coulom-
bic (C) potentials:
Enoncov(r) = ELJ + EC =
=
∑
i 6=j
ij
(rminij
rij
)12
− 2
(
rminij
rij
)6+∑
i 6=j
qiqj
4pi0rij
(1.3)
where qi stands for the partial charge of atom i, 0 is the vacuum permittivity, rminij is the
equilibrium separation between atoms i and j and ij is their equilibrium LJ interaction
energy. The Lennard-Jones potential mimics the van der Waals interactions arising from
the impenetrability of the atoms and the London dispersion forces, while the Coulombic
potential describes the electrostatic interactions between charged atoms.
The connection between the force field and the dynamics of each atom i belonging to
the molecular system is provided by the Newton equation of motion:
mi
d2
dt2
ri = mai = Fi = − ∂
∂ri
E(r) (1.4)
where Fi is the force acting on atom i and ai and mi are the acceleration and the mass
of atom i, respectively.
1.2 Solvation
Most macromolecules need to be solvated in an aqueous environment to express their
function. As an active constituent in cell biology [9], water must be properly modeled to
ensure the accuracy of MD simulations of biological processes. This is not an easy task,
since up to now more than sixty anomalous thermodynamic and physical properties of
water have been reported [10, 11]. Two approaches are commonly used to implement the
water description in MD investigations: explicit solvent and implicit solvent represen-
tation. In the former, water molecules are explicitly described with the same atomistic
resolution as the molecular system of interest. Several water models have been so far
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developed, which can be rigid or flexible, with or without treatment of polarization ef-
fects and with a variable number of interacting sites. In CHARMM, the TIP3P water
model is usually employed, which is a three-site, non-polarizable model [12]. The explicit
treatment of the water molecules is physically the most rigorous but has the disadvantage
of dramatically increasing the computational cost. This hampers the study of long time
scales processes like protein folding and aggregation, which require large scale structural
rearrangements [13].
Implicit solvent models have been specifically developed in order to obtain an accurate
but computationally cheap description of the aqueous environment [14, 15]. In this
representation, the solute is immersed in a potential of mean force which models the
mean influence of the water medium and depends only on the atom coordinates of the
solute [13]. The use of implicit solvent models significantly reduces the system size and,
in addition, lowers the viscosity arising from the friction of the water molecules, which
results in speeding up the motion of the simulated molecules [16]. The hydration free
energy of a molecule is usually decomposed in a polar term ∆Gpol, which takes into
account the electrostatic interactions of water molecules with the charged atoms of the
solute and the resulting screening of their Coulombic interactions, as well as a non-polar
term ∆Gnpol, which stems for the water cavitation term and for the van der Waals
interaction between water and solute atoms. The scheme used to approximate these
two terms characterize the different currently available implicit solvent models. Surface
area models are based on the assumption that solvation energies can be decomposed
into atomic contributions, which are governed by the local solute geometry [17, 18, 19,
20]. Continuum electrostatics approaches involve numerical solution of the Poisson-
Boltzmann equation for the electrostatic potential φ(r):
∇ · [(r)∇φ(r)] = −4piρ(r) (1.5)
where (r) is the position dependent dielectric permittivity and ρ(r) the charge distri-
bution of the solute. This method allows accurate evaluation of the polar term of the
4
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hydration free energy and has been therefore implemented into some force fields [21], but
its computational cost is still too high. Generalized Born (GB) models are related to the
continuum electrostatics method but further simplifications enable the approximation of
the Poisson-Boltzmann electrostatic solvation energy as an efficient pairwise potential.
FACTS, an implicit solvent model used in some simulations reported in this thesis, is a
GB model. In FACTS, a fully analytical evaluation of the volume and spatial symme-
try of the solvent displaced from around a solute atom by its neighbors is performed to
compute the hydration free energy [22].
1.3 Enhanced sampling techniques
MD simulations produce a set of configurations generated by iterative numerical solution
of the Newton equation of motion (1.4). We say that the system “samples” different
conformations during the simulation time. All relevant thermodynamic and structural
observables will then be computed as an average over the sampled configurational space.
This means that, if we are interested in studying a molecular process which involves
large structural rearrangements taking place on the microsecond to second time scale,
we have to perform a simulation of at least the same time length. Even more challenging
is to obtain equilibrium measurements, since they require that the studied phenomenon
happens reversibly during the simulation. Shaw and his coworkers showed that statistical
convergence represents an issue even for a 200 µs explicit water MD simulation of the
acid-unfolded state of the bovine acyl-coenzyme A binding protein, which is so far one
of the longest MD run ever performed [23]. In the case of very small systems [24],
the use of implicit solvent models can solve the problem of statistical convergence of
the simulations, but in order to investigate highly complex processes like the folding of
medium and large proteins, ligand association to intrinsically unstructured proteins [25]
or protein self-assembly, techniques that speed up and improve the sampling have to be
employed.
5
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1.3.1 Coarse-grained models
One way of simplifying the complexity of a system is to eliminate atomistic details of the
simulated biomolecules. In coarse-grained models, the atoms of a molecule are grouped
into mesoscopic units or “beads”, which mutually interact through potentials of mean
force [26]. For example, a methyl group can be represented with only one bead, if the
investigator is not interested in the hydrogen dynamics. Polar hydrogens are, on the
contrary, usually retained because they can participate in hydrogen bonds, as in the
CHARMM 19 representation [27]. When a given atomistic description is simplified as
in the previous examples, a “bottom-up” approach is applied. In another approach, a
minimal set of interactions and degrees of freedom can be chosen upfront and the model
parameters are then fitted to reproduce the essential features of the investigated process.
This approach is called “top-down”. An example of a “top-down” model is the phenomeno-
logical coarse-grained model developed by Pellarin and Caflisch [28], which is extensively
described in Chapter 2. In spite of the loss of high-resolution details, coarse-grained
models based on both simplification methods have turned out to be particularly potent
and useful to study nucleation-limited aggregation processes, because of the breadth in
the time and space scales involved [29].
1.3.2 Replica exchange molecular dynamics simulations
Another commonly used enhanced sampling technique is the Replica Exchange Method
(REM), which has been extended to MD simulations by Sugita and Okamoto [30]. The
basic idea of this technique is to simulate in parallel different copies of the same system
(replicas) at different temperature values. Each replica evolves independently but states
belonging to neighboring temperatures are periodically exchanged with a probability
which depends on the energy difference of the two states. Thus, the system performs
a random walk in the temperature space, which is equivalent to the energy space. In
this way, low temperatures simulation segments explore in details local minima, while
the high temperatures portions of the trajectories help to cross kinetic barriers, so that
the system does not get stuck in local traps on the free-energy surface. Replica exchange
6
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molecular dynamics (REMD) simulations have been successfully applied to study protein
folding [31] and peptide aggregation [32] and have proven to be more efficient than
constant temperature MD (CTMD) simulations in sampling the conformational space of
a molecular system. However, the kinetic information is available only for short intervals
of the trajectories, i.e., only between two temperature exchanges.
1.4 Multiscale computational approaches tailored for
different investigation targets
Since the first MD simulation study [2], numerous and various techniques have been devel-
oped to to study increasingly complex systems with the basic original idea of numerically
solving the equation of motion for the constituents of the studied molecular system. Each
method relies on certain approximations, whose validity depends intrinsically on the tar-
get of study. In this thesis, different computational approaches of different resolution and
complexity levels were tailored to different biological problems. In Chapter 2, an in-house
developed coarse-grained phenomenological (CGF) model to study amyloid aggregation
is extensively described and its main applications are reviewed. Chapter 3 deals with the
use of the CGF model to investigate the effects of macromolecular crowding on the kinet-
ics of self-assembly of a model peptide. This study was motivated by the observation that
amyloid aggregation usually takes place in the cellular milieu, which is a crowded environ-
ment [33, 34]. Nonetheless, most of the experimental and computational investigations
on protein self-assembly are usually performed in ideal homogeneous solutions. Molecular
dynamics CTMD simulations with the FACTS generalized Born implicit solvent model
were performed to obtain atomistic details of the structure of the early aggregates of
phenylalanine, whose fibrillar assemblies have been hypothesized to be responsible for
the neuronal damage observed in individuals affected by Phenylketonuria. The results
of the framework experimental study and of our computational contribution to it are
shown in Chapter 4. The influence of carnosine (β-alanyl-L-histidine), a dipeptide nat-
urally occurring in the brain, on the conformational features of the full-length amyloid
7
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peptide Aβ1−42 has been studied with REMD simulations performed with the FACTS
implicit solvent model. Moreover, carnosine’s potential role as aggregation inhibitor
has been investigated with CTMD simulations of aggregating Aβ segment peptides and
carnosine, using FACTS to represent the aqueous environment. Chapter 5 presents our
computational results, as well as the data obtained by our collaborators with different
experimental techniques. Explicit water CTMD simulations have been used to study the
binding site flexibility of 20 human bromodomains, protein modules which specifically
recognize acetylated lysine side chains in histones and are therefore supposed to play a
role in transcriptional regulation [35, 36]. Furthermore, we employed the same computa-
tional approach to characterize the mechanism and kinetics of acetyl-lsyine binding to the
the human Transcription initiation factor TFIID subunit 1 ( abbreviated TAF1(2)). The
results on acetyl-lysine binding to TAF1(2) and binding site plasticity of bromodomains
are shown in Chapter 6 and Chapter 7, respectively.
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I. INTRODUCTION
Amyloid fibrils are ordered polypeptide aggregates that have been implicated in several
neurodegenerative pathologies, such as Alzheimer’s, Parkinson’s, Huntington’s and prion
diseases1,2, and, more recently, also in biological functionalities3–5. These findings have
paved the way for a wide range of experimental and computational studies aimed at
understanding the details of the fibril formation mechanism. Computer simulations using
low-resolution models, which employ a simplified representation of protein geometry and
energetics, have provided insights into the basic physical principles underlying protein
aggregation in general6–8 and ordered amyloid aggregation9–15. For example, Dokholyan
and coworkers have used the Discrete Molecular Dynamics method16,17 to shed light
on the mechanisms of protein oligomerization18 and the conformational changes that
take place in proteins before the aggregation onset19,20. One challenging observation,
which is difficult to observe by computer simulations, is the wide range of aggregation
scenarios emerging from a variety of biophysical measurements21,22. Atomistic models
have been employed to study the conformational space of amyloidogenic polypeptides
in the monomeric state23–25, the very initial steps of amyloid formation26–32, and the
structural stability of fibril models33–35. However, all-atom simulations of the kinetics of
fibril formation are beyond what can be done with modern computers.
To overcome such computational limitations, simplified models have been developed
and used to investigate the kinetics and pathways of oligomerization and fibril formation
at different levels of resolution36. In this chapter we first review briefly the simplified
models of aggregation. We then present our coarse-grained phenomenological (CGF)
model of an amphipathic peptide37, and its use for studying kinetics and thermodynamics,
both in bulk conditions and in presence of other simplified (macro)molecules.
II. COARSE-GRAINED MODELS
In coarse-grained models, the complexity of a system (and therefore the computa-
tional cost) is reduced by grouping atoms into larger units or “beads”, whose mutual
interactions are usually approximated by a potential of mean force38. Several coarse-
grained models of different resolutions have been developed to study aggregation (see
Fig.1). Zhang and Muthukumar39 have created a cuboid model able of reproducing the
features of a nucleation-limited aggregation process. With their so-called “tube” model,
Auer and coworkers40 have shed light upon the conversion of a disordered aggregate into
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an aggregating nucleus. Higher resolution models like the one developed by Thirumalai
and collaborators41 or the PRIME model of Nguyen and Hall42 have also showed disor-
dered aggregates in the early steps of aggregation. Several aggregation scenarios have
been described with the three-bead model of Shea and coworkers43. In their model, the
variation of a parameter related to the dihedral flexibility is able to reproduce different
aggregation kinetics and metastable intermediates (amorphous and β-barrel like), which
is in part similar to the CGF model37. The main difference between the Shea and CGF
models is that the former is based on a coarse-graining from an atomistic description
(i.e., ”bottom-up” development), whereas the CGF model is purely phenomenological
(”top-down”) as explained in the next section.
III. THE CGF (COARSE-GRAINED PHENOMENOLOGICAL) MODEL
The coarse-grained model of an amphipathic peptide developed for studying aggre-
gation kinetics and thermodynamics is a compromise between mesoscopic detail and
computational efficiency. It must be stressed that this simplified model does not repre-
sent a particular protein sequence, i.e., it has not been generated by grouping into larger
beads the atomic structure of a given (poly)peptide. It rather was designed from scratch
for emulating the main experimental findings on fibril formation kinetics.
The peptide is approximated by 10 spherical beads, four of which represent the “back-
bone” (small beads) and six the “side chain” (large beads) (Fig. 2, top). The “backbone”
beads carry partial charges of ±0.4e, thereby generating two dipoles; this part of the
monomer is designed to interact specifically by intermolecular dipole-dipole interactions.
The large beads interact only by van der Waals forces. The non-bonding interaction cut-
off is set equal to 20 A˚. The monomer displays an amphipathic moment, since eight of the
ten beads have less favorable van der Waals interactions than the remaining two beads
(black spheres in Fig. 2, top). The amphipathicity of the “molecule” allows the forma-
tion of amorphous aggregate, such as micellar oligomers, and the assembly of fibrils. In
both of these types of aggregates, the hydrophobic spheres are buried and the hydrophilic
spheres are exposed. The micellar oligomers are spherical and fluid-like, while the fibrils
are ordered and rigid (see below).
The monomer can change its conformation by rotating around the internal dihedral
defined by the small beads (Fig. 2, bottom). Using a one-dimensional spline function44, a
dihedral potential was designed with only two minima separated by a barrier (see Fig. 3).
The only parameter that rules the relative populations of the amyloid-prone and amyloid-
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protected states is the energy difference dE = Epi − Eβ between the conformation with
perpendicular dipoles (Epi), which prevents ordered aggregation, and the conformation
with parallel dipoles, which is prone to form fibrils (Eβ). The use of a single parameter
to model a complex process was inspired by the work of Zhou and Karplus, who have
analyzed the folding kinetics of a model protein by varying a single parameter and shown
that it is possible to recover several folding scenarios45.
IV. AGGREGATION OF THE CGF PEPTIDE MODEL IN BULK SOLUTION
Unless specified explicitly, simulations are started from 125 monodispersed monomers
of the CGF peptide in a cubic box with a size of 290 A˚, corresponding to a concentration of
8.5 mM. After minimization and equilibration, simulations are performed with Langevin
dynamics at 310 K with a very small friction coefficient of 0.01 ps−1 using CHARMM46.
A. Aggregation kinetics and pathways
The range of aggregation kinetics of the CGF model is shown in Fig. 4, where the
normalized degree of polymerization as a function of time is plotted for different values
of the amyloidogenic propensity dE. The extent of aggregation is controlled by counting
the number of polar contacts: a polar contact is formed whenever two dipoles of different
monomers are closer than 5 A˚. Three different kinetic phases are visible: lag, elongation,
and final monomer-fibril equilibrium. The variable length of the lag phase and the higher
heterogeneity at longer lag times are indicative of a stochastic nucleation48. Fibril forma-
tion is much slower for the β-unstable models (dE = -2.5 and -2.25 kcal/mol) than the
β-stable models (dE = -1.0 and 0.0 kcal/mol). Both the lag phase and the elongation
kinetics are affected by the single free parameter dE of the CGF model. Interestingly,
the kinetics of aggregation are qualitatively consistent with the experimental data on
single-point mutants of Aβ40 (Ref.
49), which have shown that the β-sheet propensity and
hydrophobicity affect the features of the aggregation process. This comparison shows
that although the CGF model does not represent any particular polypeptide sequence,
variations of the single parameter dE emulate the behavior observed for (slightly) differ-
ent amyloidogenic sequences. Moreover, the anticorrelation between the length of the lag
phase and the rapidity of the fibril elongation has also been observed experimentally on
several samples prepared from amyloidogenic (poly)peptide sequences47.
The distribution function p(N) of the oligomer size N evaluated at the lag phase or
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at the final equilibrium is depicted in Fig. 5. The monomer peak ranges from N = 1 to
N = 7, the micellar peak from N = 8 to N = 60, and the fibrillar peak from N = 61
to N = 125. The micellar peak is present for the dE = -2.5 kcal/mol model at the lag
phase, but disappears at the final equilibrium, where the fibril and the monomers are the
only co-existing species. For the β-stable potential dE = 0.0 kcal/mol, the micellar peak
is not observed at any concentration value. Indeed, a comparison of the lag times with
the times of micelle formation (Fig. 6) shows that the fibril formation kinetics of the β-
unstable and β-stable models are, respectively, slower and faster than micelle formation.
In fact, micelles are intermediates consisting mainly of monomers in the pi state, whereas
the polymerization of β-stable monomers directly yields fibrils.
This observation is confirmed also by the analysis of aggregation pathways50. A total of
100 Langevin dynamics simulations for different values of dE were clustered according to
three progress variables: the size of the largest aggregate Nla, the number of monomers
in the β-state within the largest aggregate Nβla, and the number of protofilaments in
the largest aggregate Npfla , where a protofilament is defined as a file of monomers with
intermolecular dipolar interactions parallel with its axis. The aggregation state network
(Fig. 7) is a graph in which the states and direct transitions observed during the Langevin
dynamics simulations are displayed as nodes and links, respectively. Furthermore, the size
of each node reflects the statistical weight of the corresponding state. Micellar oligomers
(white nodes, Nla ∼ 20, Npfla =0) and fibrils (red nodes, Nla ∼ 100, Npfla =4) are the most
populated states during the lag phase and the final equilibrium, respectively. Strikingly,
a greater variety of aggregation mechanisms emerges for the poorly amyloidogenic CGF
peptide model (see Fig. 7, bottom) than the highly amyloidogenic CGF peptide model
(see Fig. 7, top). Indeed, the former shows the presence of intermediates, i.e., protofibrils
consisting of only two (green nodes) or three (blue nodes) protofilaments. According to
this analysis, it is reasonable to expect that a mutation that decreases the β-aggregation
tendency could result in a greater variety of prefibrillar aggregates, as in the case of
the Arctic mutant (E22G) of the Alzheimer’s Aβ peptide and the A30P mutant for α-
synuclein, for which a more pronounced in vitro formation of oligomers and protofibrils
was observed51,52.
B. Mechanism of nucleation
The nucleation properties of the CGF model are investigated by evaluating the prob-
ability of fibril formation for β-subdomains, i.e., the clusters of interacting β-monomers.
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The nucleus, defined as the oligomer containing a β-subdomain with a 50% probability
to form a fibril, shows an increasing size upon destabilization of the β-state. Significantly
different nucleation mechanisms are observed upon variation of the amyloidogenicity pa-
rameter dE (Fig. 8). For high values of the amyloidogenic propensity (−2.0 ≤ dE ≤ 0.0
kcal/mol), the nucleus size is sub-micellar, and nucleation is simply the aggregation of
monomers in the β-state. On the contrary, for poorly amyloidogenic peptides, nucleus
formation requires either spatial proximity of several monomers in the β-state (dE =
-2.25 kcal/mol) within a micelle or collision of two peptide micelles with merging of their
β-subdomains (dE = -2.5 kcal/mol). The variety of aggregation scenarios is also ob-
served experimentally. An unstructured peptide with a marginally stable β-prone state
like Aβ40 (Ref.
53,54) visits oligomeric intermediates in the lag phase, and has a very weak
dependence of the elongation rate on concentration due to the monomer-micelle equilib-
rium. This mechanism corresponds to the nucleated conformational conversion proposed
by Serio et al.55. On the other hand, a functional and non-pathological amyloid in mam-
malians56 lacks on-pathway intermediates and corresponds to the highly amyloidogenic
CGF peptide model. Once more, by varying the only free parameter dE of the CGF
model, it is possible to describe the aggregation properties of a wide and diverse range
of (poly)peptide sequences.
C. Concentration effects
The dE parameter of the CGF model has a strong influence on the concentration
dependence of the fibril formation kinetics. In agreement with the above-mentioned
mechanism of nucleation, CGF peptides poorly prone to aggregation nucleate only at
concentration values larger than the critical concentration of peptide micelle formation,
whereas CGF peptides with a high value of amyloidogenicity nucleate even at lower con-
centrations (Fig. 9, left). Furthermore, the dependence of the elongation rate on the
concentration is only marginal at low amyloidogenic tendency (Fig. 9 (b)). The reduced
concentration dependence originates from competitive polymerizations, i.e., the elonga-
tion of the fibril and the presence of micellar oligomers. This observation is a consequence
of the monomer-micelle equilibrium of the CGF peptide model, which maintains a nearly
constant concentration of isolated monomers57.
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D. Amyloid fibril polymorphism
Experiments based on electron and atomic force microscopy as well as solid-state
NMR spectroscopy revealed that changing the samples conditions, such as the pH59 or
the cosolvent concentration60, or introducing a mechanical perturbation61,62 results in
different amyloid fibril morphologies. Furthermore, even within the same sample, a num-
ber of coexisting morphologies can be detected59,63. Recently, it was observed that the
CGF peptide model is able to generate fibrils with distinct morphologies64. Interestingly,
the populations of the different morphologies are strongly and nontrivially influenced
by the amyloidogenic propensity dE, and two main mechanisms for fibril morphogenesis
emerge. When the CGF peptide is highly prone to aggregate (dE = -1.5, -2.0 kcal/mol),
the morphogenesis is under thermodynamic control, meaning that the morphology with
the highest stability will emerge with the highest probability. In contrast, when the
CGF peptide has a low amyloidogenic tendency (dE = -2.25, -2.5 kcal/mol), the fibril
morphogenesis is under kinetic control. The morphologies that nucleate more readily are
not necessarily the most stable ones, but those whose precursors are kinetically more
accessible, as revealed by the free energy profiles of the fibrillation64. For the low amy-
loidogenic scenario, the process of morphology differentiation can be represented by a
branched tree (Fig. 10). During the lag phase, the micellar oligomers are in equilibrium
with the dispersed monomers. The early morphology differentiation occurs at the nu-
cleation step, where the formation of the protofibrillar intermediates is regulated by the
structural bifurcation of the nucleus. The 2PP and 3PP1 intermediates are competent
to 4PF1 fibrils, while the 3PP2 intermediate is competent to 4PF2(+,-) fibrils. Alterna-
tively, the presence of 3PP2+ and 3PP2- intermediates that are directly competent to
4PF2+ and 4PF2- fibrils, respectively, has been observed, although these pathways were
not quantitatively analyzed. Finally, the pathway of formation of 4PF3 fibrils was not
investigated in detail, due to the small number of nucleation events of this morphology.
The multiple-pathways process observed here has a close similarity with the scenario
described by Goldsbury et al.65, where two different morphologies of Aβ have distinct
maturation pathways, either with or without the presence of metastable protofibrils.
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V. AGGREGATION IN THE PRESENCE OF LIPID VESICLES AND INERT
CROWDERS
Amyloid aggregation in vivo does not occur in bulk solution. Rather, it takes place in
the extracellular space, whose composition includes metabolites and proteins, or within
the cell, which is usually densely occupied by (macro)molecules like proteins, nucleic acids,
and polysaccharides, as well as macromolecular assemblies and organelles66. Several
research groups have investigated the interactions between lipid vesicles and amyloid
aggregates67–69, whose accumulation on the surface of lipid bilayers was observed to cause
membrane damage. Aggregation has also been studied in crowded media70–72, where the
thermodynamics and kinetics of aggregation are expected to sensibly change.
A. Effect of lipid bilayers on CGF peptide aggregation
A three-bead model of a lipid molecule has been developed to study the CGF peptide
model aggregation kinetics in the presence of a lipid vesicle73,74. Several independent
Langevin simulations at 310 K have been performed for four values of dE with 125
peptides initially monodispersed in a cubic box of length 290 A˚ and a preequilibrated
unilamellar bilayer vesicle made up of 1000 lipids. Depending on the lipid/peptide van
der Waals coupling parameter λ, between 50% and 80% of the CGF peptides are located
on the lipid vesicle surface after the initial equilibration phase, i.e., before fibril formation
(Table 1).
The effect of lipid bilayers on aggregation kinetics for different values of amyloidogenic-
ity is reported in Table 2. Highly amyloidogenic peptides fibrillate more rapidly in the
presence of lipid vesicles than in their absence, while the opposite is observed for peptides
of low amyloidogenicity. The faster aggregation kinetics of highly amyloidogenic peptides
is a consequence of their higher effective concentration on the lipid bilayer relative to the
bulk. In contrast, despite the same increase of peptide concentration on the vesicle sur-
face, fibrillation of peptides with low amyloidogenic propensity is slower in the presence of
lipid vesicles. As mentioned in section III, peptides with low amyloidogenic potential can
fibrillate only after aggregating into spherical oligomeric intermediates with hydrophobic
interior and hydrophilic surface. In the simulations with lipids, such oligomeric interme-
diates form in the bulk but not on the vesicle. Fibrillation of low amyloidogenic peptides
therefore takes place in the bulk and is slower than in the absence of a vesicle due to
the lower effective concentration of peptides in the solvent. These simulation results are
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consistent with and explain the apparently contradictory experimental observations on
faster aggregation of the Aβ(Ref.68) or α-synuclein75 peptides in the presence of lipid sur-
faces and slower aggregation of insulin (which has lower amyloidogenicity)76, and have
been confirmed by recent studies on the aggregation properties of human islet amyloid
polypeptide hIAPP1−19 in presence of lipid vesicles77.
To investigate the influence of the CGF peptides on the lipid bilayer, the simulations
were initiated with 20 spherical probes inside the vesicle. It was observed that leakage
from the lipid vesicle is enhanced during fibril formation but not by the mature fibril73.
More precisely, a comparison between the fibrillation and probe release rates (Fig. 11,
left) revealed that probe release is fastest during fibril growth, whereas the kinetics of
probe release in the presence of mature fibrils is as slow as in the absence of peptides,
indicating that mature fibrils do not damage the integrity of the vesicle. Rather, the
ongoing process of aggregation on the vesicle results in bilayer surface defects. This
observation explains why for some amyloidogenic peptides there exist mutants that form
fibrils more rapidly and are more toxic than the wild-type peptides, even though their
fibrils are not toxic78. Moreover, these computational results are in agreement with the
experiments performed by Engel et al. on membrane damage caused by human islet
amyloid polypeptide fibril growth69 (Fig. 11 right).
It has also been hypothesized that formation of toxic oligomers that induce membrane
leakage could be the result of a backward production of oligomers from the mature fibril79.
Interestingly, by modulating the attraction between the CGF peptides and the membrane,
fibril disaggregation into soluble backwards oligomers has been observed74. The disag-
gregation process is driven by entropy and results in soluble protofibrillar oligomers. The
protofibrillar oligomers are larger, more ordered, and more stable than those observed
during the aggregation process and, importantly, are not detected in disaggregation sim-
ulations carried out in bulk solution, i.e., in the absence of lipid vesicles.
B. Effect of surfactants on CGF peptide aggregation
Surfactant molecules have been modeled using a similar three-bead model as that
used for lipids. The surfactant model differs from lipid models used previously in two
parameters (Table 1): the minimum of the van der Waals energy of the two hydrophobic
beads is less favorable, and the radius of the hydrophilic bead is larger to enable the
formation of amorphous aggregates. Using these parameters, the surfactant solution
is not dominated by a micellar phase. Rather, the surfactants are organized either as
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dispersed monomers or disordered aggregates80.
In the absence of surfactants, all peptide models form fibrils within 1 µs without any
discernible lag phase (Fig. 12, dotted lines). At a surfactant:peptide ratio of 8:1, the fibril
formation kinetics of peptides with dE = -1.5 kcal/mol are almost unaffected, whereas
already at a ratio of 4:1 the ordered self-assembly of peptides with dE < -2.0 kcal/mol is
significantly slower (Fig. 12, solid lines) mainly because of a longer lag phase. Moreover,
for low-amyloidogenic peptides (dE ≤ -2.0 kcal/mol) no fibrillation is observed within
the simulation length of 2 µs at a surfactant:peptide ratio of 8:1, but instead oligomers
of ∼ 40 peptides form. These simulation results show that at a 4-fold molar excess of
surfactant, the inhibition of fibrillation already depends strongly on the amyloidogenicity
of the CGF peptide model.
C. Macromolecular crowding effect on CGF peptide aggregation
Simulations with the CGF peptide model together with softly repulsive spheres have
been carried out to assess the influence on the aggregation kinetics of excluded volume
and hindered peptide diffusion due to macromolecular crowding 81. As in the case of
lipid-bilayer vesicles, the net effect of macromolecular crowding crucially depends on
the amyloidogenicity tendency of the CGF peptide. For peptides with low aggregation
propensity, the self-association process is transition-state limited, where the kinetic bot-
tleneck is the formation of the fibril nucleus. In this case, since the oligomers, including
the nucleus, are thermodynamically favored (with respect to the isolated monomers) by
the excluded volume effect, macromolecular crowding accelerates peptide assembly and
has an effect analogous to that of an increase in peptide concentration (Fig. 13, left).
This trend is analogous to that observed experimentally by Munishkina et al., who have
studied the effect of increasing the PEG concentration on the α-synuclein aggregation
process71.
On the other hand, when the aggregation mechanism is fast and proceeds directly from
monomers to fibril, the process is diffusion limited, and the thermodynamic stabilization
of oligomers is less important than the reduction in peptide mobility. In this case, the
bottleneck is not the formation of the nucleus; the rate-limiting step for peptides that
show a direct aggregation mechanism is the elongation of the fibril. Therefore, in this
case macromolecular crowding is much less efficient in accelerating the self-association of
peptides than an equivalent increase in peptide concentration, since the peptides diffusion
is hindered by the crowders (Fig.13, right).
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VI. CONCLUSION
Atomistic simulations of aggregation are limited by short time scale, while experimen-
tal approaches to amyloid fibril formation have insufficient spatial resolution. Coarse-
grained models of polypeptide aggregation sacrifice atomistic detail to reach timescales
that allow the comparison with and interpretation of experimental data. The models pre-
sented in this chapter have shed light upon amyloid aggregation kinetics and mechanisms,
which is helpful to formulate a unified picture of the available experimental data.
The CGF model has only one tunable parameter, the difference dE between the energy
of the amyloid-competent and the amyloid-protected state of the monomer37. Variations
of this parameter reproduce several aggregation scenarios, both under homogeneous and
heterogeneous conditions. It is important to highlight that the CGF model does not
mimic any particular amyloid (poly)peptide sequence. However, the different aggrega-
tion kinetics obtained with this model can be directly compared with experiments carried
out with specific proteins. In Table 3 are reviewed the principal characteristics of the
aggregation process for both the high and low amyloidogenic tendency, and in both cases
several examples of real amyloid-forming (poly)peptide sequences are listed. It is im-
portant to note that (coarse-grained) simulations, e.g., those with the CGF37 and Shea43
models, allow for the emulation of conditions and/or phenomena that are not accessible by
(standard) experiments. As an example, the possibility to change solely the intrinsic con-
formational landscape of a monomer without affecting the inter-monomer interactions is
an advantage of the (coarse-grained) simulation methods with respect to conventional ex-
perimental techniques such as mutagenesis and solvent-induced conformational changes,
by which it is not possible to decouple changes in intra from inter-molecular interactions.
In conclusion, a slight modification of the free energy profile of an extremely simpli-
fied model of an amphipathic peptide is sufficient to observe a wide range of different
fibril formation mechanisms, providing a unifying description of the heterogeneity of the
experimentally observed kinetics of amyloid fibril formation.
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Fraction of
CGF peptides
Type of Rhydrophilic Rhydrophobic hydrophilic hydrophobic λ
a bound to Reference
molecule [nm] [nm] [kcal/mol] [kcal/mol] lipid vesicles
lipid 0.31 0.3 -0.1 -1.265 0.87-0.90 50% 73
lipid 0.31 0.3 -0.1 -1.265 0.95 80% 74
surfactant 0.35 0.3 -0.1 -0.8 1 80
TABLE 1. Three-bead lipid and surfactants models used with CGF peptide model. aScaling
factor for the vdW interactions between lipids or surfactants and peptides. Different scaling is
used to model different systems, i.e., surfactants (λ = 1), moderately attractive (λ ≤ 0.9) and
strongly attractive (λ ≈ 0.95) lipid bilayers.
Scaling of Number of Lag time t50 [ns]
peptide/lipid Amyloido- runs with with without
interactions genicity fibril formation membrane membrane
0.87 high 10/10 11 ± 1 19 ± 3
interm. 29/29 89 ± 29 56 ± 15
low 17/20 958 ± 503 124 ± 28
very low 0/10 > 2000 318 ± 133
0.90 high 10/10 10 ± 1 19 ± 3
interm. 30/30 69 ± 23 56 ± 15
low 0/20 > 2000 124 ± 28
very low 0/20 > 2000 318 ± 133
TABLE 2. Characteristic lag time of aggregation t50 for CGF peptide model for different
amyloidogenic tendency in the presence or absence of lipid vesicles73. Values in boldface are
significantly larger in the presence of the vesicles
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high amyloidogenicity low amyloidogenicity Ref.
small nucleus large nucleus [37]
fast fibril formation slow fibril formation [37]
downhill micellar intermediates [37]
no intermediates protofibrillar intermediates [50]
single pathway multiple pathways [50]
strong concentration dependence growth rate marginally dependent on concentration [37]
polymorphism under thermodynamic control polymorphism under kinetic control [64]
can promote membrane leakage does not promote membrane leakage [73]
slightly accelerated by membranes decelerated by membranes [73]
marginally influenced by surfactants decelerated by surfactants [80]
not accelerated by macromolecular crowding accelerated by macromolecular crowding [81]
Phe-Phe, GNNQQNY, transthyretin, Aβ42 Aβ40, Sup35, prion protein, myoglobin -
TABLE 3. Influence of amyloidogenic propensity on the aggregation kinetics and pathways of
the CGF model37. The last line lists some examples but it must be stressed that amyloidogenic
tendency strongly depends on external conditions, so that the same polypeptide sequence can
show drastically different amyloidogenic tendency depending on pH, temperature, etc.
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a)     b)     c)
d)     e)     f )
κ
Low β-sheet
propensity
High β−sheet
propensity
FIG. 1. Main coarse-grained models discussed in section II. a) Cuboid model39; b) tube model40;
c) lattice model41; d) CGF model37; e) Shea model43; f) Hall model42. Reprinted from36 with
permission by Elsevier.
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FIG. 2. The CGF model: sticks and beads representations of the monomer in the amyloid-
competent state β and the amyloid-protected state pi37. The large spheres are hydrophobic
(black) and hydrophilic (gray), while the two dipoles are shown with small red and blue spheres.
The size of the spheres does not represent the actual van der Waals radii, which are 2.5 A˚ for
the black and gray spheres and 2.0 A˚ for the red and blue spheres. The β and pi states of
the monomer are shown on top of the two corresponding minima of the free energy, plotted
as a function of the dihedral angle φ of the two dipoles. Reprinted from50 with permission by
Elsevier.
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FIG. 3. The dotted line is the dihedral potential with a dE = -2.5 kcal/mol energy difference
between amyloid-protected and amyloid-competent state. The five continuous lines represent
the free energy profile of the isolated monomer for five different dihedral potentials. Since the
peptide has only one degree of freedom, dE is close to the free-energy difference between the two
aforementioned states. For instance, when dE = 0.0 kcal/mol, the pi and β states are equally
populated, whereas for dE = -1.5, -2.0, and -2.25 kcal/mol, the pi state is about 15, 39, and
64 times more populated than the β state, respectively. Reprinted from37 with permission by
Elsevier.
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FIG. 4. Influence of amyloidogenic tendency on aggregation kinetics. (Left): Time series of the
fraction of ordered aggregation evaluated at four values of the amyloidogenic tendency, from
very prone to form fibrillar aggregates (dE = 0.0 kcal/mol) to marginal propensity (dE = -2.5
kcal/mol). Ten independent simulations are shown for each dE value. (Right): Fluorescence
intensity (degree of aggregation) of V18I (a), V18Q (b) and V18P (c) mutants of Aβ40 (Ref.
49).
Note that the ns-µs timescales in the CGF model simulations are much shorter than in the
experiments (hours) because of the much higher concentration in the former (8.5 mM) than in
the latter (120 µM). Reprinted from37 (left) and49 (right) with permission by Elsevier (left) and
Jon Wiley & Sons (right).
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FIG. 5. Oligomer size histograms of the dE = -2.5 kcal/mol potential (top) and dE = 0.0
kcal/mol (bottom) calculated at the lag phase (left) and at the final equilibrium (right). The
z-dimension represents the relative probability. Note that most of the results were obtained at
a concentration C = 8.5 mM which is the lowest value at which fibril formation takes place
within a reasonable simulation time for the dE = -2.5 kcal/mol model (10 µs in about 17 days
on a single Xeon 5410 processor). Reprinted from37 with permission by Elsevier.
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FIG. 6. Influence of the amyloidogenicity parameter dE on the kinetics of the CGF model. The
time needed to reach 50% of the maximal amplitude t50 (black circles and y-axis legend on the
right) and the elongation rate (red squares and y-axis legend on the left) are displayed for seven
dE values. Symbols represent the average value of ten independent runs, and the error bars are
the maximum and minimum values. The broken line and the gray band indicate the average
and the maxmin values for the time of micelle formation, respectively. Reprinted from37 with
permission by Elsevier.
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FIG. 7. Aggregation state network. The size of the largest aggregate Nla and its number
of protofilaments Npfla were used to cluster all simulation snapshots into states (i.e., nodes
of the network). The size and the colour of nodes correspond to the statistical weight and
the number of protofilaments Npfla , respectively. Links are direct transitions within 0.5 ns of
Langevin dynamics. Note the much higher heterogeneity of protofibrillar intermediates for the
β-unstable (dE = -2.5 kcal/mol, bottom) as compared to the β-stable (dE = -1.5 kcal/mol,
top) model. The insets show (proto)fibrillar structures that are representative of each region
of the aggregation state network. In these structures, monomers in the amyloid-competent
conformer β and amyloid-protected conformer pi are in red and blue, respectively. Furthermore,
hydrophobic spheres are gray and hydrophlic spheres are not shown for visual clarity. Reprinted
from50 with permission by Elsevier.
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FIG. 8. Observed nucleation scenarios of the CGF peptide model. Black and white circles
represent the amyloid-competent conformer β and amyloid-protected conformer pi, respectively.
CGF peptides with high values of amyloidogenic tendency nucleate without intermediates, while
poorly amyloidogenic CGF peptides can nucleate either through micelle-sized oligomers (dE =
-2.25 kcal/mol) or transient oligomers larger than a micelle (dE = -2.5 kcal/mol). A further
stabilization (dE = -2.75 kcal/mol) of the protected state prevents fibril formation within
the simulation time of about 20 µs. M, micelle; N, nucleus; T, transient oligomer; F, fibril.
Reprinted from37 with permission by Elsevier.
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FIG. 9. Influence of peptide concentration on aggregation kinetics. (Left) Effect of concentration
on the lag phase time t50 (a) and elongation rate (b) for low and high values (dE = -2.5
kcal/mol, black circles; dE = 0.0 kcal/mol, green squares, respectively) of the amyloidogenic
tendency. The symbols represent the average value calculated from 15 simulations for dE
= -2.5 kcal/mol and ten simulations for dE = 0.0 kcal/mol. The error bars represent the
minimum and the maximum values. The vertical dotted line indicates the critical concentration
of micelle formation. (Right) Influence of the initial monomeric concentration on the kinetics
of insulin fibril formation as measured by Thioflavin T fluorescence58. Note that the higher
the concentration of monomeric insulin is at the beginning of the experiments, the shorter is
the lag phase and the faster is the elongation rate. Reprinted from37 (left) and58 (right) with
permission by Elsevier (left) and American Chemical Society (right).
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FIG. 10. Morphology differentiation and kinetic control of fibril polymorphism. (Left) Mor-
phologies of mature fibrils and prefibrillar species. (Top) Mature fibrils display a 4-protofilament
structure (4PF). The 4PF morphologies have different orientation of the protofilaments, orga-
nization of up and down protofilaments, and thickness of the fibril. (Bottom) The prefibril-
lar species are: the micellar oligomers M, consisting of pi-monomers (blue beads) aggregated
through hydrophobic forces; the 2-protofilament protofibril (2PP), and the 3-protofilament
protofibril (3PP), which are early stages of fibril maturation, where the pi-monomers are de-
posited onto the lateral surface of the fibril, and the β-monomers make up the protofilaments
(colored ribbons). (Right) Branched tree illustration of the morphology differentiation pro-
cess as observed in the simulations. Reprinted from64 with permission by American Chemical
Society.
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FIG. 11. Comparison of CGF model simulations and experimental data on fibril formation
in the presence of lipid vesicles. (Left) Simulation results. (Left, top) Influence of peptide
amyloidogenicity on fibril growth kinetics and vesicle leakage. A single parameter, the energy
difference between amyloid-competent and amyloid-protected conformations of the peptides, is
varied in different simulations to tune amyloidogenicity. Time series of the average number of
ordered polar contacts between monomers (corresponding to the degree of fibrillation). (Left,
bottom) Average number of probes inside the vesicle, in the absence (black) or presence (colors)
of peptides, and for simulations where a preformed fibril was used instead of dispersed peptides.
(Right) Experimental data: Effect of human islet amyloid polypeptide (hIAPP) fibril growth on
membrane leakage69. Thioflavin T fluorescence intensity (Right, top) and induced membrane
leakage (Right, bottom) of three hIAPP samples (black curves), together with representative
traces for mouse IAPP variant which is known to be non-toxic amyloid polypeptide (gray
lines) and preformed hIAPP fibrils (dashed lines) are shown. The two vertical lines are shown
to facilitate comparison of the kinetic traces in top and bottom panel. Reprinted from73 (left)
and69 (right) with permission by Elsevier and by Copyright 2008 National Academy of Sciences,
U.S.A., respectively.
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FIG. 12. Amyloid aggregation in the presence and absence of surfactants. The number of
peptides in the largest aggregate is averaged over 20 runs at each simulation condition, i.e., for
each value of aggregation propensity (dE) and each surfactant/peptide concentration ratio (s:p).
Free peptides display fast aggregation without any noticeable lag phase. At surfactant:peptide
ratio of 4:1, peptides aggregate into fibrils, but aggregation is much slower for peptides with low
amyloidogenicity (see the inset for dE = -2.25 and surfactant:peptide ratio of 4:1, extended to 8
µs). At a surfactant:peptide ratio of 8:1, aggregation is completely inhibited for dE = -2.0 and
-2.25 kcal/mol, while highly amyloidogenic peptides (dE = -1.5 kcal/mol) are barely affected.
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FIG. 13. The deviation of aggregation kinetics between crowded and bulk conditions depends
on the amyloidogenicity. The time t50, at which the growing fibril has reached 50% of the
polar contacts of the mature fibril, is shown as a function of concentration. Black circles are
t50 values calculated at different peptide concentrations in the absence of crowders, while red
squares are t50 values at different equivalent concentrations Ceq obtained by varying the number
of crowders. Symbols represent the average value of 10 independent runs and the error bars are
the minimum and maximum values. Reprinted from81 with permission by American Chemical
Society.
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ABSTRACT Biological protein self-assembly occurs in the cellularmilieu, densely
occupied by other macromolecules which do not participate directly in the
aggregation process. Excluded volume effects arising in such a crowded environ-
ment deeply affect the thermodynamics and kinetics of biological processes, like
protein folding, ligand binding, and protein aggregation. Here, Langevin dynamics
simulations of a simplified model of an amphipathic polypeptide are used to
investigate how macromolecular crowding influences the amyloid aggregation
kinetics. The simulations show that the net influence ofmacromolecular crowding
on the self-assembly process is the result of two competing effects: oligomer
stabilization and solution viscosity increase. Notably, the net effect crucially
depends on the aggregation propensity and pathways. Therefore, comparative
studies of concentration and crowding effects on the kinetics of amyloid aggrega-
tion could shed light on the underlying self-assembly mechanism.
SECTION Biophysical Chemistry
A myloid fibrils are ordered polypeptide aggregates thathave been related to several neurodegenerative patho-logies, such as Alzheimer's, Parkinson's, Huntington's
and prion diseases,1,2 and, more recently, also to biological
functionalities.3,4 These findings have paved the way to a
wide range of experimental and computational studies
aimed at understanding the details of the fibril formation
mechanism.
Most of these investigations were usually performed in
ideal homogeneous conditions, though the actual cellular
milieu is amuchmore complex environment. Several studies
have pointed out the effects of geometric confinement on
fibril formation and protein folding.5,6 A universal property of
the cells is that they are crowded.7,8 Indeed, it has been
estimated that 20-30% of the cell cytoplasm is occupied by
proteins, RNA, membranes, polysaccharides, and several
organelles.9 Although the concentration of every species
is low, these macromolecules exclude a significant fraction
of the total available volume.10 The nonspecific excluded
volume effect is expected to sensibly affect all biological
reactions in which proteins are involved.11 Using scaled
particle theory,12 Minton and Ellis have predicted that macro-
molecular crowding dramatically increases the association
rate of proteins and the relative stability of the unfolded and
native state.13,14 Computational studies have shown that the
presence of inert, repulsive cosolutes stabilizes the native,
compact state of proteins15,16 and that the presence of nano-
particles is able to catalyze amyloid aggregation.17 Experi-
ments18-21 conducted with large and weakly interacting
macromolecules such as polyethyleneglycol (PEG) and Fycoll
have confirmed these theoretical predictions, showing that the
excluded volume effect is able tomodify the subtle equilibrium
between the folded, functional state and aberrant structures
prone to aggregation.
Earlier, a very simple coarse-grained model of an aggrega-
tion-prone, amphipathic peptidewas developed to investigate
the kinetics of ordered aggregation.22 The peptide monomer
has a single degree of freedom, and the relative free-energy
profile has only two minima, corresponding to the aggrega-
tion-prone and aggregation-protected states. By varying
a single parameter of the model, that is, by reducing the
β-aggregation propensity, the roughness of the free-energy
landscape and the heterogeneity of the fibril elongation
pathway increase. In previous simulation studies, heteroge-
neous kinetics of aggregation and multiple pathways were
observed in bulk solution and in the presence of lipid
bilayers. At high amyloidogenic conditions, the process of
fibril formation is downhill and fast, whereas at low amyloi-
dogenic conditions, several intermediates are detected, and
the nucleation occurs through a micellar oligomer.23 It has
also been pointed out that amyloidogenicity determines the
effect on peptide aggregation of the presence of lipid bilayer;
while aggregation-prone peptides fibrillate faster by adsorbing
on the bilayer surface, the ordered self-assembly of poorly
amyloidogenic peptides is hindered by the vesicles.24,25 In this
work, a spherical model of softly repulsive crowders is used,
together with the simple model of the amphipathic peptide, to
investigate amyloid aggregation kinetics at different concen-
trations of crowders. It is found that the influence of the
crowders has apronounceddependence on the amyloidogenic
tendency of the peptide.
The simulations were performed with 125 peptides and
a number of softly repulsive crowders ranging from 250 to
5000 (see Methods and Table 1). Snapshots of the simulation
Received Date: July 16, 2010
Accepted Date: September 12, 2010
rXXXX American Chemical Society 3028 DOI: 10.1021/jz100967z |J. Phys. Chem. Lett. 2010, 1, 3027–3032
pubs.acs.org/JPCL
systemwith a low (nC = 250) and high (nC = 3000) number
of crowders are shown in Figure 1.
To compare crowding effects with an increase in peptides
concentration, simulations in the absence of crowders with
125 peptides and a progressively decreasing volume of the
simulation box (yielding peptide concentrations ranging from
8.5 to 61.5 mM) were also carried out. For each of these
conditions, multiple runs were started (with different initial
velocities) for each of four values of the amyloidogenicity (i.e.,
dE = -2.5, - 2.25, - 2.0, and -1.5 kcal/mol; see Methods
for details) to investigate the dependence on the aggregation
propensity. The temperature in all simulations was 310 K.
Crowders Effect on Lag Phase. Supercritical oligomers are
assemblies whose size is larger than the nucleus, where the
nucleus is defined as the oligomer that has a 50% probability
to form a fibril22 (see Methods and Table S1 (Supporting
Information) for details). To specifically assess how macro-
molecular crowding influences the nucleation kinetics, the
number of supercritical oligomers has been calculated as a
function of time along each simulation (Figure 2). During the
lag phase, the number of oligomers of supercritical size is
roughly zero, that is, only small oligomers or monomers are
present in the system,while for long time, only one aggregate,
which corresponds to the mature fibril, is present. At inter-
mediate times, the number of oligomers of supercritical size
can be higher than one when two or more elongating fibrils
are present simultaneously in the simulation box. To directly
compare the effect of peptide concentration and macromole-
cular crowding, the equivalent concentration Ceq, defined as
the ratio between the number of peptides and the volume
unoccupied by crowders (seeMethods), is introduced. Concen-
tration increment andmacromolecular crowding have sensibly
different effects. They both increase the average number of
supercritical oligomers at intermediate times, but the concen-
tration also accelerates the nucleation step (corresponding to
the shift of the peak toward shorter times in the time series in
Figure 2, left), while the crowding has amuch less pronounced
influence on the nucleation step because the decrease in
peptide diffusivity limits monomer encounters.
The mean first appearance of a supercritical oligomer tN*
reports on the length of the lag phase. Crowding and concen-
tration effects yield similar lag phases only for the peptide
model with the lowest amyloidogenicity (Figure 3, left). On
the contrary, for themore amyloidogenic peptidemodels, the
lag phase becomes shorter by raising the concentration while
it is only marginally influenced by the crowder content
(Figure 3, right).
Crowders Effect on Oligomers Stability. To interpret the
kinetics at low dE, it is useful to investigate the stability of
oligomers that are competent to fibril nucleation and are
explored during the lag phase. Thepresenceof a large amount
of inert macromolecules that exclude volume to peptides
favors association.14 Since oligomers are more compact than
an equivalent amount of dispersed monomers, they are
thermodynamically stabilized by an increase of excluded
volume. Therefore, to study the thermodynamic properties
of themetastable oligomers that appear during the lag phase,
multiple simulations were carried out at different crowder
Table 1. Excluded Volume Fraction (φ), Equivalent Concentration
(Ceq=8.5mM /(1- φ)), and Peptide Self-Diffusion Coefficient (D )
at Different Crowder Contents nC
a
nC φ Ceq (mM) D (Å
2/ps)
250 0.066 9.10 1835
500 0.13 9.77 1765
1000 0.25 11.3 1435
1500 0.36 13.3 1234
2000 0.46 15.8 1075
2500 0.56 19.1 910
3000 0.64 23.4 779
3500 0.71 29.2 686
4000 0.77 37.1 617
4500 0.82 48.2 547
5000 0.87 64.2 498
aSee the Methods section for details.
Figure 1. Snapshots of simulation systems at low (nC = 250, left)
and high crowder concentrations (nC = 3000, right). Peptides are
shown in a stick model in cyan, while crowders are black spheres.
Figure 2. Peptide concentration but not crowder content accel-
erates the nucleation step. Average number of supercritical oligo-
mers (i.e., with size larger than the nucleus aggregation number
N*) as a function of simulation time. Each curve is an average over
10 runs. The size N* of the nucleus increases upon destabilization
of the amyloid prone state (see Table S1, Supporting Information).
(Left panels) Different colors represent different peptide concen-
trations, ranging from (black) C=8.5 to (cyan) 61.5mM. Note that
the y-axis range is different for the top plot. (Right panels) Diffe-
rent colors represent different crowder contents, ranging from
(black) nC = 250, Ceq = 9.1 to (orange) nC = 5000, Ceq = 64.2.
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concentrations with 125 peptides with a stable aggregation-
protected state (dE = -3.5 kcal/mol). This value has been
chosen to inhibit the fibril nucleation but not the oligomer
formation. The distribution of oligomer sizes at different
crowder concentrations shows that larger oligomers are
stabilized by the excluded volume effect, which is propor-
tional to the amount of crowders (see Figure 4). Therefore,
macromolecular crowding stabilizes oligomers, but it does so
less than an equivalent increase of peptide concentration. It
has been shown experimentally that oligomeric intermedi-
ates can be stabilized significantly by macromolecular
crowding.19 In this context, it is likely that if off-pathway
oligomers are present in the aggregation mechanism, the
aggregation kinetics will be slowed down by crowding. Such
an effect is not observed because off-pathway oligomers
cannot be reproduced by the simple model used in this
simulation study.
Crowders Effect on Fibril Formation Kinetics. Macromole-
cular crowding is more effective for the less aggregating
peptides (dE = -2.5 kcal/mol), for which the time needed
to establish half of the number of polar contacts present in the
mature fibril (t50) diminishes by anorder ofmagnitude at high
excluded volume fractions (Figure 5). This trend is analogous
to that observed experimentally by Munishkina et al., who
have studied the effect of increasing thePEG concentration on
the R-synuclein aggregation process.18 Note that the time tN*
(shown in Figure 3) reports on the lag phase, while t50 is a
mixed measure of both the lag phase and the inverse rate of
elongation. Specifically, the t50 is dominated by the lag phase
for low amyloidogenic peptide models because the nucleus
size contains almost as many monomers as half of the final
fibril. In contrast, it mainly reflects the inverse rate of elonga-
tion forhighamyloidogenicity potentialswhosenucleus size is
very small.
The effect ofmacromolecular crowding is less pronounced
for the more aggregating peptides, for which the t50 values
reach a plateau already at low crowder content. Interestingly,
for thepeptidemodelswith lowaggregation propensity (dE=
-2.5,- 2.25 kcal/mol), the effect of macromolecular crowd-
ing and peptide concentration is similar (Figure 5, left). In
contrast, for peptidesmore prone to aggregation (dE=-2.0,
- 1.5 kcal/mol), the acceleration of self-assembly promoted
Figure 3. Time of appearance of the first supercritical oligomer
tN*. Black circles are tN* values calculated at different peptide
concentrations without crowders, whereas red squares are tN*
values at different equivalent concentrations Ceq obtained by
varying the number of crowders (see Table 1). Symbols represent
the average value of 10 independent runs, and the error bars are
theminimum andmaximum values. Note that the two data points
at highest peptide concentration (black circles) in the right panel
do not have an error bar as the first supercritical oligomer
appeared within the first coordinate saving interval of 0.5 ns.
Figure 4. The increase in oligomer size is more pronounced for
higher peptide concentration than that for higher crowding con-
tent. Oligomer size distribution, evaluated for dE=-3.5 kcal/mol,
at different values of the crowder content and peptide concentra-
tion. The red curve in each plot corresponds to C=8.5 mM (nC =
0), while the blue curves correspond to the highest values of
concentration (C = 61.5 mM and Ceq = 64.2 mM in the left and
right panel, respectively). The frequencyof the isolatedmonomers
ranges from0.64 to0.12 and 0.64 to 0.31 on the left and right plots,
respectively, and is not shown to avoid compression of the
oligomeric peak.
Figure 5. Differences in aggregation kinetics upon raising the
peptide concentration or crowder content depend on amyloido-
genicity. The time t50 at which the growing fibril has reached 50%
of the polar contacts of the mature fibril is shown as a function of
concentration. Black circles are t50 values calculated at different
peptide concentrations in the absence of crowders, while red
squares are t50 values at different equivalent concentrations Ceq
obtained by varying the number of crowders (see Table 1). Sym-
bols represent the average value of 10 independent runs, and the
error bars are the minimum and maximum values.
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by the crowders is much smaller than that caused by an
equivalent increase in peptide concentration (Figure 5, right).
Moreover, this discrepancy grows by increasing the aggrega-
tion propensity (i.e., at higher dE) and is similar to the one
previously observed in the trend of the tN* for different
values of dE (see Figure 3). The different effects of crowders
and peptide concentration have not been observed pre-
viously. It would be interesting to validate them by kinetic
measurements on peptides that aggregate very fast like
diphenylalanine.26
TwoMain Scenarios of Aggregation. The aggregation kinetics
of a simple model of an amphipathic peptide have been
investigated at different concentrations of inert crowders. The
excluded volume effect stabilizes larger oligomers (Figures 2
and 4). However, at high crowder content, the solution be-
comes more viscous (Figure S1, Supporting Information), and
the peptide mobility decreases because each monomer is
locally confined by the crowders (see Table 1). The confine-
ment decreases the rate of monomer encounters and, there-
fore, association (Figures 3 and 5). Twomain scenarios emerge
from the present simulation study.
For peptides with low aggregation propensity, the self-
associationprocess is transition-state-limited,where the kinetic
bottleneck is the formation of the fibril nucleus. In this case,
since the oligomers, including the nucleus, are thermodynami-
cally favored (with respect to the isolated monomers) by the
excluded volume effect,macromolecular crowding accelerates
peptide assembly and has an effect analogous to that of an
increase in peptide concentration (Figure 5, left).
On the other hand, when the aggregation mechanism is
fast and proceeds directly from monomers to the fibril, the
process is diffusion-limited, and the thermodynamic stabiliza-
tion of oligomers is less important than the reduction in
peptide mobility. In this case, the bottleneck is not the
formation of the nucleus; the rate-limiting step for peptides
that showadirect aggregationmechanism is the elongation of
the fibril. Therefore, in this case, macromolecular crowding is
much less efficient in accelerating peptide self-association
than an equivalent increase of the peptide concentration
since the peptides motion is hindered by the crowders
(Figure 5, right). The very different relative influence of
crowders and concentration observed in the simulations is a
new finding which suggests that kinetic experiments at
different crowder contents might discriminate between dif-
ferent mechanisms of aggregation, that is, downhill from
barrier-limited.
METHODS
Peptide Model. The amphipathic peptide model adopted
here has been described in detail elsewhere.22 Briefly, each
peptide monomer consists of 10 beads. Four of the beads
carrypartial charges of(0.4e, therebygenerating twodipoles.
Four of the uncharged spheres are hydrophilic, and the other
two are hydrophobic. Interactions between monomers de-
pend on van der Waals and electrostatic forces. The former
approximate both steric and hydrophobic effects, while the
latter are specific dipole-dipole interactions responsible for
the ordered stacking of monomers incorporated in the fibril.
A parallel polar contact is formed whenever two charged
beads of different monomers are closer than 5 Å. Different
aggregation pathways are obtained by changing the relative
stability of the amyloid-competent (β) and amyloid-protected
(π) states, which are ruled by the dihedral energy difference
of the single rotatable bond of the monomer. The energy
difference of these two states, dE=Eπ - Eβ, can be there-
fore interpreted as the β-aggregation propensity of the
polypeptide. Since the peptide has only one degree of
freedom, dE is close to the free-energy difference between
the two aforementioned states. For instance, when dE =
0 kcal/mol, the π and β states are equally populated,
whereas for dE = -1.5 and -2.5 kcal/mol, the π state is
about 15 and 100 times more populated than the β state,
respectively.
Crowder Model. The crowders are neutral spherical parti-
cles that interact with the peptides and with each other by
means of the Lennard-Jones potential, given by the following
equation
Vij ¼ Eminij
Rminij
rij
 !12
- 2
Rminij
rij
 !624
3
5 ð1Þ
where Rij
min is the distance at the minimum of the potential,
or the van derWaals radius of themolecule, ɛij
min is the depth
of the potential well, and rij is the interparticle distance.
The value of Rij
min is set to 7.5 Å, and ɛ= 0.1 kcal/mol for the
crowders, which therefore behave as impenetrable soft
spheres. The mass of the crowders has been set to 6.5 kDa.
The interactions between the crowder and peptide are also
modeled with a Lennard-Jones potential. In this case, the ɛij
min
parameter is set to 0.01 kcal/mol to make the crowders softly
repulsive particles; the optimal distance is obtained by using
the arithmetic mean.
Simulation Protocol with Crowders. Each simulated system
is made up of 125 peptides in a cubic box of size equal to
290 Å, at a peptide concentration of 8.5 mM and a variable
number of crowders (see Table 1). Periodic boundary condi-
tions are imposed. All of the simulations were carried out at
310 K by means of Langevin dynamics using CHARMM.27,28
Since aggregation is a stochastic process, 10 simulations with
different starting velocities were run for every concentration
of crowders and for each value of the β-aggregation propen-
sity of the peptides. The time interval for saving the coordi-
nates of the systemwas 0.5 ns. It is important to note that the
relative populations ofβ andπ states of the isolatedmonomer
are influenced solelyby thevalueofdEandnot by the crowder
content because the interactions between crowders and
peptides are not sensitive to the two different states of the
monomers.
Simulation Protocol without Crowders. These simulations
were carried out as described above (i.e., 125 peptides and
310K) in the absence of crowders and using box sizes ranging
from 150 to 290 Å, corresponding to a peptide concentration
ranging from 61.5 to 8.5 mM, respectively.
Excluded Volume. A rigorous protocol to calculate the
volume fraction that the crowders exclude to peptides at
different concentrations has been established. According to
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the linear approximation, the excluded volume fraction is
given by the following equation
φlðnCÞ ¼ VexclVtot ¼
1
Vtot
4
3
πR3effnC
where Reff = RCþ RP is the sum of the radius of the crowder
RC and the radius of the peptide RP and nC is the number of
crowders in the total volume. This approximation holds only if
the crowders are significantly larger than the peptide, that is,
when Reff≈ RC. If the radius of the peptides is non-negligible,
the excluded volume must include two corrections arising
from the presence of crowders whose mutual distance is
lower than 2Reff (see Figure S2, Supporting Information).
Since the peptide is not fully spherical, a heuristic evalua-
tion of Reff is needed. A simulation of an “ideal” solution
mixture of 125peptides and500crowderswas run,where the
polar interactions of the peptideswere switched off, as well as
the hydrophobic ones, to prevent them from aggregating.
From a 500 ns run, the radial distribution functions g(r) for
each pair of species in the solution were calculated. The
effective radius Reff has been chosen as the radius where
the radial distribution function gCP(r) between the crowders
and the peptides has the value of 0.5 (cfr. Figure S3, Suppor-
itng Information), obtaining Reff = 11.6 Å. The effective
excludedvolume fractionφ is calculated bydividing thewhole
simulationbox in “infinitesimal”cubic elements and counting
the number of cubes whose distance from any crowder
particles center is less than Reff, which is the minimal
approachable distance between a crowder and a peptide.
Simulations of 500 ns with different numbers of crowders
were used to produce snapshots of the system with different
arrangements of the crowders. The excluded volume fraction
φ at different crowder content nC, reported in Table 1, is
calculated as an average over all snapshots of the simulations.
The equivalent concentration Ceq = 8.5 mM /(1 - φ) is the
concentration of peptides in the accessible volume.
Dimension of the Fibril Nucleus. The nucleus is defined as
the oligomer that has 50% probability to form a fibril.22 The
crucial feature of such an oligomer is that it is not only formed
by a certain number of monomers but that it also owns the
sufficient number of monomers in the β state to permit the
elongation of the fibril (Table S1, Supporting Information).
Self-Diffusion Coefficient. The self-diffusion coefficient D ,
which measures the mobility of the isolated peptides, can be
calculated through the Einstein relation
lim
t f ¥
Ær2ðtÞæ ¼ 6D t
where Ær2(t)æ is the mean-square displacement. Simulations
of 100 ns with different concentrations of crowders and 125
peptides were performed to calculate the mean-square dis-
placement functions. The polar and the hydrophobic interac-
tions of the peptideswere switched off to prevent aggregation
events and calculate the diffusivity of the single monomers.
The self-diffusion coefficients of peptides at different crowder
contents D (nC) (Table 1) were then derived by a linear fit of
the long-time behavior of themean-square displacement (see
Figure S4, Supporting Information).
SUPPORTING INFORMATION AVAILABLE Supplementary
Figures 1-4 and Table 1. Thismaterial is available free of charge via
the Internet at http://pubs.acs.org.
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1
dE (kcal/mol) Nucleus size β-Subdomain size
-2.5 35 18
-2.25 23 10
-2.0 17 17
-1.5 4 4
TABLE 1: The second column lists the number of peptide monomers in the nucleus for different
values of the amyloidogenicity dE. The β-subdomain size is the number of monomers in β confor-
mation within the nucleus. The nucleus is defined as the aggregate with 50% probability to further
evolve into a fibril and 50% probability to dissolve into isolated monomers.
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FIG. 1: Projection on the x− y plane of a 20 ns-long trajectory of a peptide at different crowders
concentration. The projection shows that at high concentration of crowders the motion of the
peptide is hindered.
3
FIG. 2: Effective volume excluded to a peptide (P) by two crowders (C). Since the radius of the
peptide is non-negligible with respect to the one of the crowder, the excluded volume evaluation
requires two corrections. The first correction accounts for the overlying volume between crow-
ders (darker blue area), and the second derives from the interstitial volume between two or more
crowders which is inaccessible to the peptides (shaded area).
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FIG. 3: Radial distribution functions of each pairs of species present in the solution (C=crowder,
P=peptide).
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FIG. 4: Long time behaviour of the peptide mean square displacement 〈r2(t)〉 (black circles) derived
from the trajectories and linear fit with Einstein’s relation (red lines) at different crowder content.
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Chapter 4
Phenylalanine assembly into toxic
fibrils suggests amyloid etiology in
phenylketonuria
Adler-Abramovich, L., Vaks, L., Carny, O., Trudler, D., Magno, A., Caflisch, A., Frenkel, D. and
Gazit, E. Nat. Chem. Biol., 2012, 8, 701-706
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Individuals with PKU can have mental retardation, epilepsy, organ damage and unusual posture, and the molecular mechanisms causing these are largely obscure. PKU is an autosomal recessive 
disorder, caused by mutations in the gene encoding phenyl alanine 
hydroxylase (PAH) located on chromosome 12. Mutations in both 
alleles of the gene result in remarkably high concentrations of 
phenylalanine1,2. In untreated patients, millimolar concentrations 
of phenylalanine accumulate in the plasma, cerebrospinal fluid and 
brain tissue3,4. The inclusion of PKU diagnosis in newborn screen-
ing programs, by semiquantitative methods such as the Guthrie test 
or modern analytical tools that measure the blood concentrations 
of phenylalanine, allows early diagnosis of affected individuals. 
This permits treatment with a phenylalanine-restricted diet before 
the onset of clinical symptoms. A high percentage of individuals 
with PKU have blood phenylalanine concentrations that are above 
target ranges, particularly in teenagers and adults, indicating 
inadequate compliance to the strict diet5. In most of the previous 
studies, pheny lalanine was considered to act as a neurotoxin, 
although the precise mechanism underlying its neurological effects 
still needed to be deciphered2.
In the past decade, the role of peptide and protein aggregation 
in many pathological disorders was revealed. Specific attention was 
drawn to the formation of ordered amyloid fibrils. It was clearly 
demonstrated that amyloid fibrils or their early intermediates are 
associated with a diverse group of diseases of unrelated etiology, 
including Alzheimer’s disease, type II diabetes and prion disorders. 
Despite their formation by a diverse and structurally unrelated 
group of proteins, all amyloid fibrils share similar biophysical and 
structural properties6,7. A variety of structural and biophysical stud-
ies indicate that aromatic residues are important in the acceleration 
of the amyloidogenic process and the stabilization of amyloidal 
structure. Although aromatic interactions are not crucial for the 
process of amyloid formation, they can substantially accelerate it, 
affect the morphology of the assemblies and reduce the minimal 
association concentrations8–11. It was previously shown that very 
short aromatic peptide fragments, as short as penta- and tetrapep-
tides, can form typical amyloid fibrils that share the same biophysi-
cal and structural properties of the assemblies formed by much 
larger polypeptides9,12. Furthermore, diphenylalanine peptide was 
shown to form well-ordered nanotubular assemblies by itself, with 
some amyloid-like structural signatures13. This short peptide rep-
resents the core recognition motif within the β-amyloid polypep-
tide, which forms amyloid plaques in Alzheimer’s disease. The two 
phenylalanine residues (Phe19 and Phe20) in the β-amyloid peptide 
were suggested to mediate the intermolecular interaction between 
polypeptide chains. This suggestion was further substantiated by 
the use of phenylalanine residues as a key component of peptide-
based inhibitors of β-amyloid fibril formation14,15.
In spite of the extensive work that is performed on short peptide 
fragments, no study has yet examined the association between single 
amino acids. Inspired by the frequent occurrence of phenylalanine 
residues in short amyloid-forming peptides9 and by the efficient 
formation of nanotubes by the self-assembly of the diphenylalanine 
peptide13, we explored the ability of phenylalanine to form amyloid- 
like nanofibrillar structures under millimolar concentrations. 
As discussed below, our finding may lead to a better understand-
ing of the pathology caused by the accumulation of phenylalanine, 
which can reach millimolar concentrations in individuals with 
PKU1,16 and lead to new approaches of treatment for this disease.
RESULTS
Biophysical characterization of phenylalanine assemblies
We examined the ability of the aromatic amino acid phenylalanine 
to form ordered assemblies under pathologically relevant concen-
trations. We observed that phenylalanine by itself, at millimolar 
concentrations, self-assembles to form amyloid-like nanofibrillar 
structures. To study the process and outcome of phenylalanine 
fibril formation, we applied a series of biophysical and biologi-
cal assays. Transmission electron microscopy (TEM) analysis of 
phenylalanine at the millimolar-concentration range indicated the 
occurrence of well-ordered and elongated assemblies (Fig. 1a). 
Scanning electron microscopy (SEM) was also used to study 
the three-dimensional structures of the fibrils (Supplementary 
Results, Supplementary Fig. 1a), and environmental SEM 
(ESEM) was used to study fibrillar structures in a humid environ-
ment (Supplementary Fig. 1b). Both SEM and ESEM micrographs 
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phenylalanine assembly into toxic fibrils suggests 
amyloid etiology in phenylketonuria
Lihi adler-abramovich1, Lilach Vaks1, Ohad Carny1, dorit trudler2,3, andrea Magno4, amedeo Caflisch4, 
dan Frenkel2,3 & ehud Gazit1*
Phenylketonuria (PKU) is characterized by phenylalanine accumulation and progressive mental retardation caused by an 
unknown mechanism. We demonstrate that at pathological concentrations, phenylalanine self-assembles into fibrils with 
amyloid-like morphology and well-ordered electron diffraction. These assemblies are specifically recognized by antibodies, 
show cytotoxicity that can be neutralized by the antibodies and are present in the hippocampus of model mice and in parietal 
cortex brain tissue from individuals with PKU. This is, to our knowledge, the first demonstration that a single amino acid can 
form amyloid-like deposits, suggesting a new amyloidosis-like etiology for PKU. 
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showed areas covered with discrete assemblies, demonstrating 
that the assemblies are relatively homogeneous and are evidently 
discrete entities with a persistence length on the order of a few 
micrometers. We have also demonstrated by SEM analysis that 
phenylalanine fibrillar structures are formed in human serum, a 
more physiologically relevant environment (Fig. 1b). Both HPLC 
and NMR analysis clearly indicated that no covalent bonds were 
formed between the phenylalanine monomers and that the highly 
ordered fibrils are supramolecular assemblies (Supplementary 
Fig. 1c). All of these data imply that phenylalanine assembles 
into amyloid-like structures and that this assembly can take place 
under pathologically relevant conditions.
Another characteristic of amyloid fibrils is the presence of typical 
yellow-green birefringence upon staining with Congo red, visualized 
by microscopic examination under cross-polarized light. The 
birefringence results from the high order of the assemblies at the 
molecular level. Thus, we examined the phenylalanine assemblies 
using Congo red staining to gain further information on their inter-
nal order. Upon microscopic exanimation, we observed a charac-
teristic birefringence similar to that of amyloid fibrils (Fig. 1c). An 
additional common method for quantitative assessment of amyloid 
fibrils is the thioflavin T (ThT) fluorescence assay, which reflects 
the change in the dye’s fluorescence upon interaction with ordered 
assemblies. We used the ThT fluorescence assay to visualize the 
pheny lalanine fibrils and observed an excitation shift typical of 
amyloid fibril binding of ThT. Fluorescence confocal microscopy 
analysis of the ThT-stained fibrils showed the presence of elongated 
ordered structures (Fig. 1d).
Another method of confirming the degree of order of fibrillar 
structures is the use of electron diffraction. This was previously 
used to probe the ultrastructure of amyloid fibrils10,17. Indeed, in 
the case of the phenylalanine fibril, electron diffraction studies also 
gave a strong indication to the high organization of the assemblies. 
An electron diffraction pattern of a single fibril was consistent with 
a unit cell of a = 11.63 ± 0.27 Å, c = 4.6 ± 0.06 Å (for n = 5 measure-
ments), where a is oriented normal to the long axis of the crystal, 
and c is along the fiber axis (Supplementary Fig. 1d).
Molecular dynamics simulations18 with a generalized Born 
implicit solvent model19 were carried out to shed light on the struc-
tures of the early aggregates of phenylalanine. Multiple microsecond-
long simulations were started with 27 monodispersed phenylalanine 
molecules at different pH values and in the presence or absence of 
counterions. Ordered aggregation was observed at some but not 
all conditions. At high pH (that is, neutral amino group and nega-
tively charged carboxy group) in the presence of counterions, fila-
mentous aggregates were observed in high concentrations and at 
all temperature values (Fig. 1e). Analysis of the ensemble of self-
assembled structures yielded a distribution of interatomic distances 
with two peaks at about 5 Å and 11 Å (Fig. 1f), which correspond to 
the distance between neighboring phenylalanines and the laminal 
spacing, respectively (Fig. 1e). Pairs of neighboring phenylalanines 
are involved in direct hydrogen bonds or salt-bridged polar inter-
actions. Notably, the distribution of distances is in agreement with 
the aforementioned electron diffraction pattern.
Taken together, the results of the set of experimental techniques 
and atomistic simulations further confirm that the high degree of 
structural order of the phenylalanine fibrillar assemblies is not the 
product of irregular aggregation. In this sense, they have charac-
teristics similar to those of amyloid fibrillar deposits. We conclude 
that the fibrils formed by phenylalanine closely resemble amyloid 
structures, as confirmed by all of the physical assays used.
cytotoxicity of phenylalanine assemblies
We examined whether, like many amyloid structures, phenylalanine 
assemblies have a cytotoxic effect. This was examined at a physiolog-
ical range of concentrations, similar to those detected in untreated 
PKU individuals, by in vitro cellular viability experiments. To this 
end, elevated concentrations of phenylalanine ranging from 0.1 μM 
to 15 mM were added to cultured PC12 cell line (Fig. 2a) and to 
cultured Chinese hamster ovary (CHO) cells (Supplementary 
Fig. 2a). The phenylalanine fibrils, at millimolar concentrations, 
had a toxic effect on the cells as measured by the 3-(4,5-dimethyl-
thiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay (Fig. 2a). 
In the presence of 1.8 mM phenylalanine, cell viability decreased to 
approximately 80%. Moreover, in the presence of 7.5 mM phenyla-
lanine, the cells’ viability was approximately 65% (Fig. 2a), suggest-
ing a dose-dependent response. Our assay was performed at much 
shorter time scales than those for disease progression, which may 
account for our use of slightly elevated concentrations compared 
to those typically found in individuals with PKU. It is also possible 
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Figure 1 | The single aromatic amino acid, phenylalanine, self-assembles 
into supramolecular fibrillar structures. (a) tEM images of elongated 
phenylalanine fibrils. scale bar is 1 μm. (b) sEM images of phenylalanine 
fibrils in human serum. scale bar is 20 μm. (c) Microscopic examination 
under polarized light following Congo red staining of phenylalanine fibrils. 
scale bar is 500 μm. (d) Confocal microscopy image of fibrils dyed with 
tht. scale bar is 10 μm. (e) Representative snapshot of the filamentous 
structure obtained by molecular dynamics simulations started with  
27 monodisperse phenylalanine molecules (cyan) at high pH in the 
presence of counterions (yellow spheres). the tight packing of the aromatic 
rings is emphasized by their van der Waals envelope (gray surface).  
(f) Distribution of distances between pairs of atoms in different 
phenylalanine molecules in the aggregates obtained by molecular dynamics 
simulations. the distances between the center of mass of all pairs of the  
27 phenylalanines were used for these histograms, and quantitatively 
similar histograms were obtained using distances between atoms instead 
of those between center of masses. the very similar distributions at 280 K 
(black) and 310 K (red) show that the ordered aggregates of phenylalanine 
are essentially the same in this temperature range and that the simulations 
have reached convergence.
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that such high concentrations of phenylalanine occur pathologically 
in individuals with PKU, owing to transient local high concentra-
tions of phenylalanine in the brain. Slightly elevated phenylalanine 
concentrations were used, similarly to the experimental studies 
of β-amyloid polypeptide, which in Alzheimer’s disease occurs at 
overall cerebral concentrations lower than 10 nM, whereas toxic-
ity studies are performed at the micromolar range20,21. Furthermore, 
alanine, an average-sized amino acid that does not form fibrillar 
structures at similar concentrations, was used as a negative control 
in the cytotoxicity assay and, as expected, did not demonstrate a 
toxic effect (Fig. 2a). Thus, it is quite clear that it is not merely the 
concentration of amino acid monomers but rather the mulitimo-
lecular entity that is the cause of toxicity.
We further assessed the influence of the phenylalanine fibrils 
on the morphology of CHO cells using SEM. We observed changes 
in CHO cell morphology following incubation with phenyl-
alanine fibrils. In the absence of phenylalanine fibrils, the cells 
had an elongated shape (Supplementary Fig. 2b,c), whereas the 
phenylalanine-treated cells seemed smaller and rounder 
(Supplementary Fig. 2d,e). We observed a very low density of 
the phenylalanine-treated cells compared to that of the untreated 
cells. On the basis of these results, we suggest that phenylalanine 
pathology in individuals with PKU may be due to the cytotoxic 
effects of fibril formation at millimolar concentrations.
Formation of antibodies against phenylalanine fibrils 
One of the key prospects for amyloid disease treatment is the use 
of antibodies that specifically recognize and clear fibrillar assem-
blies and not the corresponding monomeric species. To examine 
whether the phenylalanine fibrils represent a unique immuno-
logical entity, we tried to produce specific antibodies against the 
phenylalanine fibrils. Rabbits were immunized with the fibrils, 
and their serum was tested for specificity to the assemblies. We 
employed an immunogold assay to show the antibodies’ affinity to 
the fibrils. As can be observed in the TEM images, the fibrils were 
specifically marked with gold-labeled secondary antibodies bound 
to the serum antibodies (Fig. 2b). Control analysis of phenylalanine 
fibrils, marked with preimmune serum or only with gold-labeled 
secondary antibodies, did not show any specificity to the fibrils 
(Supplementary Fig. 3). Moreover, the specificity of the antibodies 
was demonstrated, as no cross-reactivity was found when the anti-
bodies were incubated with the Parkinson’s α-synuclein amyloid 
deposits or with diphenylalanine peptide nanotubes13, and only low 
binding was observed when the antibodies were added to phenyl-
alanine monomers dissolved in guanidine hydrochloride solution, 
reflecting their much lower ability to self-assemble. In addition, 
no binding was observed when preimmune serum was used as a 
control (Supplementary Fig. 4). This observation provides a clear 
indication for the formation of distinctive and specific immuno-
logical epitopes by the self-assembly of phenylalanine, as observed 
in amyloid disorders.
immunoprecipitation depleted phenylalanine fibril toxicity 
Antibodies against phenylalanine fibrils (anti-Phe fibril) were fur-
thermore used to immunoprecipitate the phenylalanine assemblies 
from the solution and to assess the contribution of the assemblies to 
the toxic effect on the cell culture. Figure 2c compares the cytotoxic 
effect of phenylalanine assemblies prior to and following immuno-
precipitation. Cells treated with solutions containing phenylalanine 
assemblies at concentrations of 2.5 mg ml−1 and 0.16 mg ml−1 showed 
only 40% and 68% cell viability, respectively; however, after immuno-
precipitation, the viability of cells incubated with the solutions was 
elevated to 66% and 122%, respectively, as measured by the MTT 
assay (Fig. 2c). In addition, the solutions that were incubated with 
the cells were analyzed using electron microscopy; phenylalanine 
fibrils were observed in the solution before the immunoprecipitation 
and were not detected after immunoprecipitation with anti-Phe 
fibril (Supplementary Fig. 5). As a control, cell viability after 
immunoprecipitation of the phenylalanine fibrils with preimmune 
serum was analyzed. The viability of the cells incubated with the 
2.5 mg ml−1 and 0.16 mg ml−1 solutions was moderately elevated 
to 59% and 80%, respectively. The nonspecific preimmune serum 
showed a notably lower depletion effect in comparison to the spe-
cific anti-Phe fibril depletion. The moderate elevation in viability 
may possibly be due to some sedimentation of the phenylalanine 
fibrils during the immunoprecipitation procedure. In addition, elec-
tron microscopy analysis showed phenylalanine fibrils in the pre-
immune immunoprecipitated solution, correlating with the results 
showing low viability (Supplementary Fig. 5).
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Figure 2 | Specific antibodies against phenylalanine fibrils and the toxic 
effect and interaction of phenylalanine fibrillar structures with cell 
cultures. (a) Cell viability was determined using the Mtt assay.  
the PC12 cell line was maintained in the presence of phenylalanine fibrils 
(black bars) or the control amino acid, alanine (gray bars). *P < 0.05.  
(b) tEM micrographs of phenylalanine fibrils, visualized using antibodies 
that were specifically bound to phenylalanine fibrils and then were marked 
with a secondary antibody conjugated to 18-nm gold particles. scale  
bar is 2 μm. (c) Cell viability was determined using the Mtt assay, CHo 
cell cultures were maintained in the presence of an increasing amount of 
phenylalanine fibrils (black bars) or immunoprecipitated (IP) solutions 
of phenylalanine depleted of fibrils (gray bars). As control, phenylalanine 
fibrils were also incubated with preimmune serum (white bars). *P < 0.05; 
**P < 0.001. Results for a and c are presented as mean ± s.e.m.  
(d) CHo cell cultures were incubated with phenylalanine fibrils, fixed,  
and then incubated with anti-Phe and stained using Alexa 488–conjugated 
antibody (green, marked with arrows). the cell membrane was marked 
with phalloidin (red). As controls, CHo cell cultures were incubated with 
phenylalanine fibrils then fixed and incubated with preimmune serum or 
without primary antibodies. scale bars are 10 μm.
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Phenylalanine fibrils interact with cells
Moreover, confocal microscopy was used to study the interaction of 
the fibrils with CHO cells in culture (Fig. 2d). Cells were incubated 
with phenylalanine fibrils following cell fixation and staining with 
antibody against phenylalanine (anti-Phe) and phalloidin. Analysis 
of the cells clearly demonstrated that the fibrils could be detected 
within the cells (Fig. 2d) under the conditions in which cytotoxicity 
is observed (Fig. 2a). No such staining could be observed with the 
preimmune serum (Fig. 2d) or without the addition of the primary 
antibody (Fig. 2d).
The presence of phenylalanine fibrils in Pahenu2 mice
To prove that these assemblies exist in vivo, we examined serum 
samples obtained from a genetic mouse model of PKU (Pahenu2), 
deficient in phenylalanine hydroxylase activity22. We were inter-
ested in analyzing the presence of anti-Phe fibril, which could 
indicate the presence of phenylalanine fibril in the PKU mouse 
model. Using the dot-blot assay, we were able to observe anti-Phe 
fibril specifically in Pahenu2 homozygous mouse serum (Fig. 3a). 
Moreover, anti-Phe was not detected in control Pahenu2 heterozy-
gous mouse serum and in normal mouse serum (Fig. 3a). We fur-
ther examined the presence of phenylalanine fibrils in brain tissue 
of Pahenu2 mice. We performed histology staining experiments 
using Congo red and Phe-specific antibody staining. The histol-
ogy staining results showed evidence for the presence of amyloid-
like plaques in Pahenu2 mice (Fig. 3b). A large number of plaques 
were specifically detected in the hippocampus and dentate gyrus 
(Fig. 3b), and in proximity to blood vessels (Supplementary Fig. 6a). 
Notably, considerable necrosis and edema in the dentate gyrus were 
described in previous studies on PKU23. In addition, the colocaliza-
tion of Congo red and anti-Phe staining provides evidence that the 
plaques consist of amyloid-like phenylalanine fibrils. DAPI stain-
ing (nonspecific staining of double-stranded DNA) of plaque sec-
tions detected glia cell infiltration to the region (data not shown). 
In addition, the following four histological staining controls showed 
no evidence of phenylalanine assemblies: (i) homozygous Pahenu2 
mouse brain tissue, stained with antibodies extracted from immu-
nized serum depleted of its Phe fibril–specific antibodies by prein-
cubation with phenylalanine fibrils; (ii) homozygous Pahenu2 mouse 
brain tissue, stained with antibodies derived from preimmune 
serum; (iii) heterozygous Pahenu2 mouse brain tissue stained with 
anti-Phe; (iv) heterozygous Pahenu2 mouse brain tissue stained with 
preimmune serum (Supplementary Fig. 6b–e).
immunohistology of phenylalanine fibrils in PKU patients
We examined the presence of phenylalanine fibrils in the brain 
tissue of individuals with PKU. We performed histological staining 
with both anti-Phe fibril and Congo red. As shown in Figure 3c, 
evidence was found for the presence of phenylalanine deposi-
tion in the brain tissue using both immunostaining and Congo 
red staining (Fig. 3c). The control sample stained with Congo 
red showed positive staining;  however, the preimmune serum 
did not recognize this area (Fig. 3c, right column). These find-
ings demonstrate the specificity of the anti-Phe fibril. The phe-
nylalanine assemblies’ co-staining was mainly detected in the 
parietal cortex, which was previously suggested to be involved in 
the pathology of PKU in a rat model, in terms of changes in the 
structural organization of the cortex and decreased number of 
dendritic processes24. Thus, the phenylalanine assemblies not only 
are clear supramolecular entities but also are most relevant to the 
disease, as determined by the mouse model experiments.
DiScUSSioN
The current study presents a new paradigm to explain the pathology 
of PKU and suggest new routes for potential therapy. Our study indi-
cates, for what is to our knowledge the first time, the ability of phenyl-
alanine, a single amino acid, to form well-ordered fibrillar assemblies 
at the nano scale. These assemblies are not irregular aggregates, 
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Figure 3 | Dot-blot analysis and histological staining indicates the presence of phenylalanine fibrils in model mice and PKU patient brain tissues.  
(a) Dot-blot analysis of phenylalanine fibrils. Column 1, serum of homozygous mouse (Pahenu2) strongly bound the phenylalanine fibrils. Column 2, serum of 
heterozygous mouse (Pahenu2) did not bind the phenylalanine fibrils. Column 3, serum of wild-type mouse did not bind phenylalanine fibrils. (b) Histological 
staining of homozygous Pahenu2 mouse brain. the 20-μm-thick brain slices were stained with rabbit anti–Phe fibril antibodies and Congo red and then were 
examined using fluorescent microscopy. the detected amyloid-like plaques showed colocalization of the fluorescent signal obtained from Congo red and 
antibody staining. (c) the brain of an individual with PKu was stained with anti–Phe fibril serum or with preimmune serum, examined using light microscopy 
and co-stained with Congo red. Phenylalanine-positive depositions were found in the parietal cortex. scale bars are 100 μm.
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as they have typical fibrillar morphology, characteristic birefringence, 
ThT fluorescence patterns and, above all, clear electron diffraction 
patterns. In all of these aspects, the properties of these fibrils highly 
resemble those of amyloid assemblies, which are related to numerous 
pathological disorders. The formed structures not only are ordered 
as amyloid fibrils but also have strong and clear cytotoxic activi-
ties, as other amyloid assemblies do25,26. Moreover, the formation 
of phenylalanine aggregates could be detected in the brain of PKU 
model mice and individuals with PKU using Phe-specific antibodies. 
These findings suggest that PKU is closely related to the family of 
amyloid-related diseases and might have similar etiology. Moreover, 
the phenylalanine fibrils represent a distinct immunological entity, 
like amyloid assemblies, and many concepts and experimental stud-
ies that are used for the development of immunological treatment for 
amyloid diseases may also be used in this case27,28.
mEThoDS
Materials. Amino acids were purchase from Sigma (purity ≥98%). Fresh stock 
solutions were prepared by dissolving the amino acid in double-distilled H2O 
(ddH2O), PBS or DMEM (Beit Haemek) or human serum at various concentra-
tions ranging from 6 μM to 120 mM.
TEM. Phenylalanine was dissolved in ddH2O to a concentration of 6 mM and  
incubated at 25 °C for 2 h. A 10-μl aliquot of this solution was placed on 400-mesh 
copper grids. After 1 min, excess fluids were removed. For negative staining, the 
grid was stained with 2% (w/v) uranyl acetate in water, and after 2 min excess 
fluids were removed from the grid. Samples were viewed using a JEOL 1200EX 
electron microscope operating at 80 kV.
Molecular dynamics simulations. Molecular dynamics simulations with a general-
ized Born implicit solvent model19 were carried out. Multiple microsecond-long 
simulations were started with 27 monodispersed phenylalanine molecules at  
different pH values and in the presence or absence of counterions. Four different 
concentrations of phenylalanine (1 mM, 6 mM, 30 mM and 100 mM) and three 
temperature values (280 K, 300 K and 310 K) were used.
Antibodies formation. Phenylalanine was dissolved in ddH2O at a concentration 
of 120 mM to form fibrils; rabbits were immunized five times subcutaneously at 
14-d intervals with the fibrils and Freund’s adjuvants. Seven days after each injec-
tion, the rabbits were bled, and their serum was tested using dot-blot analysis.
Rabbit antibody immunotesting using TEM analysis. The immunolabeling 
was visualized using goat anti-rabbit conjugated with 18-nm gold (Jackson 
ImmunoResearch; catalog no. 111-215-144 1:20). Phenylalanine was adhered to 
the copper grid as described in the TEM section. Then, the grid was blocked with 
1% (w/v) BSA and 3% (w/v) goat serum for 30 min. Samples were incubated with 
the serum diluted 1:200 in PBS in 1% milk for 30 min, washed five times with 0.1% 
BSA, then incubated with the secondary antibody for 30 min and similarly washed. 
Samples were viewed using a JEOL 1200EX electron microscope operating at 80 kV.
Immunoprecipitation and cell cytotoxicity experiments. Phenylalanine solu-
tions at concentrations of 2.5 mg ml−1, 1.25 mg ml−1, 0.16 mg ml−1 and 0.04 mg 
ml−1 were either incubated with CHO cells or immunoprecipitate, and then the 
solutions, with or without the fibrils, were incubated with CHO cells according 
to the cell cytotoxicity experiments detailed in the Supplementary Methods. 
Samples were immunoprecipitated with either anti-Phe fibril or preimmune 
serum (1:10) overnight at 4 °C (previously purified on protein A column, in PBS 
plus 2% (w/v) BSA).
Interaction of phenylalanine fibrils with CHO cells. The interaction of the fibrils 
with cells in culture was visualized by immunocytochemistry staining. Cells were 
seeded on a cover slip in a 24-well plate. Cells were washed with PBS and fixed 
with 4% (v/v) paraformaldehyde (PFA) in PBS for 30 min at 25 °C and then were 
washed twice with PBS and permeabilized with 0.1% Triton in PBS for 2 min. 
Following two PBS washes, cells were blocked with 10% (v/v) normal goat serum 
in 3% (w/v) BSA for 30 min and incubated with anti-Phe diluted 1:1,000 and  
4 μg ml−1 phalloidin (Sigma) for 1 h, followed by an additional hour of incubation 
with Alexa 488–conjugated goat anti–rabbit IgG (Jackson ImmunoResearch;  
catalog no: 711-545-152; diluted 1:500). After being thoroughly washed with PBS, 
cells were mounted using ProLong Antifade (Invitrogen). Images were taken with 
LSM META confocal microscope (Zeiss).
Congo red staining of brain tissue of Pahenu2 mice. Fifteen-micrometer coronal 
brain sections of Pahenu2 homozygous and heterozygous mice were prepared using 
cryostat. Brain samples were fixed in 70% (v/v) ethanol for 1 min, washed in 
ddH2O for 2 min and stained with previously filtered Congo red solution for  
10 min. Following staining, the samples were washed in ddH2O for 2 min and 
washed 8–10 times in NaOH-ethanol solution (0.5 ml 1% (w/v) NaOH plus 49.5 ml 
50% (v/v) ethanol) until the excess red color disappeared. Finally, the samples 
were washed in ddH2O, and the signal was detected using fluorescent microscopy 
(absorption at 498 nm, emission at 614 nm).
Immunohistological staining of mouse brain tissue. Black and tan, brachyuric  
(BTBR)-Pahenu2 brain samples were fixed in 4% PFA (in PBS) for 5 min and 
washed for 5 min in ddH2O. The slices were blocked with 2% BSA solution  
(in PBS) for 20 min, then washed three times in ddH2O and incubated with rabbit 
anti-Phe fibril solution, dilution 1:20 (previously purified on a protein A column, 
in PBS plus 2% (w/v) BSA) for 1 h at 25 °C. Following the incubation, the  
samples were washed three times in ddH2O and incubated with goat rabbit-
specific secondary antibody conjugated to Alexa F488 (Invitrogen; catalog no. 
A11008; diluted 1:250). Signal was detected by fluorescent microscope  
(absorption at 495 nm, emission at 519 nm).
Immunohistological staining of human brain tissue. Brain samples, acquired 
from the London Neurodegenerative Diseases Brain Bank (part of BrainNet 
Europe), were fixed in paraffin. Consecutive sections were deparaffinized with 
xylene, fixed in 4% (v/v) PFA and treated with 0.3% (v/v) H2O2 (in PBS). Sections 
were then heated in citric acid (pH 6) for 5 min and were treated with 0.25% (v/v) 
Triton X-100 for 3 min. The sections were blocked using 2% (w/v) BSA solution 
(in PBS) for 20 min, then washed three times in PBS and incubated with rabbit 
anti-Phe fibril solution, dilution 1:50 (previously purified on protein A column, 
in PBS plus 2% (w/v) BSA) for 1 h at 25 °C, along with preimmune rabbit serum 
as control. Following the incubation, the samples were washed 3 times in PBS 
and incubated with goat rabbit-specific secondary antibody conjugated to biotin 
(Vector laboratories, BA-1000) diluted 1:250 for 1 h at 25 °C and washed with PBS. 
Sections were then treated with ABC reagent (Vector Laboratories, Vectastatin 
ABC kit, PK-6100) and developed with diaminobenzidine and hydrogen peroxide 
(Vector Laboratories, SK-4100). Signal was detected by light microscope.
Statistical analysis. Two-tailed Student’s t-test was performed when two groups 
were compared. The one-way analysis of variance followed by Bonferroni’s multiple 
comparison tests was carried out for multiple samples. Statistical significance was 
determined at P < 0.05.
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Supplementary Results 
Monomer concentration at equilibrium: 
We measured the phenylalanine absorption at 256 nm and calculated its 
concentration. The absorbance of the assemblies' solution was 0.856 and the 
calculated concentration was 5 mM. Then, the assemblies were sediment using ultra-
centrifugation and the supernatant monomers solution absorbance at 256 nm was 
0.08. Therefore, the calculated concentration was 0.476 mM. 
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Supplementary Figure 1: (a) Scanning electron microscopy (SEM) image of the 
phenylalanine fibrils. (b) Environmental scanning electron microscopy image of the 
phenylalanine fibrils. Scale bars for a, b are 20 µm. (c) HPLC and NMR analysis of 
phenylalanine assemblies indicating that no covalent bonds between the 
phenylalanine monomers were formed. (d) Electron-diffraction analysis of a single 
fibril. Axis a* is oriented normal to the long axis of the crystal. a* and c* are the 
reciprocal lattice vectors in the diffraction pattern. 
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Supplementary Figure 2: The toxic effect of phenylalanine fibrillar structures on 
CHO cells. (a) Cell viability was determined using the MTT assay. CHO cell line was 
maintained in the absence or presence of increasing amounts of phenylalanine fibrils. 
(b-c) Scanning electron microscopy (SEM) images of untreated CHO cells. (d-e) 
SEM image of CHO cells incubated with phenylalanine fibrils. Scale bars for b, d are 
10 μm and for c, e are 1 μm. 
 
 
Supplementary Figure 3: Transmission electron microscopy of phenylalanine fibrils 
with the presence of secondary antibodies conjugated to 18 nm gold particles. (a) In 
the absence of primary antibodies. This control sample does not show specific binding 
to the fibril. (b) In the presence of pre-immune serum. The non-specific antibodies 
were not bound to the phenylalanine fibrils. Scale bars are 1 μm. 
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Supplementary Figure 4: Dot-blot binding analysis of the immune and pre-
immune serum. (a) Serum from immunized rabbit was bound to the phenylalanine 
fibrils and demonstrated the specific binding of the serum antibodies to the 
phenylalanine fibrils. (b) Serum from immunized rabbit was incubated with 
phenylalanine monomers dissolved in guanidine hydrochloride solution reflecting a 
much lower self-assembly ability. (c) Serum from immunized rabbit was incubated 
with diphenylalanine peptide nanotubes, and demonstrated the inability of the 
antibodies to bind to the diphenylalanine peptide nanotubes. (d) Pre-immune serum 
was incubated with phenylalanine fibrils, and demonstrated the inability of the 
antibodies to bind to the fibrils. All the rows represents decreasing concentrations 
from top to bottom. 
 
 
 
Supplementary Figure 5: Transmission electron microscopy micrographs of the 
solution that were incubated with CHO cells (a) Phenylalanine fibrils were observed 
prior to the IP. (b) Phenylalanine fibrils were observed following the IP with pre-
immune serum. (c) Phenylalanine fibrils were not detected after IP with anti-Phe fibril 
antibodies. Scale bars for a, c are 500 nm and for b is 2 μm. 
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Supplementary Figure 6: Histological staining of homozygous and heterozygous 
pahenu2 mice brains. (a) Homozygous Pahenu2 mouse brain slices were stained with 
rabbit anti–Phe fibril antibodies and Congo red and then were examined using 
fluorescent microscopy. The detected amyloid-like plaques showed colocalization of 
the fluorescent signal obtained from Congo red and antibody staining in proximity to 
blood vessels. (b) Homozygous mouse brain slices were stained with immunized 
serum that was antibody depleted (c) Homozygous mouse brain slices were stained 
with antibodies from pre-immune serum (d) Heterozygous mouse brain stained with 
immunized serum (e) Heterozygous mouse brain stained with pre-immune serum. b-d 
were stained with Congo red, then examined using fluorescent microscopy. b-e Do 
not show any specific staining. Scale bars are 100 µm.  
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Supplementary Methods 
Scanning electron microscopy. Phenylalanine was dissolved in ddH2O or 10% 
human serum to a concentration of 6 mM or 12mM respectively, and incubated at 
room temperature for two hours. A 10 μl aliquot of the solution was placed on 
microscope glass cover slip and coated with gold. Scanning electron microscopy 
images were taken using a JSM JEOL 6300 SEM operating at 5 kV. 
 
Environmental scanning electron microscopy. Phenylalanine was dissolved in 
ddH2O to a concentration of 6 mM and incubated at room temperature for two hours. 
A 10 μl aliquot of the solution was placed on a metal stand. Environmental scanning 
electron microscopy images were taken using Quanta 200 FEG Field Emission Gun 
ESEM operating at 10 kV. 
 
Congo red staining and birefringence. Phenylalanine was dissolved in ddH2O to a 
concentration of 6 mM and incubated at room temperature for two hours. A 10μl 
aliquot of the solution was allowed to dry on a glass microscope slide. Staining was 
performed by the addition of 10 μl solution of 80% ethanol saturated with Congo red 
and NaCl. Birefringence was determined with a SZX-12 Stereoscope (Olympus, 
Hamburg, Germany) equipped with a polarizing stage. 
 
ThT staining and confocal laser microscopy imaging. 10 µl ThT solution (2 mM, 
PBS buffer) were mixed with 10 µl phenylalanine fibril (6 mM, ddH2O). An LSM 
510 confocal laser scanning microscope (Carl Zeiss Jena, Germany) was used at 
excitation and emission wavelengths of 458 and 485 nm, respectively. 
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Electron diffraction. Phenylalanine was dissolved in ddH2O to a concentration of 6 
mM and incubated at room temperature for two hours. Then, a 10 μl aliquot of this 
solution was placed on 400 mesh copper grids. After 1 minute, excess fluid was 
removed. Electron diffraction experiments were performed on an FEI Tecnai F20 
microscope FEI at 200 kV with a field-emission gun, and samples cooled to liquid 
nitrogen temperatures using a Gatan 626 cryoholder. Low-dose methods were used 
with total dose to the sample of ~50 electrons per Å2. Electron diffraction patterns 
were recorded directly to the CCD camera (TVIPS F415).  
 
NMR. NMR spectra were recorded on a AC 200MHz, Bruker spectrometer, using 
Bruker Topspin 2.1 software. The chemical shifts were expressed in δ relative to TMS 
(δ=0 ppm).  The spectra were recorded in D2O as a solvent, at room temp. 1H-NMR 
(D2O-d6): δ = 2.9-3.3 (m, CH2), 3.8-3.9 (m, CH), 7.1-7.3 (m,5H aromatic).  
 
HPLC. Reverse phase HPLC showed >97% purity. Dionex HPLC system with 
Ultimate 3000 pump, Ultimate 3000 autosampler and Ultimate 3000 variable 
multiwave detector, controlled via Chromeleon chromatography workstation. 
Column: LiCroCART  Purospher STAR RP  4.6 mm, 5 µm C18e, Buffer A: 0.1% 
TFA in water, Buffer B: 0.1% TFA in acetonitrile, Flow: 1 ml/min, Binary Gradient: 
t=0-5; %A=100%, t=5-20; %B=0%-100%, t=20-25, %B=100%, 260 nm, Diluent 
100% A, TFA (Sigma) ≥99.0% (GC), for HPLC, Acetonitrile (Bio-Lab) HPLC grade, 
Water (Bio-Lab) HPLC grade. 
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Phenylalanine concentration at equilibrium. Phenylalanine was dissolved in water 
to a concentration of 1 mg/ml, the solution absorbance was measured at 256 nm. Then 
the assemblies were centrifuged in Optima TLXl Benchtop Ultracentrifuge for 1 hour 
at 4°C. The supernatant absorbance was measured at 256 nm. 
 
Cell cytotoxicity experiments. PC12 and CHO cells (2×105 cells/mL) were cultured 
in 96-well micro plates (100 L/well) and incubated overnight at 37°C. 100 L of 
phenylalanine dissolved in Dulbecco’s Modified Eagle Medium (DMEM) (Beit 
Haemek, Israel) at various concentrations were added to each well. Each experiment 
was repeated 3 times. Following incubation for 6 hours at 37°C, cell viability was 
evaluated using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide 
(MTT) assay. Briefly, 20 µL of 5 mg/mL MTT dissolved in PBS was added to each 
well. After 4 hours incubation at 37°C, 100 µL of the extraction buffer [20% SDS 
dissolved in a solution of 50% dimethylformamide and 50% DDW (pH 4.7)] were 
added to each well, and the plates were incubated again overnight at 37°C. Finally, 
color intensity was measured using an ELISA reader at 570 nm. Results are presented 
as mean +/- the standard error of the mean. 
 
Scanning electron microscopy imaging of cells. CHO cell were cultured on glass 
cover slips located in 24-well micro plates, then incubated with various concentration 
of phenylalanine fibrils for 6 hour at 37 ºC, as described in the cell cytotoxicity 
experiments section. Cells were then fixated on the glass cover slip with 2.5% 
glutaraldehyde, then dehydrated and coated with gold. Scanning electron microscopy 
images were made using a JSM JEOL 840A SEM operating at 5 kV. 
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Rabbits Antibodies' Immuno-testing using dot-blot analysis. 100 μl solution of 
phenylalanine fibrils (0.125, 0.062, 0.32 mg/ml) were applied via a vacuum manifold 
onto a nitrocellulose filter using a dot-blot apparatus. After blocking the membrane 
with 1% milk in TBS for 1 hour at room temperature, the membrane was briefly 
washed with TBS and incubated with the serum diluted 1: 500 in TBS / 2% milk for 
1 hour at room temperature. Then, the membrane was briefly washed with TBS and 
incubated with HRP-conjugated goat anti rabbit antibodies. The membrane was 
developed using ECL reagents (NEN, USA) according to the supplier's instructions. 
The blot was visualized using X-ray film. For the control binding analysis of rabbit's 
antibodies (1) diphenylalanine peptide (Bachem) was dissolved in water at 65 °C for 
30 minutes, then cooled at room temperature to form the peptide nanotubes. (2) 
Phenylalanine was dissolved in 6M guanidine hydrochloride. (3) Phenylalanine fibrils 
that were applied to nitrocellulose were incubated with pre-immune serum. The 
solutions  were applied via a vacuum manifold onto a nitrocellulose filter using a dot-
blot apparatus followed by the protocol stated above. 
 
Dot blot analysis of pahenu2 mice. Proteins or samples in a total volume of 100 μl 
ddH2O or PBS were applied via a vacuum manifold onto a PVDF membrane filter 
using a dot–blot apparatus (Schleicher and Schuell, USA). After blocking the 
membranes with 3% (v/v) non-fat milk in PBS for overnight at 4ºC, the membrane 
was briefly washed with PBS followed by incubation with mouse (pahenu2 
homozygous, pahenu2 heterozygous and wild-type) plasma or specific anti-Phe fibrils 
rabbit serum (previously purified on protein A column, in PBS + 2% BSA) for 1h at 
room temperature. The signal was detected using the appropriate anti-mouse and anti-
 10
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rabbit HRP-conjugated secondary antibodies (Jackson Laboratories, West Grove, 
PA). After three washes with PBS the PVDF filter membranes were developed with 
the ECL reagent (Pierce, USA). The protein blot was visualized using X-ray film. 
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Carnosine Inhibits Ab42 Aggregation by Perturbing the H-
Bond Network in and around the Central Hydrophobic
Cluster
Francesco Attanasio,[a] Marino Convertino,[b] Andrea Magno,[b] Amedeo Caflisch,[b]
Alessandra Corazza,[c] Haritha Haridas,[c] Gennaro Esposito,[c] Sebastiano Cataldo,[d]
Bruno Pignataro,[d] Danilo Milardi,*[a] and Enrico Rizzarelli[a, e]
Introduction
Alzheimer’s disease (AD), the most common form of senile de-
mentia, is a neurodegenerative disease characterized by the
presence of neurofibrillary tangles and amyloid plaques in the
brain.[1] The main constituents of the plaques are two peptides
(40 and 42 amino acids long) called amyloid b peptides (Ab40
and Ab42).[2] At first, attention was entirely focused on amyloid
fibrils as the cause of AD, but more recent studies have sug-
gested that the small-sized, soluble Ab oligomers formed
during the early steps of peptide aggregation are the main cy-
totoxic agents,[3] whereas Ab monomers show a neuroprotec-
tive role.[4] Although a causal relationship between the mor-
phology of Ab aggregates and the severity of the disease re-
mains open to discussion, considerable evidence indicates that
a key event in AD pathogenesis is the conversion of Ab from
its neuroprotective, soluble, monomeric state[4] into various
toxic aggregated assemblies in the brain. Therefore, the design
of effective molecules to prevent the self-assembly of Ab into
toxic oligomers is widely recognized as the primary goal of
a number of therapeutic strategies under development or in
clinical trials. Despite the identification of oligomers as the crit-
ical pathogenic form of Ab aggregates, uncertainty concerning
the structural features triggering toxic oligomerization persists
due, in part, to the transient lifetimes of early intermediates
and the dynamic transition into the thermodynamically fa-
vored fibrils. Recently, Ahmed et al. reported an Ab42 fibril
model with a turn spanning residues 24–27 in both oligomers
and fibrils,[5] and a salt bridge connecting the side chains of
residues D23 and K28 has been suggested as a hallmark of Ab
aggregation.[6] Other reports have suggested that Ab42-medi-
Aggregation of the amyloid-b peptide (Ab) into fibrillar struc-
tures is a hallmark of Alzheimer’s disease. Thus, preventing
self-assembly of the Ab peptide is an attractive therapeutic
strategy. Here, we used experimental techniques and atomistic
simulations to investigate the influence of carnosine, a dipep-
tide naturally occurring in the brain, on Ab aggregation. Scan-
ning force microscopy, circular dichroism and thioflavin T fluo-
rescence experiments showed that carnosine does not modify
the conformational features of Ab42 but nonetheless inhibits
amyloid growth. Molecular dynamics (MD) simulations indicat-
ed that carnosine interacts transiently with monomeric Ab42
by salt bridges with charged side chains, and van der Waals
contacts with residues in and around the central hydrophobic
cluster (17LVFFA21). NMR experiments on the nonaggregative
fragment Ab12–28 did not evidence specific intermolecular in-
teractions between the peptide and carnosine, in agreement
with MD simulations. However, a close inspection of the spec-
tra revealed that carnosine interferes with the local propensity
of the peptide to form backbone hydrogen bonds close to the
central hydrophobic cluster (residues E22, S26 and N27). Final-
ly, MD simulations of aggregation-prone Ab heptapeptide seg-
ments show that carnosine reduces the propensity to form
intermolecular backbone hydrogen bonds in the region 18–24.
Taken together, the experimental and simulation results (cumu-
lative MD sampling of 0.2 ms) suggest that, despite the inabili-
ty of carnosine to form stable contacts with Ab, it might block
the pathway toward toxic aggregates by perturbing the hydro-
gen bond network near residues with key roles in fibrillogene-
sis.
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ated toxicity is caused by a turn at positions E22 and D23 that
favors the formation of toxic oligomers.[7]
Thus far, a number of diverse compounds have been used
to prevent or reduce the aggregation of Ab, such as curcu-
min,[8] Congo Red derivatives,[9] antibodies,[10] osmolytes,[11] and
peptidic b-sheet breakers,[12–14] but with limited success and
often with dramatic side effects. Targeting amyloid toxicity by
stimulating the endogenous protective responses of the cell
might represent an attractive alternative, because this would
make use of mechanisms that have evolved to specifically deal
with amyloid toxic assemblies.
Carnosine (b-alanyl-l-histidine) is a naturally occurring dipep-
tide that is present in the muscle and brain tissues of humans
and other vertebrates at relatively
high concentrations (1–
20 mm).[15,16] Although its physio-
logical role is not fully established,
this compound has been postulat-
ed to act as a proton buffer, metal
chelator, antioxidant, and as an
antiglycating and antiaggregating
agent.[17–22] In vitro and in vivo
studies have revealed that carnosine can exert neuroprotective
effects through various mechanisms. For example, it has been
shown to protect neuronal cultures against glutamate-induced
toxicity.[23,24] Carnosine has also been reported to protect PC12
cells from oxygen–glucose deprivation, thanks to its anti-oxida-
tive properties.[25,26] Interestingly, carnosine has been shown to
prevent Ab-amyloid aggregation in rat brain endothelial
cells[27] and to rescue cells from Ab-induced neurotoxicity.[28–32]
Furthermore, lower carnosine plasma levels have been found
in AD patients than in age-matched controls.[33] Despite all
these promising findings, however, no molecular interpretation
is available as to how carnosine inhibits Ab amyloid toxicity.
Indeed, investigating the molecular mechanism of the inhibi-
tion effects of carnosine on Ab aggregation would seem a
highly promising challenge, as it might suggest novel lead
compounds in anti-AD approaches.
In the present work, scanning force microscopy (SFM), circu-
lar dichroism (CD), and thioflavin T (ThT) fluorescence have
provided consistent evidence that carnosine is able to inhibit
Ab42 aggregation and amyloid growth in the test tube with-
out affecting its conformational preferences. However, these
experimental approaches cannot provide a molecular descrip-
tion of how carnosine inhibits Ab42 aggregation. Thus, implicit
solvent molecular dynamics (MD) simulations were carried out
to shed light on the specificity and persistence of the interac-
tions between carnosine and monomeric Ab42. Furthermore,
2D TOCSY and 2D NOESY NMR spectra of the water-soluble
fragment Ab12–28 were also recorded (in the absence and
presence of carnosine) in experimental conditions designed to
minimize Ab–Ab interactions. Based on our MD and NMR
results, as well as previous biophysical experiments[34–37] and
atomistic simulations,[38,39] we focused our investigation on the
Ab region with the highest b-aggregation propensity, to
obtain details about the Ab aggregation–inhibition mecha-
nism. To this aim, additional MD simulations were performed
on eight replicates of each of the following capped heptapep-
tide segments: Ab14–20, Ab16–22, and Ab18–24, in the ab-
sence (blank test) and presence of one single carnosine mole-
cule. The simulations show van der Waals contacts between
carnosine and several residues in the N-terminal half of Ab, as
well as transient electrostatic interactions with residues K16,
E22, and K28, with concomitant perturbation of the propensity
to form intermolecular hydrogen bonds in region 18–24. The
experimental data and simulation results provide evidence that
binding of carnosine, albeit mainly transient, reduces the self-
assembly tendency of Ab.
Results
Carnosine inhibits Ab42 amyloid growth
Firstly, we studied whether carnosine could inhibit aggregation
of Ab42 by using a ThT assay (see the Experimental Section).
The measurements were performed in 10 mm phosphate
buffer (pH 7.4). Ab42 samples were prepared and incubated
without carnosine or in the presence of a 5-, 10-, 20-, or 100-
fold molar excess of carnosine for four days at 37 8C. The inhib-
itory effect of carnosine on Ab42 fibrillogenesis is shown in
the upper panel of Figure 1.
The ThT results show that, at all the investigated concentra-
tions, carnosine has a considerable effect on Ab42 fibrillogene-
sis. In particular, at 20-fold molar excess carnosine exhibited
a noticeable antiaggregating effect (70% reduction in fluores-
Figure 1. Top: normalized ThT fluorescence emission at 485 nm of samples
containing 100 mm Ab42 incubated at 37 8C for four days in the presence of
increasing concentrations of carnosine in 10 mm phosphate buffer (pH 7.4).
Bottom: CD spectra of 15 mm Ab42 in 10 mm phosphate buffer (pH 7.4) at
time t=0 (c) and after incubation at 37 8C for four days in absence (····) or
presence (a) of 0.1 mm carnosine. The dashed curve represents the differ-
ence spectrum obtained by subtracting the CD signal of carnosine from the
CD curve of Ab42 coincubated with 0.1 mm carnosine at 37 8C for four days.
 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 583 – 592 584
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cence), and an 80% reduction was observed at a 100-fold
molar excess. To analyze the effect of carnosine on the confor-
mational behaviour of Ab42, CD experiments were carried out
in the presence of the dipeptide. CD spectra of carnosine
alone were also acquired under the same experimental condi-
tions and subtracted from the Ab42/carnosine curves. The CD
spectrum of Ab42 obtained at time t=0 showed that the pep-
tide adopts a typical random-coil conformation (Figure 1B,
solid line). After four days of incubation with carnosine, the
spectrum exhibited a negative minimum at 220 nm, thus sug-
gesting the presence of a b-sheet structure (Figure 1B, dashed
line). The CD curve of pure Ab42 (dotted line) exhibited similar
spectral features but with a lower amplitude, ascribable to
Ab42 precipitation. These results confirm that the presence of
carnosine does not significantly modify the conformational fea-
tures of Ab42 but, rather, interferes with its self-assembling
process, thereby leading to a decrease in the total amount of
fibrils formed at the end of the process. These findings were
also demonstrated by SFM.
Figure 2A shows the two types of structure that characterize
the morphology of Ab42 on mica: fibrils and globular aggre-
gates. Magnifications of these structures are shown in Fig-
ure 2B and C. In particular, Figure 2B shows a group of woven
fibrils about 4 nm tall and 30–40 nm wide (the latter value was
corrected for the well-known tip-broadening effect; see Experi-
mental Section). Size distribution histograms of fibril lengths
and aggregate heights (Figure 2D and E) were estimated over
a large number of measurements in different regions of the
sample. We observed that most of the fibrils were about 100–
150 nm in length, although a small percentage reached some
microns (not shown). Globular aggregates were mostly less
than 1 nm in diameter (range 0.5–6.0 nm). Given that the
smallest aggregate was about 0.5 nm tall (and assuming this
was for one monomer, as observed by SFM), this size distribu-
tion likely includes oligomers, or packed aggregates of mono-
mers, composed of 1 to 10 units.
Figure 3 shows the SFM analysis of the Ab42 sample treated
with carnosine. A large number of globular structures random-
ly dispersed on the surface are evident. Importantly, fibril ag-
gregation was limited to a very few systems. The aggregates
are much more apparent in the 3D magnification (Figure 3B),
and the related histogram (Figure 3C) shows a monodispersed
height distribution (~0.4 nm), which, as above, is consistent
with the presence of monomers or small oligomers.
Interactions of carnosine with Ab
Implicit solvent simulations were carried out on ten different
systems (Table 1). At 300 K, carnosine was in contact with Ab42
for only 20% of the simulation time (and only 10% with
Ab12–28)[40] at the concentration (5 mm) used in the simula-
tions. Although the data at temperatures below 320 K were
marred in part by incomplete convergence of sampling, it
seems from analysis of the secondary structure that carnosine
does not influence the overall secondary structure content of
monomeric Ab42 (Figure 4) or the secondary structure profile
along the sequence (Figure S1 in the Supporting Information).
The profile of the interaction energies along the Ab42 se-
quence indicates that van der Waals contacts are transient and
significantly more pronounced in segment 3–22 than in the C-
terminal region (Figure 5, top). Moreover, the electro-
static interactions (Figure 5, bottom) are rather pro-
miscuous, with most of the positively and negatively
charged side chains (including the terminal groups)
of Ab42 in transient contact with the carboxyl and
amino group, respectively, of carnosine. Of note, the
electrostatic interaction of carnosine with E22 is
more pronounced than with the other negatively
charged side chains (D1, E3, D7, and D23). This
shows that, albeit disordered, the binding of carno-
sine to Ab42 is influenced by sequence-specific ef-
fects.
NMR characterization of Ab12–28/carnosine
contacts in solution
Ideally, to assess the presence of contacts between
Ab and carnosine by NMR the full length peptide
Ab42 should be used. However, because of its poor
solubility, Ab42 is not suitable for NMR analysis in
aqueous solvent. Because of this, and the interaction
profile observed in the MD simulations with Ab42,
we used the small, water-soluble fragment Ab12–28.
We also focused on this central region of Ab42 be-
cause it encompasses residues known to be critical
for Ab aggregation.[6,41] Figure 6 depicts the overlay
of the amide connectivity propagation from 2D
Figure 2. SFM analysis of the structures obtained by drop-casting a solution of Ab42.
A) 2D large-scale image; B) and C) 3D representations of the areas marked in (A) by
dashed and dotted squares, respectively; D) length distributions of fibrils ; E) height
distributions of globular aggregates.
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TOCSY spectra of Ab12–28, alone and in the presence of car-
nosine (peptide/carnosine 1:2). For each stoichiometric equiva-
lent addition of carnosine, the pH value increased progressive-
ly from 7.36 to 7.48, but no noteworthy shift was detected for
the residues with carboxyl groups (E22, D23, and the C termi-
nus). Chemical shift invariance with respect to carnosine addi-
tions was also observed for all the other resonances of Ab12–
28, including those of the aromatic hydrogens; this suggests
lack of a stable interaction between the two molecules, or the
existence of transient interactions not detectable within the
timescale of NMR experiments. However, to better characterize
the effect of carnosine on the peptide, the possible involve-
ment of Ab12–28 amide protons in H-bonding was ascertained
by measuring the corresponding chemical shift thermal coeffi-
cients (Dd/DT) over the range 6.7–12 8C. The temperature-in-
duced migration of the individual NH signals was reconstruct-
ed from 2D TOCSY spectra. Table 2 lists the amide thermal co-
efficients with respect to carnosine presence: no difference is
evident. The rather large Dd/DT values (average (7.41.4) and
(7.61.3) ppb per degree, without and with carnosine, respec-
tively) are consistent with a lack of stable H-bonds. The lowest
Dd/DT values (at E22 and segment S26–N27) could be inter-
preted as reflecting a local trend towards H-bond formation,
but somehow reduced by carnosine. The Ha chemical shifts,
however (including those of S26 and N27) are very close to the
values observed for statistically disordered peptides,[42] except
for A21 and E22 where upfield shifts by 0.10 and 0.15 ppm
were measured, independent of presence of carnosine. The Ha
chemical shift deviations (DdHa) from the tabulated values for
random structures are diagnostic for secondary structure re-
Figure 3. SFM analysis of the structures obtained by drop-casting solutions
of Ab42 and carnosine (0.1 and 10 mm, respectively). A) 2D large-scale
image; B) 3D detail of the area marked in (A); C) height distribution of glob-
ular aggregates.
Table 1. Simulation parameters.
Compound Ab Ratio No. of Length Protocol[a] Total
segment runs of each sampling at
run [ms] 300 K [ms]
carnosine Ab1–42 1:1 2 1.5 REMD[c] 3
– Ab1–42 0:1 2 1.5 REMD[c] 3
carnosine Ab12–28[b] 1:1 3 5 CTMD 15
– Ab12–28[b] 0 :1 3 5 CTMD 15
carnosine Ab14–20 1:8 2 10 CTMD 20
– Ab14–20 0:8 2 10 CTMD 20
carnosine Ab16–22 1:8 2 10 CTMD 20
– Ab16–22 0:8 2 10 CTMD 20
carnosine Ab18–24 1:8 2 10 CTMD 20
– Ab18–24 0:8 2 10 CTMD 20
[a] REMD: replica exchange molecular dynamics; CTMD: constant temper-
ature (300 K) molecular dynamics. [b] This simulation protocol is de-
scribed in ref. [40] . [c] The temperatures of the individual replicas in
REMD were 280, 290, 300, 310, 315, 320, 330, and 345 K.
Figure 4. Secondary structure content [%] of monomeric Ab42 with (*, *)
and without (*, *) carnosine, as a function of REMD simulation temperature.
Data are plotted separately for two independent REMD runs for each of the
two systems. Error bars represent the standard deviation calculated by block
averaging at each temperature and run. The b propensity does not reach
convergence below 320 K, as indicated by the significant deviation between
the two REMD runs in the presence of carnosine. Overall, the temperature
profiles indicate a negligible influence of carnosine on the tendency of Ab42
to form regular elements of secondary structure.
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gions when not below 0.1 ppm and when occurring as consec-
utive groups.
However, based on the evidence from NOESY data
(Figure 7), it is possible to attribute a structural meaning to the
upfield deviations detected for A21 and E22: bending into
a local a-like conformation that introduces a loose turn geom-
etry. To investigate the possibility of peptide–carnosine associa-
tion phenomena, we performed DOSY measurements in aque-
ous phosphate.
The results of these experiments are reported in Table 3 in
terms of the hydrodynamic radii (Rh) of Ab12–28 and carno-
sine, calculated according to a procedure reported else-
where.[43] From these data, we can confirm that, with or with-
out carnosine, Ab12–28 is predominantly monomeric in aque-
ous phosphate at neutral pH and low temperature.
The apparent Rh value of carnosine increases in the presence
of Ab12–28 because of the transient fast interaction. Although
less pronounced, the Ab12–28 diffusion coefficient (and hence
the apparent Rh value) is also affected by the fast intermolecu-
lar interaction. Sample aging did not alter significantly the
monomeric state of Ab12–28, at least over three to four weeks,
independently of the presence of carnosine. In fact, the Rh
values are constant.
The monomeric state of Ab12–28 is not affected by temper-
ature. In fact, no aggregation due to hydrophobic interactions
(in principle favored with increasing temperature) can be infer-
red from the Rh values at higher temperatures. Rather, a de-
crease in these values was observed at higher temperatures,
which should be determined by fast conformational dynamics
resulting in changes in the average hydrodynamic dimensions
of Ab12–28. The failure to observe all the amide resonances in
the spectra acquired at T25 8C (because of the fast solvent
exchange expected above neutral pH) is consistent with a stat-
Figure 5. Interaction energy between carnosine and monomeric Ab42 aver-
aged over the REMD segments at 300 K (total sampling of 3 ms). The two
arrows highlight the segment Ab12–28 used in the NMR spectroscopy ex-
periments. Top: van der Waals interaction energy. The horizontal line at
0.5 kcalmol1 is a somewhat arbitrary threshold to help discriminate
strongly from weakly interacting residues. Bottom: electrostatic (*) and total
(*) interaction energies. The 300 K interaction energy profiles plotted sepa-
rately for the two REMD runs show that these data are converged (Fig-
ure S8).
Figure 6. 2D 1H TOCSY regions of 0.46 mm Ab12–28 in H2O/D2O (92:8) with
4 mm NaOH and 16 mm phosphate (pH 7.36) at 6.7 8C, in the absence (red)
and in the presence (black) of 0.95 mm carnosine (CRN). A) The amide con-
nectivities to the aCHs (and bCH2 for S26); B) the propagation to the other
resonances of the spin systems. Under these conditions, excess carnosine
raised the pH to 7.48, but no shift was detected for E22, D23, or K28 connec-
tivities.
Table 2. Thermal coefficients (Dd/DT) in ppb per degree of Ab12–28[a]
amide hydrogen chemical shifts in the absence and presence of carno-
sine[a] , measured over the range 6.7–12 8C. The experimental error for all
values is 0.9 ppb per degree.
Dd/DT [ppb/degree]
Residue Ab12–28 Ab12–28+carnosine
H13/H14 6.9 7.2
Q15/K16 8.0 8.9
L17 9.1 9.8
V18 8.8 8.8
F19 9.4 9.3
F20 7.3 7.4
A21 6.6 6.9
E22 6.2 6.5
D23 6.9 7.2
V24 9.0 8.8
G25 7.0 7.3
S26 5.8 6.1
N27 4.8 5.5
K28 6.8 6.8
[a] Ab12–28 0.46 mm in 92:8 H2O/D2O, 16 mm phosphate and 4 mm
NaOH, at pH 7.36. On addition of 0.95 mm carnosine, pH increased to
7.48. For the unresolved H13/H14/D23 and Q15/K16 amide crosspeaks
(Figure 6), single Dd/DT values were determined.
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istical conformational averaging. In accordance with the NMR
analysis, MD simulations of the Ab12–28 peptide evidenced
that carnosine interacts mainly with the E22, K16, and K28 side
chains of Ab12–28, and that all these interactions are short-
lived[40] (Figures S2 and S3). The decomposition of intermolecu-
lar energy into contributions of individual pairs of functional
groups illustrates that the main interactions involve formal
charges of opposite sign, that is, the N-terminal amino group
of carnosine with E22 and D23 side chains, and the C-terminal
carboxy group of carnosine with K16 and K28 side chains.
Molecular dynamics simulations of octameric Ab
heptapeptides with carnosine
The following analysis is based on MD simulations at 300 K of
six systems: octameric Ab14–20, octameric Ab16–22, and octa-
meric Ab18–24, each of these three systems with and without
one molecule of carnosine (Table 1).
The total sampling for each of the octameric heptapeptide
system was 20 ms. A comparison of the distribution of the
number of interpeptide backbone hydrogen bonds in the MD
simulations with and without carnosine shows that the dipep-
tide reduces the aggregation tendency of the octameric Ab18–
24 system significantly, but only marginally for octameric
Ab14–20 and Ab16–22 (Figure 8, top, see also the time series
in Figures S4 and S5). The number of intrapeptide backbone
hydrogen bonds increased significantly only for the Ab18–24
heptapeptide (Figure 8F) which is consistent with the decrease
in interpeptide hydrogen bonds. The change in the distribu-
tion of the interpeptide interaction energy (Figure 8, bottom)
confirms that carnosine has a minor effect on the mainly b-
sheet aggregates of the octameric Ab14–20 and Ab16–22 sys-
tems while it has a stronger influence, that is, larger shift to
less favorable values, for octameric Ab18–24. Note that the dis-
tributions shown in Figure 8 are not affected by statistical error
as shown by block averaging in Figure S6. The short residence
time of carnosine on Ab42 and on the Ab heptapeptide sys-
tems indicate that the intermolecular interactions are weak
and exhibit a transient nature (see Figures S3, S4 and S7).
Discussion
Carnosine, a naturally occurring dipeptide, is becoming a clini-
cally accepted nutritional supplement with uses across a con-
siderable spectrum of chronic diseases, from senile cataract to
dementia. It is found in excitable tissues such as the myocardi-
um, skeletal muscles and brain, but it is normally destroyed by
the enzyme carnosinase. Normally, carnosinase acts fast and
reduces the serum levels of carnosine, thus diminishing its ef-
fectiveness in clinical treatments.[21] There have been attempts
at stabilizing carnosine against carnosinase degradation, for
example, by conjugating it with vitamin E derivatives[44] or
small sugars,[45,46] but research in this area is still underway. It is
Figure 7. Overlay of 2D TOCSY (red) and 2D NOESY (blue) regions of
0.46 mm Ab12–28 in H2O/D2O (92:8) with 4 mm NaOH and 16 mm phos-
phate (pH 7.36) at 6.7 8C. A) The intense HaHN connectivities ; B) HbHN
connectivities. It is worth noting that all these connectivities occur within
segment L17–V24.
Table 3. Hydrodynamic radii (Rh) of Ab12–28
[a] and carnosine measured
as a function of temperature and sample age.
T [8C] Rh Ab12–28 [nm] Rh carnosine [nm] Sample age [d]
6.7 1.040.09 – 1
6.7 1.040.06 0.380.02 1
6.7 – 0.340.01 1
6.7 0.970.05 – 7
6.7 0.980.06 0.400.03 7
6.7 0.990.03 – 20
6.7 1.010.03 0.400.03 20
12 0.960.01 – 21
12 0.990.02 0.370.01 21
25 0.92 – 28
25 0.92 0.37 28
30 0.93 – 28
30 0.93 0.37 28
[a] Ab12–28 0.46 mm in 92:8 H2O/D2O, 16 mm phosphate, and 4 mm
NaOH, at pH 7.36. When 0.95 mm carnosine was present, the pH in-
creased to 7.48. The Rh values were determined from the average diffu-
sion coefficients determined by single exponential fitting of different
Ab12–28 methyl signals and the b-alanine methylene signals of carnosine.
Rh uncertainties are the standard deviations calculated from the disper-
sion of the diffusion coefficients. The values at 25 and 30 8C were ob-
tained from the diffusion coefficients estimated directly from the corre-
sponding DOSY maps. In this case uncertainty should be 5–10%, as the
Rh of TSP (the NMR chemical shift internal reference) was 0.29 nm at both
temperatures, thus ensuring the reliability of the determinations.
 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 583 – 592 588
CHEMBIOCHEM
FULL PAPERS www.chembiochem.org
known that carnosine can protect cells exposed to high levels
of Ab42 and it has been postulated that the mechanism for
protection might lie in its anti-glycating, antioxidant and/or
metal-chelating activities. Inspired by the consistent body of
evidence supporting a neuroprotective activity of carnosine,[47]
we show here that millimolar concentrations of this dipeptide
are able to effectively hinder Ab growth in tube tests. This
property of carnosine could be particularly important as direct
interference with Ab aggregation is a major target in AD thera-
peutics,[48] especially as a nutraceutical antagonist of Ab self-as-
sembly[49] has recently reached the phase II clinical trial step.
On the other hand, the recent failure of the small molecule tra-
miprosate in phase III clinical trials calls for novel inhibitors
with alternative mechanisms of modulation of Ab aggrega-
tion.[48] Carnosine/Ab interactions are weak and characterized
by short-lived contacts localized around the central hydropho-
bic cluster of Ab. These interactions do not significantly affect
the conformational preferences of Ab42. Consistent with bio-
physical experiments and MD simulations, NMR spectra of the
fragment Ab12–28 showed that the upfield shifts of the signals
from A21 and E22, which are ascribable to local loose turn ge-
ometries, are not affected by carnosine. However, a closer in-
spection of NMR spectra collect-
ed at different temperatures
could be interpreted as a local
trend towards H-bond formation
in E22 and in the segment S26–
N27 being reduced by carnosine.
Consistent with NMR data, MD
simulations of heptapeptide seg-
ments of Ab show a significant
decrease of the number of inter-
peptide H-bonds in the region
18–24. Notably, a toxic confor-
mer of Ab42 with a turn at posi-
tions 22 and 23 (the toxic turn)
has recently been identified by
solid-state NMR, and it was dem-
onstrated that a monoclonal
antibody against the toxic turn
mainly detected Ab oligomers in
the brains of AD patients.[7]
Moreover, the salt bridge be-
tween the side chains of D23
and K28 is also known to play
a critical role in Ab toxicity, and
agents that drive these residues
towards non-salt-bridge-forming
conformations are thought to
have therapeutic applications in
AD.[50] Our data support the hy-
pothesis that, albeit transiently,
carnosine interacts with the
charged groups surrounding the
central hydrophobic cluster of
Ab and interferes with the net-
work of H-bonds near the turn
at positions 22 and 23, thereby hindering self-assembly. Our re-
sults, along with analogous studies, might explain in part the
beneficial effect of carnosine (or derivatives thereof) in the
treatment of AD.
Experimental Section
Chemicals: Ab42 and Ab12–28 were purchased from Anaspec (Fre-
mont, CA). Carnosine, trifluoroacetic acid (TFA) and 1,1,1,3,3,3-hexa-
fluoropropan-2-ol (HFIP) were from Sigma–Aldrich. The purity of all
peptides was >95%. All other chemicals were of the highest avail-
able grade and were used without further purification. Ultrapure,
metal-free Milli-Q water (EMD Millipore, Billerica, MA) was used in
all experiments.
Ab peptide preparation and analysis: Monomeric Ab42 was pre-
pared as reported elsewhere.[51,52] The peptide was initially dis-
solved in TFA (1 mgmL1) and sonicated in a water bath for
10 min. Then, TFA was evaporated under a gentle stream of argon
and HFIP (1 mL) was added. After incubation (37 8C, 1 h), the pep-
tide solution was dried under a stream of argon, and then solubi-
lized again by adding HFIP (2 mL). Finally, HFIP was removed in an
argon stream, followed by drying in a lyophilizer for 1 h. The dried
peptide was first dissolved in freshly prepared NaOH (2 mm), then
Figure 8. Influence of carnosine on the interpeptide hydrogen bonds (top graphs), intrapeptide hydrogen bonds
(middle), and interpeptide interaction energy (bottom) in the octameric Ab heptapeptide systems. Each distribu-
tion was calculated from the complete sampling (20 ms). The statistical error is much smaller than the difference
between the distributions with and without carnosine (see Figure S6).
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the appropriate volume of phosphate buffer (10 mm, pH 7.4) was
added to a final peptide concentration of 100 mm. Ab42 samples
without and with carnosine were incubated for four days at 37 8C.
Circular dichroism: The CD spectra of the Ab42 sample (15 mm in
phosphate buffer (10 mm, pH 7.4)) at time t=0 and after incuba-
tion at 37 8C for four days in the absence or presence of carnosine
(0.1 mm) were recorded at 25 8C on a J-810 spectropolarimeter
(Jasco), thermostated with a Jasco peltier accessory. Raw CD data
acquired in a quartz cell (path length 10 mm) were processed by
Spectra Manager 1.5 software (Jasco) and corrected by subtraction
of the background solvent spectrum obtained under identical
experimental conditions. The final CD curves represent averages of
ten spectra.
ThT fluorescence measurements: Fluorescence emission spectra
of ThT undergo a red shift upon incorporation into b-sheet amy-
loid structures. Aliquots of incubated Ab42 peptide (100 mm) with
different amounts of carnosine, were added to ThT in phosphate
buffer (10 mm, pH 7.4); final concentrations: 30 mm ThT, 10 mm
Ab42. Fluorescence emission spectra were recorded in a quartz cell
(light path of 1 cm) by an LS55 spectrofluorimeter (lex=440 nm;
PerkinElmer). Excitation and emission bandwidths were set to
5 nm. ThT spectra were corrected by subtraction of the back-
ground solvent spectrum obtained under identical experimental
conditions. Ten consecutive spectra were recorded and averaged;
the experiments were performed in triplicate. Emission at 485 nm
was plotted as function of carnosine concentration.
Scanning force microscopy: Samples were prepared by drop cast-
ing Ab42 (100 mm, 5 mL) or Ab42/carnosine (100 mm/10 mm, 5 mL)
onto a freshly cleaved mica surface and incubating for 5 min. Sur-
faces were then rinsed with ultrapure Milli-Q water and dried with
a stream of dry nitrogen. SFM imaging was performed with a Multi-
mode/Nanoscope IIIA (Bruker, Santa Barbara, CA) with commercial-
ly available etched-silicon Vista probes (nanoScience Instruments,
Phoenix, AZ). For each image, 512512 points were collected
(scan rate 1 Hz). To get dimensional data for proteins, we used
mainly height data. This is because it is well-known that the SFM
lateral investigation of nanostructures is affected by the “tip-broad-
ening effect”.[53] Accordingly, tip/surface convolution leads to
broadening of more than 10 nm, as typically observed by conven-
tional SFM probes for structures (e.g. , proteins) that are few nano-
meters in size.[54, 55] The following algorithm can be used to com-
pensate for tip broadening:
Wobs ¼ 4
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
W
2
 Rtip
r
where Wobs and W are the observed and real width respectively
and Rtip is the tip radius.
[56] Particle height and fiber length data
were recorded by Nanoscope software and then gathered into
a single data set and statistically analyzed with Origin 8 software.
Distribution histograms were obtained from hundreds of elements.
Molecular dynamics: Implicit solvent simulations were performed
with ten different systems (Table 1). Six simulation systems had
eight copies each of the capped heptapeptides Ab14–20, Ab16–22,
or Ab18–24, both in absence or presence of a single carnosine
molecule (8:1 ratio). The remaining four systems consisted of mon-
omeric Ab42 or monomeric Ab12–28 without or with carnosine
(1:1 ratio). All Ab peptide segments were capped by acetyl and N-
methylamide groups at the N- and C-terminal residues, respective-
ly, to avoid spurious charges not present in full length Ab42. All
simulations were performed with the CHARMM program;[57,58] pep-
tides and carnosine were modeled by using the united atoms
CHARMM PARAM19 force field with its default truncation scheme
for nonbonding interaction (cutoff 7.5 ). Protonation states of ti-
tratable residues were considered at pH 7.0; in particular, the imi-
dazole of carnosine was neutral (protonated at Nd) while its amino
and carboxy groups were treated as positively and negatively
charged, respectively. The electrostatic contribution to solvation
was accounted for by using FACTS, an efficient generalized Born
implicit solvent model, which is based on the fully analytical evalu-
ation of the volume and spatial symmetry of the solvent that is dis-
placed from around a solute atom by its neighboring atoms.[59] The
nonpolar contributions to solvation energy was approximated by
a term proportional to the surface of the solute, by using a sur-
face-tension-like, multiplicative parameter (0.0075 kcalmol12).
The simulations were prepared by initially placing eight monodis-
persed replicates of the same heptapeptide (for the octameric sys-
tems) or one Ab42 or Ab12–28 peptide (for the monomeric sys-
tems), with or without a single carnosine molecule in the simula-
tion box. Note that the initial relative positions and orientations
are irrelevant because of the length of the individual trajectories
(each of several microseconds), which yielded multiple association/
dissociation events. Simulations were carried out with a periodic
boundary condition and at a fixed peptide concentration
(4.88 mm ; the simulations boxes were set to 132  for Ab14–20,
Ab16–22, and Ab18–24, and to 69  for Ab42 and Ab12–28) with
a Langevin integrator at low friction (coefficient 0.15 ps1). The oc-
tameric heptapeptide systems were simulated at 300 K, which
yielded reversible aggregation. The same temperature was used
for the Ab12–28 segment. The simulations of full length Ab42 with
and without carnosine were conducted with the Replica Exchange
Molecular Dynamics (REMD) technique at the temperatures listed
in Table 1. Every 20 ps, states i and j from neighboring tempera-
tures were swapped according to a Metropolis-like algorithm; this
yielded an average acceptance ratio of 40% for temperature
swaps. For each octameric system, ten 2 ms runs were carried out,
starting from randomly placed heptapeptides without any intermo-
lecular interaction. Analogously, simulations in the presence of car-
nosine were started without any contact between carnosine and
Ab (full length or segment). The cumulative MD sampling at 300 K
was 156 ms (198 ms when considering REMD sampling at different
temperatures; Table 1).
Analysis of trajectories : The interaction energy of carnosine with
Ab42 was calculated with CHARMM, with the same threshold as
for the simulations (7.5 ). The program Wordom[60,61] was em-
ployed to calculate secondary-structure propensities according to
the DSSP algorithm.[62] Carnosine influence on the ordered aggre-
gation of octameric Ab14–20, Ab16–22, and Ab18–24 was analyzed
by the average number of inter- and intrapeptide H-bonds and
their distributions along the simulations for each studied system.
The following hydrogen bond criteria were employed: distance
threshold 2.5  for the HO distance, and cut off >1308 for the
NHO angle. The carnosine effect on Ab heptapeptide aggregation
was estimated by calculating the interpeptide interaction energy,
which is the CHARMM nonbonded energy (van der Waals plus
electrostatic) of a single Ab peptide with the remaining seven pep-
tides, without considering the carnosine molecule.
NMR measurements: All NMR experiments were carried out at
11.7 T in an Avance 500 spectrometer (Bruker) equipped with
triple-axis magnetic field gradients, by observing the hydrogen
spectrum at 500.13 MHz. To avoid Ab12–28 aggregation and pre-
cipitation, the peptide was first dissolved under basic conditions
(2.3 mm in NaOH (20 mm), pH>10).[63] Fivefold dilution in phos-
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phate buffer led to final concentrations of peptide, phosphate, and
NaOH of 0.46, 16, and 4 mm, respectively, in H2O/D2O (92:8,
pH 7.36). Carnosine additions were performed with aliquots (5–
10 mL) from a stock solution in phosphate buffer (50 mm, pH 7.42))
to reach stoichiometric ratios 1:1 and 2:1 (carnosine:Ab12–28),
with a final pH of 7.48. To inhibit hydrophobic interaction, all oper-
ations were performed in an ice bath, and solutions were stored at
4 8C. For NMR measurements, the temperature was set initially to
6.7 8C and subsequently increased stepwise: 6.7–12 8C, then 25–
30 8C. Chemical shifts were referenced to internal 3-trimethyl-silyl
2,2,3,3-tetradeutero sodium propionate (TSP). In addition to 1D
spectra, 2D TOCSY[64] and NOESY[65] experiments were performed,
typically with 2048512 (t2t1) data-point matrices for spectral
widths of 6 kHz in each dimensions with 64 scans per t1 point,
64 dummy scans, and relaxation delay of 1 s. The TOCSY MLEV17[66]
isotropic mixing intervals were 80 ms at gB2/2p=8.3 kHz; for
NOESY, mixing times of 250 ms were employed. Quadrature in the
indirect dimension was obtained by time-proportional phase incre-
mentation,[67] and solvent suppression was implemented by ap-
pending a WATERGATE spin-echo module to the sequences, per-
formed in the excitation-sculpting mode.[68,69] This solvent suppres-
sion scheme was also used in diffusion ordered spectroscopy
(DOSY)[70] experiments for the measurement of the diffusion coeffi-
cients. A sequence including bipolar gradients and longitudinal
eddy current suppression was employed in a double-stimulated
echo module delay for cancellation of convection artifacts,[71] to
collect 80 points with linear increments from 2 to 95% of the z-
axis magnetic field gradient (65 Gcm1), with delays D=90 ms, s=
22 ms, and 128 scans/increment. All data were processed with
TOPSPIN software (Bruker).
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Figure S1. Secondary structure propensities along the Aβ42 sequence at T = 300K, with and without carnosine. For 
each system, two independent simulations have been performed with the REMD technique (solid lines). Moreover, a 
constant temperature molecular dynamics (CTMD, dashed lines) simulation has been run at 300 K to increase 
confidence in the statistical robustness of the results. The panel in the bottom shows an enlargement of the profile with 
the highest statistical noise which is the β-propensity of the segment from Ser8 to Glu22. 
 
 
Figure S2. Interaction energy matrix for carnosine and monomeric Aβ12-28. Each colored square shows the interaction 
energy between a single functional group of carnosine and a single Aβ12-28 residue (backbone and side chain atoms) 
averaged over the whole 15 microsecond sampling. The decomposition of intermolecular energy into contributions of 
individual pairs of functional groups illustrates that the main interactions involve formal charges of opposite sign, i.e., 
the N-terminal amino group of carnosine with the E22 and D23 side chains, and the C-terminal carboxy group of 
carnosine with the K16 and K28 side chains. Although the electrostatic contribution seems to dominate, one has to 
underline that desolvation effects are not taken into account in the interaction energy matrix. The electrostatic 
desolvation of charged groups is unfavorable and does significantly counter-balance the favorable electrostatic 
interactions between the termini of carnosine and the charged side chains of Aβ. There are also favorable van der Waals 
interactions involving the imidazole ring of carnosine with mainly the aromatic side chains of Aβ but also other Aβ 
residues, as well as the carboxy group of carnosine and the Aβ12-16 segment. 
 
 
Figure S3. Cumulative distribution of the time of carnosine unbinding from Aβ12-28 extracted from the MD trajectories 
(filled circles). The kinetics of unbinding show a negligible dependence of the energy threshold used to define a binding 
event in the range from -20 to 0 kcal/mol. The cumulative distribution of the time of unbinding of carnosine from 
Aβ12-28 can be fitted by a double-exponential (red dashed line and legend) with similar amplitude for the slow and fast 
phase. This result and the characteristic time of only 58 ps for the slow phase indicate that the intermolecular 
interactions are transient (fast unbinding). The transient nature of the association of carnosine to monomeric Aβ12-28 is 
consistent with the increase of the hydrodynamic radius (Rh) of carnosine and the minor increase of the Rh of Aβ12-28 
as derived from the NMR DOSY measurements. Note that the unbinding times of carnosine represent lower bounds 
because of the low friction used in the Langevin simulations, and it is likely that the real unbinding times are 10-100 
times slower as suggested by previously reported comparisons of implicit solvent simulations with experimental data on 
peptide folding times (Hiltpold et al. 2000). In any case, even upon correcting for the lack of friction, unbinding time 
scales of about 0.5 ns to 5 ns still correspond to weak/short lived association. 
 
Figure S4. Transient binding of carnosine to oligomers of Aβ14-20 (top), Aβ16-22 (middle), and Aβ18-24 (bottom). 
The figure shows the time series (left column) and distribution (right column) of the number of Aβ heptapeptides in 
contact with carnosine. The time series show a trajectory subsegment of only 100 ns for clarity. The distributions are 
normalized to one by including in the count fully isolated carnosine whose data point (at x=0) is not shown as it lies 
outside the y-axis range. (Middle column) The cumulative distribution of the time of carnosine unbinding from the Aβ 
heptapeptide oligomers is shown with fitting curves and parameters in red and blue for double-exponential and single-
exponential fitting, respectively. The residence time of carnosine on the oligomeric Aβ heptapeptide systems can be 
visualized by the time series of the number of Aβ heptapeptides in contact with carnosine (left). The double exponential 
fitting yields characteristic times of about 10 ps and 50 ps. Visual analysis of the trajectories of Aβ14-20 and Aβ16-22 
indicates that the slow phase originates from carnosine dissociation from aggregates with significant intermolecular β-
sheet structure, with which carnosine is involved in multiple transient interactions.  
 
 
Figure S5. Time series of number of inter-peptide backbone hydrogen bonds. The horizontal lines at y=15 and y=25 are 
drawn to facilitate the comparison of the different plots.  
 
 
 
 
 
 
 
 
 
 
Figure S6. Distributions of number of intermolecular hydrogen bonds (top), intramolecular hydrogen bonds (middle),  
and intermolecular energy (bottom). For each system, block averaging was carried out by dividing the total sampling of 
20 µs (ten 2-µs runs) into two blocks of 10 µs each  (five MD runs). The differences in the presence and absence of 
carnosine (compare red with black lines) are significantly larger than the statistical noise (compare lines of same color).  
Moreover, the almost indistinguishable histograms of the two blocks of each system indicate that the statistical error is 
negligible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Interaction energy matrix for carnosine and Aβ14-20 (left), Aβ16-22 (middle), and Aβ18-24 (right). 
 
 
Figure S8. The 300 K interaction energy profiles of carnosine with Aβ42 plotted separately for the two REMD runs 
show that these data are converged. The two vertical arrows emphasize the segment Aβ12-28 used in the NMR 
experiments. 
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ABSTRACT: Bromodomains are four-helix bundle proteins that speciﬁcally recognize
acetylation of lysine side chains on histones. The available X-ray structures of
bromodomain/histone tail complexes show that the conserved Asn residue in the loop
between helices B and C is involved in a hydrogen bond with the acetyl-lysine side
chain. Here we analyze the spontaneous binding of acetyl-lysine to the bromodomain
TAF1(2) by the ﬁrst molecular dynamics simulations of histone mark binding to an
epigenetic reader protein. Multiple events of reversible association sampled along the
unbiased simulations allow us to determine the pathway and kinetics of binding. The
simulations show that acetyl-lysine has two major binding modes in TAF1(2) one of
which corresponds to the available crystal structures and is stabilized by a hydrogen bond to the conserved Asn side chain. The
other major binding mode is more buried than in the crystal structures and is stabilized by two hydrogen bonds with conserved
residues of the loop between helices Z and A. In the more buried binding conformation, three of the six structured water
molecules at the bottom of the binding pocket are displaced by the acetyl-lysine side chain. The kinetic analysis shows that the
two binding modes interconvert on a faster time scale with respect to the association/dissociation process. The atomic-level
description of the binding pathway and binding modes is useful for the design of small molecule modulators of histone binding to
bromodomains.
■ INTRODUCTION
Bromodomains are protein modules of about 110 residues
which recognize acetylated lysine side chains mainly in histones
and are thus involved in transcriptional regulation.1,2 In the
human genome 46 proteins with a total of 61 diﬀerent
bromodomains have been identiﬁed, with up to 6 bromodo-
mains per protein.3 Bromodomains occur often in tandem with
a PHD module or with other bromodomain(s), suggesting that
combinatorial readout may be at work in translating the histone
code.2,4,5 The potential role of bromodomains in tumors and
inﬂammation4,6,7 has spurred large-scale structural studies with
the ultimate goal to facilitate the discovery of small-molecule
inhibitors able to interfere in the process of reading acetylated
lysine.8,9 In 1999, the ﬁrst three-dimensional structure of a
human bromodomain was solved;10 since then, the crystal and/
or solution structures of more than 40 human bromodomains
have been reported.11,12
All available structures show a conserved four-helix bundle
topology in which the ZA-loop and BC-loop connect the ﬁrst
two α helices (called Z and A) and last two α helices (called B
and C), respectively.12,13 The acetyl-lysine binding site is very
similar in all structures of bromodomains.12 There are several
crystal structures with bromodomains in complex with acetyl-
lysine4 (e.g., PDB codes 3P1C, 3O34, and 3O35) or peptides
with two acetylated lysine side chains (PDB codes 3UVW,
3UVX, 3UVY, and 3UW9). These structures share a common
intermolecular hydrogen bond between the side chain of the
conserved Asn in the BC loop and the acetyl oxygen of the
ligand. The binding mode is further stabilized by a network of
water-mediated hydrogen bonds at the bottom of the binding
groove and hydrophobic contacts.14 In addition to the
structural characteristics, thermodynamic parameters of histone
tail binding have been measured by isothermal titration
calorimetry using mono- and diacetylated histone peptide
segments.4 The measured dissociation constants are in the high
micromolar range, and seem rather insensitive to the peptide
length. In general, the dynamical character of the process of
ligand binding makes it a challenging investigation subject.15
Molecular dynamics (MD) simulations with explicit solvent
provide a useful tool to study binding of small molecules to
proteins at the atomic level of detail.15−22
Here, we have employed MD simulations in conjunction
with cut-based free energy proﬁle analysis15,23,24 to shed light
on the spontaneous association of acetyl-lysine to the second
bromodomain of the human transcription initiation factor
TFIID subunit 1 (abbreviated as TAF1(2)). This bromodo-
main was chosen based on a previous study25 in which the side
chain of the conserved Asn showed two interconverting
orientations. In particular, the side chain amide nitrogen of
TAF1(2) Asn1604 populates a solvent exposed orientation
which is rotated by about 180 degrees with respect to the
orientation observed in most crystal structures. In this context
there are several interesting questions which can be addressed
by simulations: Is conventional MD able to reproduce the
experimentally observed binding mode of the acetyl-lysine side
chain? On which time scale does spontaneous binding take
place? Which role does the side chain orientation of the
conserved Asn play in the binding process? Are there
alternative binding modes? The simulations describe with
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atomistic resolution acetyl-lysine binding to the position
observed in the crystal structure. Moreover, they reveal an
alternative binding mode and provide kinetic information on
the binding/unbinding processes.
■ RESULTS AND DISCUSSION
Twenty-four independent simulations of 0.5 μs each were
started with acetylated lysine (with neutral blocking groups at
its termini, abbreviated as Kac, see Figure 1 for the 2D
structure) positioned randomly at a distance of more than 20 Å
from the binding site of TAF1(2). No artiﬁcial guiding force or
bias toward the binding site was used. In 16 of the 24 MD runs
at least one event of spontaneous binding to the acetyl-lysine
pocket was observed. In the remaining 8 MD runs Kac did not
reach the binding site and remained most of the time in the
solvent or was sporadically involved in unspeciﬁc association to
diﬀerent regions of the TAF1(2) surface. Unless stated
otherwise, the following analysis refers to the 8-μs sampling
of the 16 runs in which binding events were observed (a total of
4 × 105 snapshots).
Spontaneous Binding. The time series of some of the key
interactions show that spontaneous and reversible binding of
Kac to the acetyl-lysine pocket can take place in the 0.5 μs time
scale of the MD runs (Figures 1 and 2 and Supporting
In f o rma t ion F igu r e s S1 , S2 , and mov i e ﬁ l e s ,
c t 4 0 0 3 6 1 k _ s i _ 0 0 1 . m p g ( M o v i e S 1 ) a n d
ct400361k_si_002.mpg (Movie S2)). From the analysis of
hydrogen bond frequencies, it emerges that the hydrogen bond
between the acetyl oxygen of the Kac side chain and the side
chain of the conserved Asn1604 in the BC loop is present in
nearly 40% of the snapshots of the bound state. Interestingly,
Figure 1. Spontaneous binding of Kac to TAF1(2). (top left) Two-dimensional structure of Kac. The red oval highlights the Kac side chain. (bottom
left) Spheres representing the position of the carbonyl carbon atom of the Kac side chain. Their color reﬂects the simulation time from red to blue.
The backbone of TAF1(2) and the side chains involved in binding are shown by a green ribbon and sticks, respectively. (right) Time series of key
interactions along two independent simulations. The inset emphasizes the binding event shown in the bottom left panel and in Supporting
Information Movie S1. The red and blue dashed rectangles in the inset illustrate the two most populated binding modes and correspond to the
colors of the spheres in the bottom left panel.
Figure 2. Spontaneous binding to the crystallographic binding mode.
The plot shows the time series of the RMSD from the X-ray structure
(black) together with the distances that characterize the hydrogen
bond observed in the crystal structures (red) and the hydrogen bond
of the more buried binding mode revealed by the present MD study
(green). Note the frequent interconversions between the two binding
modes. The RMSD of the Kac side chain atoms was calculated upon
optimal overlap of the Cα atoms in the four helices. The reference
structure for the RMSD calculation is the crystal structure of CREBBP
in complex with Kac (PDB code 3P1C) as there is no crystal structure
of TAF1(2) with Kac or a histone tail peptide. The MD run used for
this plot is shown in Supporting Information Movie S2.
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two residues of the ZA loop are also involved in hydrogen
bonds with Kac. The backbone oxygen of Pro1548 (in the so-
called WPF shelf) and the side chain hydroxyl of Tyr1561 act
frequently as hydrogen bond acceptor and donor, respectively.
Two Major Binding Modes. The trajectories with
spontaneous events of association and the corresponding
time series of key intermolecular distances indicate that there
are two distinct binding modes (red and blue spheres,
respectively, in Figure 1 bottom, left). From the unbound
state, Kac adopts ﬁrst a binding mode matching the one
observed in several crystal structures with the hydrogen bond
between the Asn1604 Nδ atom and the Kac side chain oxygen
Oac (called N-binding mode hereafter). The time series of the
Kac root-mean-square deviation (RMSD) from the crystallo-
graphic binding mode shows several simulation segments
during which the RMSD oscillates between 0.5 and 1.5 Å (e.g.,
the last 60 ns of the MD run shown in Figure 2) which
conﬁrms that the N-binding mode corresponds to the binding
mode determined experimentally. Note that the structure of
TAF1(2) does not change upon Kac binding as monitored by
the RMSD of the Cα atoms from the structure at the beginning
of the MD run (see Supporting Information Figure S3) and
also shown in Supporting Information Movie S2.
From the N-binding mode, Kac can reach reversibly a
binding conformation which is more buried than in the crystal
structure and in which the oxygen atom of Pro1548 acts as
hydrogen bond acceptor for the Kac side chain Nζ (called P-
binding mode hereafter). Further stabilization is provided by a
hydrogen bond between the hydroxyl group of Tyr1561 and
the Kac side chain Oac, as well as between atom Nδ of Asn1604
and either of the two oxygen atoms in the backbone moiety of
Kac, i.e., Ocap (N-terminal capping group) or O (C-terminal
group). An MD run with a spontaneous binding event and
further interconversions between N- and P-binding modes is
shown in Figure 1 and Supporting Information Movie S2.
Clustering of the snapshots based on pairwise RMSD of the
Kac side chain atoms and consecutive calculation of the cut-
based free energy proﬁle23 conﬁrm the existence of two major
Figure 3. Geometric variables used to analyze binding (top) and cut-based free energy proﬁle (abbreviated as cFEP) calculated using the mean ﬁrst
passage time from the representative node of the P-binding mode (bottom). The reaction coordinate of the cFEP is the relative partition function
(see the Methods section). The colors of the cFEP reﬂect the three main basins whose representatives are shown with TAF1(2) in ribbon model and
Kac in sticks (insets). The unbound state is in black in the cFEP. The 400 000 MD snapshots were ordered according to the free-energy sub-basin
they belong to. In this way, each of the sub-basins on the free energy proﬁle is annotated with the corresponding values of the geometric variables. As
an example, the ﬁrst sub-basin on the left is the P-binding mode which has hydrogen bond distance for Pro 1548 OKac Nζ and Tyr1561 OηKac
Oac whereas the Asn1604 NδKac Oac distance is about 8−9 Å.
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binding modes (Figure 3). It is important to note that the P-
binding mode is more buried (Figure 1 bottom, left) and
slightly more populated than the N-binding mode. The former
includes about 50% of the MD snapshots in the bound state
while the latter includes about 40%. Since the P-binding mode
has not been reported as of today, we decided to run additional
simulations of Kac binding to TAF1(2) with a force ﬁeld
diﬀerent from CHARMM27.26 The N- and P-binding modes
are also observed in each of four 1 μs runs with the AMBER27
force ﬁeld, and they show similar statistical weight (Supporting
Information Figure S4).
We also wanted to exclude the idea that the more buried P-
binding mode is an artifact due to the simpliﬁed model of the
ligand. For this purpose, we run eight additional simulations of
1 μs each with the Kac-Gly-Gly-Kac tetrapeptide (derived from
the diacetylated histone tail H4K5/K8) using two diﬀerent
bromodomains (i.e., CREBBP and BRD4(1)) and with two
diﬀerent force ﬁelds (CHARMM2726 and AMBER,27 Support-
ing Information Table S1). The P-binding mode is populated
also by the tetrapeptide ligand in each of the two
bromodomains and irrespective of the force ﬁeld used
(Supporting Information Figure S4). Thus, the results of the
control simulations provide evidence that the P-binding mode
is not an artifact of the force ﬁeld or the simpliﬁed ligand. It is
also important to note that in the N-binding mode the RMSD
from the crystal structure of the side chain of the N-terminal
Kac is almost always below 2 Å (Supporting Information Figure
S5). Moreover, the C-terminal Kac, i.e., the acetyl-lysine side
chain that is not in contact with the conserved Asn, has a more
pronounced ﬂexibility than the N-terminal Kac (Supporting
Information Figure S5) which is consistent with the larger
temperature factors of the C-terminal than the N-terminal
acetyl-lysine in the crystal structure of the complex with
BRD4(1) (PDB code 3UVW).
Kinetics. The existence of two major binding modes calls
for further investigations of the time scales required for
binding/unbinding and how they relate to the transitions
within the bound state. For this analysis, ﬁrst individual free
energy basins were isolated by the cut-based free energy proﬁle
method following an iterative procedure reported previously24
(see also the Methods section). Besides the two major binding
modes, there is a metastable state (called P/N-intermediate and
populated at about 10%) formed by MD snapshots in which
the side chain of Kac points inside the binding groove but is
arranged such that direct hydrogen bonds with Pro1548,
Tyr1561, or Asn1604 are not possible. This binding
conformation is stabilized mainly by a water-bridged hydrogen
bond between Kac Nζ and Asn1604 Oδ (see bottom, right inset
in Figure 3).
The mean ﬁrst passage time (MFPT) between free energy
basins was evaluated using representative clusters selected
according to statistical weight as published previously.24 The
MFPT values indicate that there are two well-separated time
scales (Table 1). While the two major binding modes
interconvert relatively fast, i.e., with an MFPT of ≈20 ns,
binding/unbinding takes place on a much slower time scale
(MFPT ≈ 300 ns). Figure 4 illustrates these two kinetic
regimes by the free energy proﬁles plotted together with the
MFPT to the reference state. The free energy barrier to exit the
bound state (located at a value of the reaction coordinate of
about 0.4 in Figure 4) is signiﬁcantly higher than the barriers
between the three basins in the bound state. The number of
direct transitions between basins is shown in Table 1. The large
number of direct transitions between P-binding and N-binding
modes compared to the much smaller number of binding/
unbinding events reﬂects the kinetic separation of the two
processes which emerges also from the MFPT calculations. It is
important to note that the number of binding and unbinding
events (20 and 10, respectively) determined using the
deﬁnition of basins by the cut-based free energy proﬁle agrees
with the visual inspection of the trajectories and the time series
presented in Supporting Information Figures S1 and S2. Such
agreement provides strong evidence that the clustering and the
deﬁnition of free energy basins by the cut-based free energy
proﬁle method capture the relevant features of the binding and
unbinding processes.
Dissociation Constant. The multiple events of sponta-
neous and reversible binding allow one to calculate the
dissociation constant from the ratio of the oﬀ-rate and on-
rate. The oﬀ-rate is the inverse of the MFPT from any of the
binding modes to the unbound state (i.e., 1/320 ns−1; see Table
1). The on-rate is the inverse of the MFPT to any of the bound
states multiplied by the concentration of Kac in the simulation
box (1/(220 ns × 6 mM)). It thus follows that the dissociation
constant is about (220 × 6)/320 ≃ 4 mM. This value is about 1
order of magnitude higher than the dissociation constants of
mono- and diacetylated histone peptides as measured by
isothermal titration calorimetry4 which is probably a con-
sequence of the smaller ligand used in the simulations than in
the experiments.
Orientation of the Side Chain Amide Group of the
Conserved Asn. The preferred orientation of the side chain of
the conserved Asn1604 diﬀers from the one observed in most
bromodomain crystal structures, i.e., the Nδ atom points
preferentially toward the solvent (χ2 ≈ −70°, Figure 3 top)
rather than the bottom of the binding site (χ2 ≈ 120°). The
solvent exposed orientation of the Asn1604 −NH2 group is
stabilized by a water-bridged hydrogen bond between the Asn
side chain carbonyl and the side chain hydroxyl of Ser1600 in
the C-terminal turn of helix B. This observation raises the
question whether diﬀerent binding modes of Kac prefer
diﬀerent orientations of the Asn1604 side chain. Here, it is
important to note that based on a previous work25 half of the
simulation runs were started with the solvent exposed
orientation of the Asn1604 NH2 group and the other half
with its orientation toward the binding site (see Methods).
Figure 5 shows the histograms of the Asn1604 χ2 dihedral
values computed over the snapshots belonging to the three
individual binding modes as well as for the segments of the
trajectories during which the ligand is unbound. Note, that for
the unbound conformation the histogram is characterized by
two peaks corresponding to the two diﬀerent orientations with
a preference for the solvent exposed orientation. Importantly,
Table 1. Kinetics Data Extracted from the Simulationsa
transitions (MFPT
[ns]) from\to unbound P-binding N-binding
P/N-
intermediate
unbound 1 (220) 14 (220) 5 (220)
P-binding 2 (320) 129 (28) 310 (20)
N-binding 4 (320) 135 (15) 17 (29)
P/N-intermediate 4 (320) 312 (6) 16 (30)
aThe table shows the number of direct transitions between pairs of
states as observed in the MD simulations. The MFPT values in
nanoseconds are given in parentheses. Note that the MFPT values are
calculated from the transition matrix, i.e., they take into account both
direct and indirect transitions.
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as experimentally observed in several X-ray structures of the
acetyl-lysine−bromodomain complex, the N-binding conforma-
tion peaks at χ2 ≈ 120°, i.e., the orientation of Asn1604NH2
pointing toward the binding site. On the contrary, in the P-
binding and the P/N-intermediate modes the orientation of the
NH2 group of Asn1604 toward the solvent is preferred, since
in the former it frequently acts as donor for the O or Ocap
atoms of Kac, while in the latter a water molecule coordinates
Oδ of Asn1604, Oγ of Ser1600, and Nζ of Kac (see Figure 3).
Furthermore, it is interesting to analyze the role of Asn1604
during the binding process. For this purpose, the N-binding
mode is decomposed into two sub-basins made up of snapshots
with positive and negative values, respectively, of the Asn1604
χ2 dihedral. Strikingly, 12 out of the 14 transitions from the
unbound state to the N-binding state take place when the Nδ
atom of the Asn1604 points toward the solvent (Supporting
Information Table S2 and Movie S1). The Kac ligand can then
further penetrate the binding groove, ending up in one of the
major binding modes.
Conserved Water Molecules in the Acetyl-Lysine
Binding Site. Six water molecules stabilized by hydrogen
bonds with polar groups in the bottom of the acetyl-lysine
binding site seem to be conserved in most crystal structures of
bromodomains.8 In the N-binding mode, the six conserved
water molecules are arranged in the same fashion as observed in
the crystal structures. In contrast, in the P-binding mode, water
Figure 4. Four panels show the cut-based free energy proﬁles with the three equilibrium bound conformations or the unbound state as reference.
Each panel is labeled with the state used as reference which is the ﬁrst basin on the left. Individual basins are colored according to the same color
scheme as in Figure 3, i.e., green, red, orange, and black for P-binding mode, N-binding mode, P/N-intermediate, and unbound state, respectively.
The empty circles in the bottom left panel represent the nodes on the barrier between the N-basin and the unbound state. The reaction coordinate is
the relative partition function (see the Methods section). The MFPT values to the representative node of the reference basin are also shown (blue
lines with y-axis on the right). The MFPT is a monotonous growing function because the nodes are sorted according to their kinetic distance from
the reference basin. Note that the three binding modes have approximately equal kinetic separation from the unbound conformation (i.e., 320 ns; see
Table 1). Thus, there is a signiﬁcant overlap of the three binding modes when plotting the proﬁle from a node belonging to the unbound
conformation (bottom right panel).
Figure 5. Histograms of the two main conformations of the χ2 angle of
the conserved Asn1604 for the individual binding modes (colors) and
the unbound state (black). Positive values of the χ2 angle correspond
to the orientation of Asn1604 Nδ toward the bottom of the binding
site while negative values to the orientation of Asn1604 Nδ toward the
solvent.
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molecules 2, 3, and 4 (nomenclature of Figure 1 of ref 8) are
replaced by the Kac side chain which, as mentioned above, is
more buried than in the N-binding mode (Figure 6). This
simulation result is useful for the design of small molecule
modulators of histone binding to bromodomains. In particular,
some of the conserved water molecules need not necessarily be
present in high-throughput docking campaigns. Moreover,
optimization of known binders could focus on the replacement
of one or more of the structured water molecules by functional
groups with similar hydrogen bonding properties.
■ CONCLUSIONS
We have analyzed the pathway and kinetics of Kac binding to
the TAF1(2) bromodomain by multiple MD simulations of
spontaneous and reversible binding. The MD trajectories reveal
two major binding modes of Kac which diﬀer in the
bromodomain residues providing the anchoring interactions.
From the unbound state, Kac reaches ﬁrst a position in which it
is stabilized by a hydrogen bond between its side chain carbonyl
oxygen and the side chain amide of the conserved Asn. This
binding mode is identical to the binding mode observed in
several crystal structures of bromodomains with Kac or short
peptide segments from histone tails. From the crystallographic
binding mode Kac further penetrates the binding site and
reaches a more buried binding mode in which the Kac side
chain is involved in a hydrogen bond with the carbonyl group
of the conserved Pro in the so-called WPF shelf. The WPF shelf
is a highly conserved motif of the bromodomain sequence and
has been highlighted as an important hotspot to increase
binding aﬃnity of small molecule inhibitors.28,29 Moreover, the
binding of diacetylated histone tails involves the WPF shelf
which interacts with the acetyl-lysine side chain that is not in
contact with the conserved Asn.4,30 Furthermore, the six
structured water molecules observed in most crystal structures
are present in the crystallographic binding conformation, while
three of them are replaced by the Kac side chain in the more
buried binding mode. Importantly, in several crystal structures
of bromodomains in complex with inhibitors (e.g., PDB codes
4HXK, 4HXO, 4IR3, 4A9I, and 4ALC) the carbonyl oxygen of
the Pro of the WPF shelf is involved in a polar interaction with
the inhibitor, e.g., with an aromatic CH of the [1,2,4]triazolo-
[4,3-a]pyridine moiety in the complex structure with BRD4(1)
(PDB code 4HXO).31 The crystal structure of the complex
between BRD4(1) and 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-
yl(1H-imidazol-1-yl)methanone (PDB code 4HXK) is of
particular interest as the 6,7-dihydrothieno[3,2-c]pyridin
moiety is almost as buried as acetyl-lysine in the P-binding
mode (Supporting Information Figure S6). Moreover, one of
the structured water molecules is displaced by the dihydrothie-
no ring.31
The two binding modes observed in the MD simulations are
distinct and separated by a free energy barrier which is smaller
than the barrier of unbinding. In other words, upon binding
there are several transitions between the two binding modes
which can interconvert about 1 order of magnitude faster than
the time required for full dissociation which is about 300 ns.
The simulation methods used here, unbiased MD with explicit
solvent (carried out on conventional compute clusters) and cut-
based free energy proﬁle analysis, can be applied to determine
the binding mode(s) and kinetics of small molecules to proteins
thus providing dynamical information which is useful to
complement the static picture obtained by conventional
experimental techniques. Although the histone code may
consist of multiple post-translational modiﬁcations, the
mechanism and kinetics of acetyl-lysine binding to bromodo-
mains is a ﬁrst step toward the in-depth understanding of the
role of bromodomains in transcriptional regulation.
■ METHODS
Simulation Protocols. The coordinates of the TAF1(2)
bromodomain (PDB code 3UV4) were downloaded from the
protein database (URL www.pdb.org).32 To reproduce neutral
pH conditions, the side chains of aspartates and glutamates
were negatively charged, those of lysines and arginines were
positively charged, and the histidine side chains were neutral.
Thirteen crystal water molecules inside or close to the binding
site were kept while the remaining water molecules were
deleted. Subsequently, the structure was solvated in a water box
whose size was chosen to have a minimal distance of 12 Å
between the boundary and any atom of the protein. The
simulation system contained sodium and chloride ions to
approximate an ionic strength of about 150 mM and to
compensate for the total charge of the bromodomain.
Preliminary MD simulations were carried out with
CHARMM,33 while the production runs were carried out
with GROMACS 4.5.434 using the CHARMM PARAM27 all
atom force ﬁeld26,35 and the TIP3P model of water.36
Periodic boundary conditions were applied, and electrostatic
interactions were evaluated using the particle-mesh Ewald
summation method.37 The van der Waals interactions were
truncated at a cutoﬀ of 10 Å. The temperature of 310 K was
kept constant by an external bath with velocity rescaling,38 and
the pressure was kept close to 1 atm by the Berendsen
barostat.39 The LINCS algorithm was used to ﬁx the covalent
bonds involving hydrogen atoms. The integration time step was
2 fs, and snapshots were saved every 20 ps.
Figure 6. Structured water molecules are conserved in the N-binding
mode while three of them are displaced by the tip of the Kac side chain
in the P-binding mode. The representative snapshots of the N-binding
mode (red) and P-binding mode (green) are aligned structurally to the
crystal structure of apo TAF1(2) (PDB code 3UV4) using only the Cα
atoms of the bromodomain helices. The bromodomain backbone, Kac,
and structured water molecules are shown (ribbons, sticks, and
spheres, respectively) for the two binding modes. For the crystal
structure, only the structured water molecules are shown (black
spheres) to avoid overcrowding of the ﬁgure. The Asn1604 side chain
of the P-binding mode representative is also shown (carbon atoms in
green). The labeling of the structured water molecules is the same as
in ref 8. Water molecules 2−4 are displaced in the P-binding mode.
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Multiple independent MD runs of spontaneous binding of
Kac to TAF1(2) were carried out. To mimick the context of the
longer histone sequence, the N-terminus and C-terminus of
Kac were neutralized by capping with acetyl and N-methyl-
amide, respectively (Figure 1). Two diﬀerent starting structures
were generated for TAF1(2) by swapping the coordinates of
Asn1604 Oδ and Nδ atoms in the X-ray structure (before
hydrogen generation). Thus two diﬀerent χ2 dihedrals of
Asn1604 were represented. Six starting positions for the Kac
molecule were generated by randomly placing Kac with its
center of mass ≈20 Å away from the center of mass of Asn1604
using the package PyMOL.40 For each of the six Kac starting
positions and each of the two TAF1(2) starting structures, two
simulations with diﬀerent seeds were started for a total 24
independent runs of 0.5 μs each (Supporting Information
Table S1). Each 0.5 μs run took about 1 week on 64 cores of
Xeon 5500-series processors.
Control simulations were carried out with the tetrapeptide
Kac-Gly-Gly-Kac to investigate potential diﬀerences between
the isolated Kac and histone tails. As in the runs with Kac, the
tetrapeptide was capped with acetyl and N-methyl-amide
groups at the N-terminus and C-terminus, respectively. The
coordinates of the tetrapeptide and of the bromodomain
BRD4(1) were taken from the PDB structure 3UVW. For
CREBBP, the tetrapeptide was placed into its bindig site after
structural overlap of the CREBBP coordinates (PDB entry code
3P1C) onto the ones of BRD4(1). From each of these two
starting structures, two independent 1 μs runs were performed
with the CHARMM PARAM27 force ﬁeld. In addition, two
independent 1 μs simulations with the AMBER force ﬁeld were
carried out for each of the two bromodomains. An overview of
all simulations is given in Supporting Information Table S1.
Ligand Parametrization. For the simulations with the
CHARMM PARAM27 force ﬁeld, Kac was parametrized using
the CHARMM general force ﬁeld41 for small molecules which
is compatible with CHARMM PARAM27. For the simulations
performed with the AMBER99 SB27 force ﬁeld, the parameters
of the Kac side chains were taken from a previous computa-
tional study.42
Clustering and Cut-Based Free Energy Proﬁle. The 16
MD trajectories with one or more binding events were used for
further analysis (a total of 400 000 snapshots from 8 μs of
MD). The snapshots were aligned structurally to the ﬁrst frame
of one of the MD trajectories using only the Cα atoms of the
helical segments of TAF1(2). Subsequently, the snapshots were
clustered using a tree-based algorithm43 implemented in
CAMPARI.44 As a measure of pairwise similarity, the root-
mean-square deviation (RMSD) of the acetyl-lysine side chain
heavy atoms including Cα was computed without further
alignment. The clustering was carried out with eight levels of
the tree using 8 and 1 Å as RMSD thresholds for the coarsest
and ﬁnest clustering level, respectively. This led to a total
number of 149 024 clusters 126 552 of which contained only
one snapshot (called singletons). The number of singletons
seems large, but it has to be noted that in the unbound state,
where the peptide moves freely around the bromodomain, the
RMSD between two relative positions of Kac is almost always
larger than 1 Å and thus the unbound state consists mainly of
singletons. Other clustering methods which are able to partially
solve the problem of the singletons were also tested but led to
worse kinetic separation of the diﬀerent states. Upon clustering,
a free energy proﬁle was computed using a method based on
the equilibrium kinetic network which preserves the free energy
barriers.23,24,45 This approach emulates the cuts in ﬂow-
networks, and the computed proﬁle is therefore named cut-
based free energy proﬁle. The nodes and links of the
equilibrium kinetic network are the clusters (determined by
the tree-based algorithm as explained above) and the direct
transitions between them sampled along the MD runs,
respectively.46 For each node, the set of nodes is partitioned
into two groups A and B using the mean ﬁrst passage time
(MFPT) to the reference node as an order parameter. The free
energy is related to the maximum ﬂow between sets A and B
and calculated as G = −kT ln(ZAB/Z), where ZAB/Z is the
relative partition function which represents the statistical weight
of the transitions between sets A and B (see refs 23 and 24 for
details). The result is a one-dimensional proﬁle along the
reaction coordinate ZA/Z (i.e., the relative partition function
representing the statistical weight of set A) which preserves the
barrier height between the free energy basins. The evaluations
of cut-based free energy proﬁles, interatomic distances, and
dihedral angles were performed with the simulation analysis
package WORDOM.47,48
Identiﬁcation of Basins. The free energy basins were
isolated from the cut-based free energy proﬁle using a
previously published procedure.24 First the most populated
cluster is used as reference to isolate the ﬁrst basin which
consists of the set of clusters on the left side of the ﬁrst barrier
on the proﬁle. Due to possible overlap on the right side of the
barrier (i.e., similar kinetic distance from two or more basins to
the reference cluster), the isolation of each basin requires a
separate proﬁle24 (Supporting Information Figures S7−S10). In
other words, the procedure used for the ﬁrst basin is iterated for
the second basin which is isolated using as a reference cluster
the largest cluster that is not in the ﬁrst basin. Clusters on top
of barriers are not assigned to any basin to avoid spurious
ﬂuctuations, i.e., shortcuts along the trajectories. Transitions
between basins were calculated from the MD trajectories when
the system passed from one basin to another either by a direct
transition or via the not assigned snapshots (the barrier region).
Analysis of Hydrogen Bonds. Hydrogen bonds were
analyzed using GROMACS.34 A hydrogen bond between a
donor and an acceptor atom was considered to be formed if the
donor−acceptor distance was lower than 3.5 Å and the
acceptor−donor−hydrogen angle lower than 30°.
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S-1
Bromodomain (PDB code) Ligand Force Field Starting structure No. of runs Total sampling [µs]
TAF1(2) (3UV4) Kac CHARMM Unbound, Asn1604 χ2 up 12 6
TAF1(2) (3UV4) Kac CHARMM Unbound, Asn1604 χ2 down 12 6
TAF1(2) Kac AMBER P-binding from CHARMM 2 2
TAF1(2) Kac AMBER N-binding from CHARMM 2 2
BRD4(1) (3UVW) Tetrapeptide CHARMM X-Ray 2 2
CREBBP (3P1C) Tetrapeptide CHARMM Overlap on 3UVW 2 2
BRD4(1) Tetrapeptide AMBER from CHARMM run 2 2
CREBBP Tetrapeptide AMBER from CHARMM run 2 2
Table S1: Simulations performed.
Transitions
from \ to Unbound P- N- N- P/N-
binding binding binding Intermediate
DOWN UP
Unbound - 1 2 12 5
P-binding 2 - 119 10 310
N-binding 2 118 - 18 4
DOWN
N-binding 2 17 18 - 13
UP
P/N-Intermediate 4 312 6 10 -
Table S2: The number of transitions between the different basins after splitting of the
N-binding basin into two sub-basins characterized by different values of Asn1604 χ2.
S-2
Figure S1: Time series of the interatomic distances between donor and acceptor atoms of three inter-
molecular key interactions (red, green, and magenta, y-axis on the right) together with the time series
of the χ2 dihedral angle of the conserved Asn1604 (cyan, y-axis on the left) for the 12 individual runs
started with the Nδ atom of Asn1604 pointing towards the solvent (Up). The letters a and b distinguish
two runs started from the same starting structure using different seeds.
S-3
Figure S2: Same as in Figure S1 for the 12 individual runs started with the Nδ atom of Asn1604 pointing
towards the binding site bottom (Down).
S-4
Figure S3: (Top) Time series of the RMSD from the X-ray structure (black) together with the distances
that characterize the hydrogen bond observed in the crystal structures (red) and the hydrogen bond of
the more buried binding mode revealed by the present MD study (green). The RMSD of the Kac side
chain atoms was calculated upon optimal overlap of the Cα atoms in the four helices. The reference
structure for the RMSD calculation was the crystal structure of CREBBP in complex with Kac (PDB
code 3P1C) as there is no crystal structure of TAF1(2) with Kac or a histone tail peptide. (Bottom) Time
series of the RMSD from the equilibrated conformation of TAF1(2) Cα atoms (orange) and Cα atoms
in helices only (maroon). These time series show that upon Kac binding the bromodomain structure
becomes slightly less flexible but does not undergo any relevant conformational change.
S-5
Figure S4: Control simulations with the AMBER force field and/or the tetrapeptide Kac-Gly-Gly-Kac.
(Top) Time series of the interatomic distances between donor and acceptor atoms of three intermolecular
key interactions (red, green, and magenta, y-axis on the right) together with the time series of the χ2
dihedral angle of the conserved Asn in the binding site (cyan, y-axis on the left) for the control simulations
of TAF1(2) and Kac with AMBER force field. (Bottom) Time series of interatomic distances between
the N-terminal Kac of the tetrapeptide Kac-Gly-Gly-Kac and BRD4(1) or CREBBP for the simulations
with the CHARMM (bottom left) or AMBER (bottom right) force field.
S-6
Figure S5: Control simulations with the CHARMM force field and the tetrapeptide Kac-Gly-Gly-Kac.
Time series of the RMSD of the side chain atoms of the two Kac’s (black) and only the N-terminal Kac
(red) for two independent runs each with BRD4(1) (left) and CREBBP (right). The RMSD was calculated
upon optimal overlap of the Cα atoms in the four helices of the bromodomain. The reference structure
for the RMSD calculation was the crystal structure of BRD4(1) in the complex with Kac-Gly-Gly-Kac
from the histone 4 peptide H4K5acK8ac (PDB code 3UVW).
S-7
Figure S6: Small molecule inhibitors of brodomains can penetrate deeply into the acetyl-lysine binding
pocket similarly to the P-binding mode of Kac observed in the MD simulations. Representative snapshots
of acetyl-lysine in the P-binding mode (green) and N-binding mode (red) are structurally aligned, using
only the Cα atoms of the bromodomain helices, to the crystal structure of BRD4(1) in complex with a
recently published inhibitor (brown, PDB code 4HXK). The bromodomain backbone, Kac/inhibitor, and
structured water molecules are shown as ribbons, sticks and spheres, respectively.
S-8
Figure S7: Geometric annotation and cFEP (bottom panel) with the P-binding mode representative as
reference node. The RMSD (second panel from the bottom) of the Kac atoms with respect to the X-ray
structure reported in 3P1C was calculated after overlap of the TAF1(2) Cα atoms to the corresponding
atoms of CREBBP in 3P1C.
S-9
Figure S8: Geometric annotation and cFEP (bottom panel) with the N-binding mode representative as
reference node. For further details see legend of Figure S7.
S-10
Figure S9: Geometric annotation and cFEP (bottom panel) with the P/N-Intermediate representative
as reference node. For further details see legend of Figure S7.
S-11
Figure S10: Geometric annotation and cFEP (bottom panel) from the unbound state. For further details
see legend of Figure S7.
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a b s t r a c t
Bromodomains are protein modules that selectively recognize histones by binding to acetylated
lysines. Here, we have carried out multiple molecular dynamics simulations of 20 human bromod-
omains to investigate the ﬂexibility of their binding site. Some bromodomains show alternative side
chain orientations of three evolutionarily conserved residues: the Asn involved in acetyl-lysine
binding and two conserved aromatic residues. Furthermore, for the BAZ2B and CREBBP bromodo-
mains we observe occlusion of the binding site which is coupled to the displacement of the two aro-
matic residues. In contrast to available structures, the simulations reveal large variability of the
binding site accessibility. The simulations suggest that the ﬂexibility of the bromodomain binding
site and presence of self-occluded metastable states inﬂuence the recognition of acetyl-lysine on
histone tails.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
Bromodomains, protein modules of about 110 residues, recog-
nize acetylated lysine side chains mainly in histones and are thus
involved in transcriptional regulation [1,2]. In the human genome
there are 46 proteins with a total of 61 different bromodomains,
with up to six bromodomains per protein [3]. Due to the potential
role of bromodomains in tumors and inﬂammation [4–6], large
scale structural studies have been carried out with the ultimate
goal to facilitate the discovery of small-molecule inhibitors able
to interfere in the process of reading acetylated lysine [7]. Since
1999, when the ﬁrst three-dimensional structure of a human
bromodomain was solved [8], the crystal and/or solution struc-
tures of more than 40 human bromodomains have been reported
[9,10]. All available structures show a conserved four-helix bundle
topology (Fig. 1) in which the ZA-loop and BC-loop connect the ﬁrst
two a helices (called Z and A) and last two a helices (called B and
C), respectively [10,11]. The acetyl-lysine binding site is very sim-
ilar in all structures of bromodomains [10]. The BC-loop contrib-
utes the evolutionary conserved Asn side chain [12] which acts
as hydrogen bond donor to the acetylated lysine side chain. More-
over, two conserved Tyr residues [13] are present in the ZA-loop
and BC-loop, respectively (Fig. S1). In striking contrast to the abun-
dance of available three-dimensional structures, there are only few
computational studies on bromodomains [14–16]. In particular, it
seems that the dynamic properties of human apo bromodomains
have not been investigated yet by atomistic simulations. Here,
we have studied the binding site ﬂexibility of 20 bromodomains
(covering seven of the eight families of human bromodomains)
by explicit solvent MD simulations. The simulation results reveal
a surprisingly high heterogeneity of the plasticity and accessibility
of the acetyl-lysine binding site.
2. Results and discussion
A sequence alignment of the 20 simulated bromodomains with
indication of important structural features and investigated key
residues is given in Fig. S1. Family memberships are listed in
Table S-I. The time series of root mean square deviation (RMSD)
of the Ca atoms show that the overall fold of the simulated brom-
odomains is stable over the 1-ls time scale and 310 K temperature
of the MD runs (Fig. S2). Most of the ﬂuctuations are localized in
the ZA-loop, BC-loop, and the termini (Fig. S3). The ZA-loop and
BC-loop are involved in binding the histone tail whereas the ter-
mini are located far away from the acetyl-lysine binding site so
that their motion can be neglected. Importantly, we observe multi-
ple events of reversible rotation of the side chains investigated in
the present study along the 0.5- to 1-ls time scale of the MD runs
(Figs. S4 and S5). These rotations take place on a time scale about
one order of magnitude smaller than the length of the simulations
so that the following analysis is not marred by statistical errors.
We ﬁrst investigated the ﬂexibility of the conserved Asn which
is directly involved in acetyl-lysine binding (i.e., Asn1944 in BAZ2B,
Asn1168 in CREBBP, Asn1604 in TAF1(2), etc.). For most of the
bromodomains studied here, there are many events of reversible
0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.05.032
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rotations of the side chain amide of the conserved Asn (Figs. S4 and
S5). The rotation (of about 180 degrees) around the v2 angle of the
conserved Asn switches between an orientation in which the side
chain –NH2 group caps the C-terminal turn of a helix B (by donat-
ing a hydrogen bond to the backbone carbonyl of the n-4 upstream
residue, e.g., the hydrogen bond between the Asn1168 side chain
and the carbonyl group of residue 1164 in CREBBP) to a completely
solvent exposed orientation of the –NH2 group (Fig. 2, top). Note
that the former orientation is observed in most (13 of 17) X-ray
structures of the apo bromodomains used in this study (three of
them have Thr (PHIP(2) and WDR9(2)) or Tyr (ASH1L) instead of
the conserved Asn), as well as in the X-ray structures of BRD4(1)
with three different diacetylated peptides (PDB codes 3UVW,
3UVY, and 3UW9) and in the CREBBP/acetyl-lysine complex (PDB
code 3P1C). Interestingly, in seven of the 17 bromodomains the
Asn –NH2 group is oriented towards the solvent during more than
one third of the simulation time (Figs. S4 and S5). These bromodo-
mains are: TAF1L(2) (90% of the snapshots with solvent-exposed
orientation of the Asn –NH2 group), TAF1(2) (81%), TAF1(1)
(68%), GCN5L2 (44%), ATAD2 (43%), BAZ2B (39%), and PB1(2)
(38%). For TAF1L(2), TAF1(2), and TAF1(1) (all belonging to a single
clade of family VII in the bromodomain phylogenetic tree [10]) the
solvent exposed orientation of the Asn -NH2 group is stabilized by
a water-bridged hydrogen bond between the Asn side chain car-
bonyl and the hydroxyl group of the Ser in position n-4 upstream
(Fig. 2, bottom). It has to be noted that most bromodomains have
Ala or Cys at position n-4 upstream of the conserved Asn so that
these side chains cannot form a (water-bridged) hydrogen bond.
Note also that an in-depth analysis of the water molecules in the
Fig. 2. Rotational ﬂexibility of the conserved Asn side chain as observed in MD simulations of CREBBP (top) and TAF1(2) (bottom). (Middle) Time series of Asn v2 angle of
conserved Asn (red) and distance between Asn side chain and residue n-4 upstream (black). (Left and right) Representative MD snapshots.
Fig. 1. Ribbon illustration of the crystal structure of the complex between CREBBP
and acetyl-lysine (PDB code 3P1C). Each of the four a-helices and two binding site
loops is displayed with a different color. The side chains of the conserved Tyr1125 of
the ZA-loop, and Tyr1167-Asn1168 of the BC-loop are emphasized (sticks) together
with the side chain of acetyl-lysine (sticks, light colors). The N-terminus and C-
terminus are shown with a blue and red sphere, respectively.
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binding site along the MD trajectories goes beyond the scope of
this paper and will be presented elsewhere together with a com-
parison with the ﬁve water molecules that seem to be conserved
in the crystal structures [10].
We further analyzed the motion of residues adjacent to the con-
served Asn to shed light onto the accessibility of the acetyl-lysine
binding site. The MD trajectories of some of the 20 simulated
bromodomains unmask a large ﬂexibility of the side chain of the
evolutionary conserved Tyr (Phe in BAZ2B and SMARCA4) in the
BC-loop, i.e., the residue preceding in the sequence the Asn in-
volved in acetyl-lysine binding (Figs. S4 and S5). The side chain
of this Tyr (or Phe) rotates from an inward orientation in which
the aromatic ring is part of the binding site surface (v1 angle in
trans) to an outward orientation in which the same side chain
points towards the exterior surface of the bromodomain (v1 angle
values around 60 degrees) (Fig. 3). The ﬁve bromodomains with a
population larger than 10% of the outward orientation of the BC-
loop Tyr (or Phe) side chain are BRDT(1) (100%), CREBBP (31%),
BAZ2B (24%), SMARCA4 (21%), and BRD1 (11%). This simulation re-
sult is a novel ﬁnding because only two of the more than 50 brom-
odomain crystal and solution structures (i.e., the X-ray structure of
BRDT(1) and the NMR structure of KIAA1240, PDB codes 2RFJ and
2DKW, respectively) show a similar outward orientation of the side
chain of the conserved Tyr on the BC-loop. Note that in contrast to
the solution structure, the crystal structure of KIAA1240 (PDB code
3LXJ) does not show the outward orientation of the conserved Tyr.
To further investigate the inﬂuence of the displacement of the
BC-loop Tyr on the binding site accessibility, two-dimensional his-
tograms were calculated for each of the 20 simulated bromodo-
mains (Figs. 3(b) and S6). According to the two-dimensional
histograms the 20 bromodomains can be assigned to three differ-
ent groups. The largest group consists of the bromodomains with
an open binding site, and in which the side chain of the conserved
Tyr of the BC-loop is part of the binding site surface (v1 angle al-
ways in the trans orientation, e.g., TAF1(2)). The second group in-
cludes the bromodomains in which the conserved Tyr changes its
orientation without affecting the binding site accessibility (e.g.,
BRD1 and SMARCA4). The third group includes the bromodomains
Fig. 3. Swapping out of the aromatic residue preceding the conserved Asn in the BC-loop. (a) Representative snapshots extracted from the MD simulations of CREBBP. (b)
Two-dimensional histograms of binding site solvent accessible surface area (SASA) versus side chain v1 angle of the conserved Tyr (Phe in BAZ2B) in the BC-loop. The
horizontal line at 100 Å2 is an arbitrary threshold drown solely to help the eye. The cyan and red rectangles in the histogram of CREBBP emphasize the metastable states
corresponding to the cyan and red structures, respectively, in panel (a). The black to yellow coloring of frequency values follows a logarithmic scale and is shown in the legend
bar. (c) Time series of four geometrical variables used to analyze the binding site. This panel shows run 2 of BAZ2B while the equivalent time series for the other MD runs are
shown in Figs. S7–S10. The variables are the RMSD of the Ca atoms of the ZA-loop from the crystal structure (black), the Phe1943 v1 dihedral angle (red), the binding site SASA
(blue, running average calculated over time intervals of 10 ns for clarity), and the distance between the hydroxyl oxygen of Tyr1901 and the nitrogen atom of the Asn1944
side chain (green).
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in which the outward orientation of the BC-loop Tyr promotes a
rearrangement of other binding site residues resulting in a partially
occluded, i.e., shallower binding site (e.g., BAZ2B and CREBBP,
Figs. 3(b) and 4). More precisely, one observes large ﬂuctuations
of the ZA-loop that are associated frequently with the swapping
out of the BC-loop Tyr (Figs. 3(c), S7 and S8) and with changes in
the accessibility of the binding site (Figs. S9 and S10). In particular,
in the BAZ2B and CREBBP simulation segments during which the
conserved Tyr of the BC-loop points outward, the conformational
plasticity of the ZA-loop results (in 20% to 25% of the saved snap-
shots) in the formation of a direct hydrogen bond between
Asn1168 and ZA-loop Tyr1125 in CREBBP (Figs. 3(c) and 4), and
Asn1944 and ZA-loop Tyr1901 in BAZ2B. Note that these two side
chains are separated by two water molecules in the X-ray struc-
tures (PDB codes 3DWY and 3G0L). In essence, it emerges from
the MD trajectories that the ZA-loop Tyr side chain can occupy
the same position and can be stabilized by the same hydrogen
bond to Asn as the natural ligand acetyl-lysine (Fig. 4).
The ZA-loop shows signiﬁcant plasticity and large deviations
from the crystal structure (Figs. 3(c), S7 and S8). This ﬂexibility is
consistent with the structural heterogeneity of the ZA-loop ob-
served by overlapping the available X-ray structures [10] as well
as with the length of the ZA-loop (about 25–30 residues, Fig. S1).
Figs. 3(c), S9 and S10 show that the displacement of the ZA-loop
inﬂuences the binding site accessibility (note that 4 of the 6 resi-
dues used to calculate the binding site accessibility are in the ZA-
loop). In particular, the accessibility can change signiﬁcantly in
the MD trajectory segments during which the ZA-loop RMSD from
the crystal structure is large, while the accessibility is less variable
in segments with mainly rigid ZA-loop. Interestingly, the ZA-loop
conformational ﬂexibility has been shown to play an important
role at the protein-protein interface for HIV-1 Tat binding to brom-
odomain PCAF [14]. In the present simulations of CREBBP and
BAZ2B, the rearrangement of the ZA-loop and thus of several resi-
dues lining the binding site reduces its aperture which could hin-
der histone peptide recognition.
In conclusion, the MD trajectories reveal a heterogeneous ﬂex-
ibility of the acetyl-lysine binding site in different bromodomains.
The analysis of the trajectories shows that the accessibility of the
binding site ranges from fully preserved (for the majority of brom-
odomains) to almost completely inaccessible during simulation
segments of hundreds of ns (e.g., in BAZ2B and CREBBP). Of practi-
cal importance, the presence of metastable states in a small subset
of bromodomains can be exploited [17–19] to design selective
small-molecule inhibitors few of which have been reported as of
today [4,20–23]. The present simulation results shed some light
on the binding mechanism of histone tails to bromodomains which
seems to be mainly conformational selection, though a (partial) in-
duced ﬁt cannot be deﬁnitively excluded. More precisely, with the
present simulations of apo bromodomains it is not possible to ex-
clude a ligand-promoted displacement of some of the side chains
in the acetyl-lysine binding site. The self-occluded conformation
of the acetyl-lysine binding groove suggests a possible auto-regu-
latory mechanism of histone tail recognition and binding.
3. Methods
The coordinates of the 20 bromodomains were downloaded
from the protein database [24]. To reproduce neutral pH conditions
the side chains of aspartates and glutamates were negatively
charged, those of lysines and arginines were positively charged,
and the histidine side chains were neutral. For each bromodomain
the crystal water molecules close to the binding site and with low
B factor value were kept while the remaining water molecules
were deleted. For most bromodomains a B-factor of 15 Å2 was used
as threshold for keeping crystallographic water molecules. For the
few bromodomains with overall higher B-factors a threshold of
30 Å2 was used. With this arbitrary choice of thresholds between
Fig. 4. Occlusion of the acetyl-lysine binding site by the conserved Tyr of the ZA-
loop. (a) The ribbon structure is a representative MD snapshot of the CREBBP
simulations in which the conserved Tyr of the ZA-loop is involved in a hydrogen
bond with the Asn that binds acetyl-lysine. The three conserved side chains (sticks)
are shown together with three water molecules (red spheres). The position of
acetyl-lysine (light-colored sticks) and three water molecules (light red spheres)
from the crystal structure of the CREBBP/acetyl-lysine complex (PDB code 3P1C)
was obtained by structural superposition of the Ca atoms. Surface representation of
a representative MD snapshot with partially occluded, i.e., shallower, binding site
(b) and the crystal structure of CREBBP (PDB code 3P1C) (c). The color coding
reﬂects atomic elements (carbon, nitrogen, and oxygen atoms in yellow, blue, and
red, respectively). The location of the acetyl-lysine binding site is indicated with a
black oval.
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4 and 15 crystal water molecules were retained for each bromod-
omain. Importantly, in our simulations the structured water mole-
cules exchange rapidly (residence times ranging from 0.01 to 1 ns)
with the water molecules in the bulk solvent. Furthermore, in test
simulations without crystal water molecules, bulk water molecules
rapidly occupied the conserved positions in the binding site. Thus,
the exact number of kept crystal waters does not inﬂuence the re-
sults of our simulations because individual runs have a length of
0.5 or 1 ls.
Subsequently, the structure was solvated in a water box whose
size was chosen to have a minimal distance of 11 Å between the
boundary and any atom of the protein. Solvation water molecules
within 2.4 Å of any heavy atom of the protein or crystal water were
removed. The simulation system contained sodium and chloride
ions to approximate an ionic strength of about 150 mM and to
compensate for the total charge of each bromodomain. The MD
simulations were carried out with Gromacs 4.5.4 [25] using the
CHARMM PARAM22 force ﬁeld [26] and the TIP3P model of water
[27].
Periodic boundary conditions were applied and electrostatic
interactions were evaluated using the particle-mesh Ewald sum-
mation method [28]. The van der Waals interactions were trun-
cated at a cutoff of 10 Å. The temperature of 310 K was kept
constant by an external bath with velocity rescaling [29] and the
pressure was kept close to 1 atm by the Berendsen barostat. The
SHAKE algorithm was used to ﬁx the covalent bonds involving
hydrogen atoms. The integration time step was 2 fs and snapshots
were saved every 10 ps and 4 ps for the 1-ls and 0.5-ls runs,
respectively.
Multiple independent MD runs of 1 ls each were carried out for
four bromodomains belonging to four different families: BAZ2B
(family V), BRD1 (IV), CREBBP (III), and TAF1(2) (VII). In addition,
16 bromodomains covering all but one of the families were simu-
lated for 0.5 ls each (Table S-I). The crystal structures solved by
the Structural Genomics Consortium [10] were used as starting
conformations.
The solvent accessible surface area (SASA) was calculated with
the SURF tool of Wordom, using the GEPOL algorithm [30,31] and
1.4 Å as radius of the water probe. The following procedure was
used to deﬁne the acetyl-lysine binding site for the SASA calcula-
tion. First, using the X-ray structure of the CREBBP/acetyl-lysine
complex (PDB code 3P1C) residues were selected which had at
least three heavy atoms within 6 Å of the ligand. From this set
Tyr1167 and Asn1168 were excluded to avoid redundancy in the
two variables used for the two-dimensional histograms. Of the
six remaining residues (Pro1110, Phe1111, Val1115, Tyr1125,
Ala1164, Val1174), only the side chain atoms were used to evalu-
ate the binding site SASA. For the other bromodomains the equiv-
alent residues upon structural overlap were chosen. Robustness of
the selection of binding site residues is shown in Fig. S11.
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Simulation systems
Bromodomain Family PDB entry Number of Total sampling (µs) Number of available
independent runs X-ray/NMR structures
CECR2 I 3NXB 1 0.5 1
FALZ I 3UV2 1 0.5 2
GCN5L2 I 3D7C 1 0.5 2
PCAF I 3GG3 1 0.5 2
BRD4(1) II 2OSS 1 0.5 1
BRDT(1) II 2RFJ 1 0.5 1
BRD3(2) II 2OO1 1 0.5 2
PHIP(2) III 3MB3 1 0.5 1
WDR9(2) III 3Q2E 1 0.5 1
CREBBP III 3DWY 5 4.5 1
EP300 III 3I3J 1 0.5 1
ATAD2 IV 3DAI 1 0.5 1
BRD1 IV 3RCW 5 4.5 1
BAZ2B V 3G0L 5 4.5 1
TAF1(1) VII 3UV5 1 0.5 2
TAF1L(2) VII 3HMH 1 0.5 1
TAF1(2) VII 3UV4 4 4.0 2
ASH1L VIII 3MQM 1 0.5 1
PB1(2) VIII 3HMF 1 0.5 1
SMARCA4 VIII 3UVD 1 0.5 3
Table S-I: The digit in parentheses in the first column indicates the position of the bro-
modomain along the polypeptide sequence, e.g., TAF1(2) is the second bromodomain
of the human Transcription initiation factor TFIID subunit 1 (TAF1). Multiple inde-
pendent MD runs were carried out for the four bromodomains in boldface. The family
classification and number of available X-ray/NMR structures are taken from Ref.1
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Figure S2: Root mean square deviation (RMSD) of Cα atoms. The time series
of the RMSD from the minimized structures (i.e., starting structure of the MD runs) is
plotted for all Cα atoms (black line) and excluding the Cα atoms in the ZA-loop, BC-loop,
and the termini (red line). For CREBBP Cα’s of residues 1104-1134 and 1168-1172 as well
as 3 terminal residues on each N- and C-terminus were excluded for the latter calculation.
For BAZ2B, BRD1 and TAF1(2) the corresponding residues upon structural overlap were
neglected. Note that similar RMSD values are observed for the other 16 bromodomains.
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Figure S3: Root mean square fluctuations (RMSF). Profile of the RMSF of the
Cα atoms (black line, y-axis on the left) of CREBBP, BAZ2B, BRD1 and TAF1(2) and
crystallographic B-factors (green line, y-axis on the right) as a function of residue number.
The RMSF values were averaged over simulation intervals of 5 ns. The fluctuations are
highest for the ZA-loop, BC-loop, and termini. Note that the major discrepancies between
RMSF along the simulations and crystallographic B-factors are due to crystal contacts in
the latter, e.g., for the loops of CREBBP which are stabilized by the nearest neigbors in
the crystal (PDB code 3DWY).
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Figure S4: Conserved Asn and Tyr/Phe: Time series of dihedrals and distances.
The χ2 dihedral of the conserved Asn (i.e., Asn1168 of CREBBP) is shown (black). Note
that for PHIP(2) and WDR9(2) χ1 of Thr equivalent to Asn1168, and for ASH1L χ2
of Tyr equivalent to Asn1168 are shown. The χ1 of Tyr/Phe preceding in sequence the
conserved Asn (i.e., Tyr1167 in CREBBP) is also shown (red). The distance between
the side chain ND2 of the conserved Asn and the hydroxyl oxygen of the ZA-loop Tyr
pointing inside the binding groove (i.e., Tyr1125 in CREBBP) is also shown (green); in
case of a Thr or Tyr in position of the conserved Asn, Thr OG1, resp. Tyr OH were used
instead of Asn ND2. Note that the ZA-loop Tyr is conserved in all the 20 bromodomains
investigated here (see Figure S1).
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Figure S5: Conserved Asn and Tyr/Phe: Time series of dihedrals and distances.
Same as Figure S4 for the four bromodomains for which multiple MD simulations were
carried out.
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Figure S6: Binding site accessible surface. Two-dimensional histograms of binding
site accessible molecular surface (SASA) versus χ1 dihedral of Tyr/Phe preceding the
conserved Asn in the BC-loop. Coloring according to frequencies follows a logarithmic
scale.
S-8
Figure S7: Flexibility of ZA-loop and side chain rotation of the conserved
Tyr/Phe in BC-loop. Each panel corresponds to an independent simulation (of the
bromodomain indicated in the top) and shows the time series of RMSD of the Cα atoms of
the ZA-loop (black, y-axis on the left) and the χ1 dihedral angle of the conserved Tyr/Phe
in the BC-loop (red, y-axis on the right). The RMSD of the ZA-loop from the energy-
minimized crystal structure was calculated upon structural overlap of the MD snapshots
using the Cα atoms of the four α-helices.
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Figure S8: Flexibility of ZA-loop and side chain rotation of the conserved
Tyr/Phe in BC-loop. See caption of Figure S7.
S-10
Figure S9: Flexibility of ZA-loop and changes in binding site SASA. Each panel
corresponds to an independent simulation (of the bromodomain indicated in the top) and
shows the time series of RMSD of the Cα atoms of the ZA-loop (black, y-axis on the left)
and the binding site SASA (blue, y-axis on the right, running average calculated over
time intervals of 10 ns for clarity). The RMSD of the ZA-loop from the energy-minimized
crystal structure was calculated upon structural overlap of the MD snapshots using the
Cα atoms of the four α-helices.
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Figure S10: Flexibility of ZA-loop and changes in binding site SASA. See caption
of Figure S9.
S-12
Figure S11: Robustness of two-dimensional histograms. The very similar two-
dimensional histograms of binding site SASA vs. χ1 of Tyr1167 for CREBBP, calculated
using seven different selections of binding site atoms, demonstrate robustness. The subset
of binding site residues used for each of the seven panels are the side chain heavy atoms
of the residues whose numbers are mentionend above each panel. Coloring according
to frequencies follows a logarithmic scale. The one-dimensional histogram of the χ1 of
CREBBP Tyr1167 is also shown (middle right).
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Chapter 8
Conclusions
Molecular dynamics (MD) simulations are a powerful tool, which are widely employed
in several scientific areas since they provide a direct route from the microscopic details
of a system to its macroscopic, experimentally observable features. In this thesis, a
wide spectrum of MD techniques were employed to study several different biophysical
issues, which range from peptides self-assembly in a crowded environment or in presence
of a small inhibitor, to bromodomains recognition of acetylation marks. The numerous
molecular processes investigated in this thesis differ in their characteristic time scales
and in the complexity of the microscopic mechanisms they involve.
Using a coarse-grained phenomenological model, we could assess how macromolecu-
lar crowding affects aggregation kinetics, showing that its net effect on the self-assembly
process depends crucially on the intrinsic amyloidogenic propensity of the studied pep-
tide: the less a peptide is prone to aggregate, the greater is the acceleration exerted on
its aggregation from macromolecular crowding.
Implicit solvent constant temperature MD simulations were performed to shed light
on the structures of the early aggregates of the amino acid phenylalanine, whose fib-
rillar assemblies were shown in experiments to have a cytotoxic effect and were then
hypothesized to play a crucial role in the etiology of Phenylketonuria. The structure we
proposed was in very good agreement with the electron diffraction pattern experimentally
obtained.
147
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The use of replica exchange MD simulations in conjunction with an implicit solvent
model allowed us to study the interaction of carnosine with the amyloid β-peptide (Aβ)
and to explain its role as an amyloid aggregation modulator. In agreements with ex-
perimental studies, our results showed that carnosine establishes transient, non-specific
interactions with the Aβ monomer and that its conformational ensemble is not signifi-
cantly affected from the presence of carnosine. However, a reduction in the formation of
interpeptide hydrogen bonds in presence of carnosine was observed in simulations of Aβ
peptide segments.
Explicit solvent MD simulations were performed to investigate the binding site plas-
ticity of 20 bromodomains and the binding process of acetylated lysine to one of them.
Simulations revealed a large variability in the available orientation of conserved residues
in the binding cleft of several bromodomains, which for some of them was also accom-
panied by partial occlusion of their binding site. Moreover, we demonstrated that our
computational approach is able to reproduce the experimentally observed binding pose of
acetyl-lysine to various bromodomains. Interestingly, our study unveiled the presence of a
second stable binding pose, and showed that the system can interconvert between the two
binding conformations on a much faster time scale with respect to the binding/unbinding
kinetics.
The results collected in this thesis prove that molecular dynamics techniques are
indeed a versatile and useful investigation method in biophysics, which is able to cor-
roborate and extend the picture of molecular processes obtained by experiments and
theoretical models.
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